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ABSTRACT
Lipopolysaccharide (LPS) is a major constituent of the outer membrane
of all Gram-negative bacteria and is known to be responsible for the
range of pathophysiological features of endotoxic shock. This thesis
considers the expression of Escherichia coli LPS under different
environmental conditions and its detection in the serum of septic
patients by means of monoclonal antibody (MAb) probes.
From an existing panel of MAbs, reactive with either Lipid A, core
oligosaccharide and O-polysaccharide components of LPS, eleven were
selected and characterized in a number of assay systems. Immuno-
blotting established that core reactive MAbs were reactive against
either core not substituted with O-antigen or both substituted and
unsubstituted core material. Core-glycolipid reactive MAbs demon¬
strated either full cross reactivity against all E. coli core types, or
preferential binding to selective E. coli core types. Flow cytometric
and ELISA analysis on whole bacteria showed that the absence of 0-
antigens on rough mutants increased accessibility of core-glycolipid
LPS to antibodies. Analysis of the whole cell ELISA technique
established that the.expression of whole cells on ELISA plates differed
from those in suspension.
Sandwich ELISA methods employing suitable combinations of solid phase
and biotinylated secondary MAbs were developed for the detection of E.
coli core types R1-R4, specific core types R1 and R3 and E. coli 018,
O-antigen. The sensitivity of the assay using the two most cross-
reactive MAbs was between 0.01 and 10 ng ml ' E. coli LPS, depending on
the core type. The sensitivity of assays for the detection of specific
core and O-types was between 0.01 and 0.1 ng ml ^ E. coli LPS. Assay
sensitivity was significantly reduced for the detection of LPS in
spiked serum. Methods to improve the sensitivity were investigated.
MAb probes were used to study the expression of LPS on E. coli strains
grown under a variety of conditions in batch culture which mimicked
some of the in vivo environmental conditions of an infected host.
Growth in heat-inactivated sheep serum and magnesium depleted condi¬
tions demonstrated increased expression of LPS core and subsequent
increased binding of anti-core MAbs. Iron depleted bacteria also
showed increased binding of anti-core MAbs. Nitrogen deficient/high
carbon conditions, chosen to promote capsule production, resulted in
increased expression of 0-antigen and decreased binding of anti-core
»n,
MAbs. The expression of LPS/Xin vivo grown bacteria was investigated
using chamber implants and a mucin-haematin septicaemia model. In vivo
bacteria expressed greater amounts of 0-antigen and unsubstituted core
material as well as an overall increase in 0-antigen chain length.
ELISA inhibition studies of anti-core MAb binding established greater
inhibitory activity of in vivo cells against in vitro cells.
The binding capacity of anti-LPS MAbs to E. coli bacteria grown in the
absence and presence of sub-minimum inhibitory concentrations (sub-
MICs) of various antibiotics was studied. Treatment with ampicillin,
chloramphenicol and ciprofloxacin resulted in enhanced binding of anti-
core reactive MAbs to most E. coli strains. Overall, treatment with
gentamicin produced the least effect on MAb binding. The presence of
chloramphenicol decreased the expression of high molecular mass 0-
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antigen and/or an increased expression of low molecular mass substi¬
tuted E. coli LPS. The outer membrane proteins of E. coli strains
grown in the presence of sub-MICs of ciprofloxacin and gentamicin,
expressed several additional minor high molecular mass proteins.
The relevance and significance of these studies, in relationship to the
patient with septic shock, is discussed.
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Infections by Gram-negative bacteria are a serious and increasing
problem, especially those associated with the clinical syndromes of
septicaemia and septic shock. The presence of bacteria in the blood,
termed bacteraemia, can often be transient and of minimal consequence
particularly for immunocompetent individuals. Conversely, bacteraemia
may proceed to septicaemia, a condition associated with a systemic
response to the presence of microorganisms or their products in the
bloodstream or tissues, characterized by several clinical findings
(Dudley, 1990). Septicaemia frequently progresses to septic shock,
described as peripheral circulatory failure with inadequate tissue
perfusion and cell death secondary to an infectious process (Dipiro,
1990). The infectious process resulting from a focus of infection is
often referred to as 'sepsis'. One of the first descriptions of Gram-
negative bacteraemia dates back to the 19th century (Brill & Libman,
1899). Prior to the advent of antimicrobial agents, Gram-negative
septicaemia was a clinical and laboratory curiosity (Young et al,
1977). However, the extensive use of antimicrobial agents over the
past 30 years has heralded the emergence of Gram-negative opportunist
pathogens as an important group of organisms responsible for high
morbidity and mortality. Despite the availability of potent antib¬
iotics, the use of vasoactive drugs and intensive care, the mortality
rate of septic shock is currently 60-80% (Wardle, 1979; Ziegler et al,
1982; Bryan et al, 1983; Ispahani et al, 1987). Since 1950 the
incidence of Gram-negative septicaemia and shock has increased to a
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level that it is a frequent complication in the management of hospital¬
ized patients. In the United States the rate has risen from 1 per
1,000 hospital admissions in 1950 to about 13 per 1,000 in 1980 (Kreger
et al, 1980a). Consequently, septic shock is presently the commonest
cause of death in intensive care units in the United States (Wilson,
1984).
Experimental and clinical evidence suggests that endotoxin, primarily
the lipopolysaccharide (LPS) component of the Gram-negative bacterial
outer membrane, is one of the most important components in the develop¬
ment of severe septicaemia and shock (Ryan, 1985). The terms Gram-
negative shock or endotoxic shock are commonly used to reflect the
aetiology and the central role played by bacterial LPS.
1.2 AETIOLOGY
Although the causative organisms of septicaemia are many and varied,
those caused by aerobic or facultative Gram-negative rod-shaped
bacteria predominate, accounting for between 20% and 50% (Dudley,
1990). Since mortality rates from Gram-negative bacteraemia range from
20 to 60% these organisms are recognized as important agents of
infection (Kreger et al, 1980a; Ispahani et al, 1987; Gransden et al,
1990).
The organisms responsible for the majority of septicaemic cases have
been determined in a number of published studies of septicaemia, both
from the United Kingdom (Young, 1982; Ispahani et al, 1987; Eykyn et
al, 1990) and elsewhere (Bruun et al, 1982; Weinstein et al, 1983;
Peltola et al, 1987; French et al, 1990; Neu et al, 1990). Despite
inherent variation because of differences in patient population and
2
hospital practices, the predominance of certain organisms is common to
all. The comprehensive septicaemic study of Eykyn et al (1990) covered
nearly A,000 episodes at St Thomas' Hospital from 1969-1988. Table 1
summarizes the organisms commonly isolated from both hospital and
community acquired septicaemic patients in this report.
Table 1. Significant microbial isolates from septicaemic patients
(Eykyn et al, 1990)
Percentage of Infections
Hospital acquired (2,518) Community acquired (1,750)
Escherichia coli 20 Escherichia coli 25
Staphylococcus aureus 19 Streptococcus pneumoniae 22
Klebsiella species 9 'viridans' streptococci 10
Pseudomonas species 9 Staphylococcus aureus 10










Similar to other published series the most common isolate was E. coli
(22%). Other members of the Enterobacteriaciae are also well repres¬
ented, particularly in hospital acquired infection, together with non-
enteric Pseudomonas species. Despite the predominance of E. coli, only
eight 0-serotypes from a total of over 160 are associated with more
than 50% of E. coli septicaemias (Kreger et al, 1980a; Cross et al,
1984). Similarly, Pseudomonas aeruginosa (Moody et al, 1972; Dick et
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al, 1988) and Serratia marcescens (Gaston et al, 1988) both show an
association of certain O-serotypes with septicaemia. S. aureus is
commonly second only to E. coli as a cause of septicaemia, accounting
for 15%, (Eykyn et al, 1990) a figure comparable with the 17.8%
reported by Young (1982) and the 11% by Ispahani et al (1987).
Septicaemia complicated by septic shock is associated with an increase
in mortality rate (Dudley, 1990). Although endotoxin has been strongly
implicated in the syndrome of septic shock, not all cases are caused by
Gram-negative bacteria (Cohen, 1989). The current view is that other
organisms, including Gram-positive bacteria, may also cause a shock¬
like syndrome indistinguishable from that induced by Gram-negative
bacteria (Bayston & Cohen, 1990). Overwhelming S. aureus septicaemia,
and the pneumococcal septicaemia of splenectomized patients provide
good illustrations of serious Gram-positive sepsis associated with
shock (Easmon, 1990). Recent evidence indicates that whilst endotoxin
is perhaps the most potent mediator of septic shock, it is probably one
of several important bacterial products that can produce the disease
(Bate et al, 1988; Jupin et al, 1988; Natanson et al, 1989). It
appears that regardless of aetiology, a final common pathway is
involved in the production of septic shock. Nevertheless endotoxin is
likely to be responsible for cases of shock associated with Gram-
negative septicaemia.
Bacteraemia is not necessarily a prerequisite for septicaemia which can
occur without a positive blood culture. Indeed, Danner et al (1991)
established that 74% of clinically diagnosed cases of septic shock with
detectable endotoxaemia had negative blood cultures, an observation
common to many others. Whilst rendering blood cultures negative, host
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defences or antibiotics or both, release endotoxin into the circulation
as a result of bacterial lysis (Shenep et al, 1985a; Cohen & McConnell,
1986; Shenep et al, 1988). Additionally, extravascular sources of
endotoxin such as the gastrointestinal tract (Ravin et al, 1960; van
Deventer et al, 1988b; Sori et al, 1988), or sequestered foci of
infection may also be important. If the leakage of endotoxins from the
gut exceeds the capacity of the natural de-toxification mechanism,
'non-septic endotoxic shock' may develop (Tamakuma et al, 1971; Cuevas
& Fine, 1972). Circulating endotoxin has also been detected in some
cases of Gram-positive or Candida septicaemia (van Deventer et al,
1988a; Danner et al, 1991). The source of this endotoxaemia may be
undetected Gram-negative bacteraemia, or alternatively release of
endotoxin from extravascular sites such as the gastrointestinal tract
as a consequence of the primary Gram-positive infection.
1.3 SEPTICAEMIA AND THE DETECTION OF ENDOTOXIN
The most widely used and most sensitive method of detecting endotoxin
is the Limulus amoebocyte-lysate (LAL) assay (Sturk & ten Cate, 1985;
Jorgenson, 1986). This bioassay takes advantage of the fact that a
lysate of blood cells (amoebocytes), from the horseshoe crab (Limulus
polyphemus), gels on exposure to picogram quantities of endotoxin
(Cohen, 1989). The relatively recent modification of the original
assay by the addition of a chromogenic substrate, has allowed the
development of a fully quantitative micro assay (Cohen & McConnell,
1984).
Although the LAL assay is put to many uses, the greatest debate
surrounds its use in the diagnosis and management of suspected Gram-
negative septicaemia. Initially it seemed as though the presence and
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degree of endotoxaemia correlated with outcome (Levin et al, 1972). It
has become apparent however, that endotoxin is not always present in
serum of patients with Gram-negative septicaemia, and that conditions
other than sepsis may result in endotoxaemia (Jorgenson, 1986). Thus
a positive Limulus test is not useful in guiding the selection of
antibiotic therapy since it does not predict the presence of Gram-
negative sepsis or the absence of Gram-positive or fungal sepsis
(Danner et al, 1991). The absence of endotoxaemia in septicaemic cases
may be due to its rapid clearance from the circulation (Thomas et al,
1984; van Deventer et al, 1988b); the sequestration of endotoxin at
local sites of infection, or that toxins other than endotoxin may be
wholly or partially responsible for producing the septic shock syndrome
in some patients (Danner et al, 1991).
Currently, the most promising use of the LAL assay in septicaemia is a
guide to prognosis. Danner et al (1991) established that qualitatively,
the presence of endotoxaemia was associated with severe septic shock
and organ injury. The same study also determined a connection between
patients with positive blood culture and endotoxaemia with high
mortality. The LAL assay has also been valuable in highlighting the
important role of endotoxaemia originating from the gut in the clinical
manifestations of liver and gastrointestinal diseases and massive
trauma (Tamakuma et al, 1971; Nolan, 1975; 1990).
1.4 EPIDEMIOLOGY
A number of underlying reasons account for the high and increasing
incidence of septicaemia. Perhaps one of the most important groups of
predisposing conditions is the use of invasive medical procedures.
Surgical manipulation can cause septicaemia or endotoxaemia as a
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consequence of contamination and infection of wounds and exposed
surfaces from environmental or endogenous sources (Freeman & Gould,
1985; Nagachinta et al, 1987; Rocke et al, 1987). The manipulation of
the gastrointestinal tract, a rich source of Gram-negative organisms
and endotoxin is of particular risk. Two frequently recorded foci of
infection in hospital acquired septicaemia include the urinary tract
and intravascular access sites, usually from catheterization or
instrumentation (Eykyn et al, 1990). These urinary tract associated
septicaemias are commonly attributed to E. coli, whilst the primary
focus for staphylococci is infected intravenous access sites. Despite
the frequency of E. coli bacteraemia, the organism has been reported
absent from infected intravenous lines (Eykyn et al, 1990; Gransden et
al, 1990). An observed increase in the prevalence of coagulase
negative staphylococci, S. aureus, and enterococci by Neu et al (1990)
was attributable to greater use of indwelling lines, and to better
practices in preventing E. coli related urinary tract infections by
attention to urinary catheters.
Underlying state of health is a well recognized influence on the
outcome of Gram-negative bacteraemia (Bryant et al, 1971; Kreger et al,
1980a). Diseases such as cancer, renal failure, congestive heart
failure, and diabetes mellitus are all related to an increase of septic
shock. An impaired liver function is also related to the development
of septicaemia or endotoxaemia (Triger et al, 1978; Gaeta et al, 1982;
Lumsden et al, 1988). Normally, LPS enters the liver continually from
the gut and is removed by the liver hepatocytes preventing both the
entry and persistence in the circulation (Fox et al, 1990). A
decreased removal of LPS by hepatocytes correlates with a lower
survival rate from septicaemia (Jacob et al, 1977; Katz et al, 1984).
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Immunosuppression induced by cancer treatments or transplantation
regimens also increases the risk of septicaemia (Dipiro, 1990), as well
as immunodeficient patients with diseases such as neutropenia (Minah et
al, 1986) and acquired immune deficiency syndrome (AIDS) (Eng et al,
1987; Sperber & Schleupner, 1987). Severe burns or multiple trauma
also result in a lowering of the immune status allowing colonisation of
wounds by organisms such as Pseudomonas species (Mason et al, 1986;
Deitch et al, 1987; Winchurch et al, 1987). Further high risk groups
include neonates and the elderly, their lowered immune status succumb¬
ing to septicaemia and meningitis caused by enterobacteria (Eykyn et
al, 1990).
McCabe & Jackson (1962) proposed a classification system for determin¬
ing the risk of mortality for Gram-negative bacteraemia according to
the severity of the underlying disease. The first category was
associated with rapidly fatal disease such as acute leukaemia, whilst
the second category represented patients whose disease was ultimately
fatal, but whose lives were not in immediate danger, for example,
patients undergoing chemotherapy or surgery for gastrointestinal
carcinomas. The third category included patients with non-fatal
diseases such as diabetes and other chronic illnesses which predisposed
them to infection. More recently, Gate11 et al (1988) devised a scheme
in which the variable associated with the highest risk of mortality
among patients with hospital acquired (also termed nosocomial) Gram-
negative bacteraemia, was shock.
Despite the prevalence of nosocomial septicaemic episodes, a signifi¬
cant number are acquired within the community. Community acquired
septicaemias arise spontaneously, often in previously healthy people,
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whereas nosocomial infections are largely the result of medical
intervention (Eykyn et al, 1990). In most reported studies the
organisms of E. coli, S. pneumoniae and S. aureus usually predominate
community acquired septicaemias, whilst enterobacteria other than E.
coli and P. aeruginosa are usually more common in nosocomial infections
(Ispahani et al, 1987; Eykyn et al, 1990; Neu et al, 1990). Many
result from infections at a local site, such as pneumococcal pneumonia
or acute pyelonephritis, or invasion of the blood, often from an
undetected site as in staphylococcal osteomyelitis or endocarditis.
1.5 CLINICAL FEATURES
Endotoxin triggers many of the adverse systemic reactions and serious
sequelae in patients with septicaemia and septic shock. The clinical
presentation is dynamic and variable depending on the severity of the
underlying illness, the duration of shock and its aetiology (Easmon,
1990). Clinically, two haemodynamic phases are recognized, although
these are not always distinct entities (Dipiro, 1990). The hyper¬
dynamic state, also referred to as early or warm shock, is character¬
ized by elevated temperature and increased respiratory rate and cardiac
output. Near normal blood pressure is maintained, despite low systemic
vascular resistance. Unsuccessful treatment at this stage is followed
by progression to the hypodynamic state, termed late or cold shock.
This state is associated with decreasing blood pressure and reduced
cardiac output, with decreased tissue perfusion, high systemic vascular
resistance and general organ dysfunction. Ultimately, death results
from single or multiple organ failure if the process is not reversible
(Parrillo et al, 1990).
Bone et al (1989) proposed the following criteria for defining the
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sepsis syndrome: temperature above 38.3°C or below 35.6°C; heart rate
above 90 beats per minute; respiratory rate greater than 20 breaths per
minute; evidence of infection at any site, and signs of inadequate
organ function and perfusion. These criteria are useful in identifying
patients before progression to the later stages of septic shock, and
were among those used by Ziegler et al (1991) for the selection of
patients for the clinical trial of an anti-endotoxin antibody.
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CHAPTER 2
THE GRAM-NEGATIVE CELL ENVELOPE
The cell envelope of Gram-negative bacteria is morphologically more
complex than Gram-positive bacteria (Hammond et al, 1984). Maintaining
both rigidity and shape on the bacterial cell, it also acts as a
barrier through which a bacterium interacts with its environment
(Costerton et al, 1974; Brown & Williams, 1985). Indeed, the envelope
phenotype expressed by a bacterium is a product of its growth environ¬
ment (Williams, 1988).
The Gram-negative cell envelope (Figure 1) consists of an innermost
cytoplasmic membrane, the peptidoglycan layer, the periplasm and the
outer membrane. Additional surface structures often present on Gram-
negative bacteria include fimbriae, flagella and discrete exopoly-
saccharide capsules or loosely attached slime layers, (Sutherland,
1977; 1985) sometimes referred to as glycocalyces (Costerton, 1984).
2.1 STRUCTURE AND COMPOSITION OF THE OUTER MEMBRANE
The outer membrane of Gram-negative bacteria represents a unique planar
lipid bilayer structure composed of three major components; LPS,
protein and phospholipid (Costerton et al, 1974; Hammond et al, 1984;
Nikaido & Vaara, 1985). Phospholipids, occupying the inner face of the
bilayer, interact hydrophobically with the lipid component of LPS which
forms the majority of the outer face. LPS, representing more than 50%
of the weight of extracted outer membrane (Costerton et al, 1974),
makes an important contribution to the assembly and maintenance of the








Figure 1. The cell envelope of a Grai-negative bacteriui.
LP = lipoprotein; LPS = 1ipopolysaccharide; P = protein; PL = phospholipid. (Fro» Hancock & Poxton,
1988).
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efficient diffusion of nutrients (Hancock, 1984; Nikaido & Vaara,
1985). Zorzopulos et al (1989) proposed that LPS is organised in a
network of particles which serves as the skeleton of the outer membrane
where the net holes are filled with phospholipids and protein. Its
central role in the pathogenicity and antigenicity of Gram-negative
bacteria is also acknowledged (Wicken & Knox, 1980; Jann & Jann, 1985).
The outer membrane also possesses protein components including
lipoproteins, which play an important role in maintaining the structure
and stability of the outer membrane, and major and minor outer membrane
proteins, many of which perform specialized functions (Williams, 1988).
Flagella and fimbriae are other proteinaceous appendages exposed at the
surface of some Gram-negative bacteria, conferring the functions of
motility and attachment respectively.
2.2 LIPOPOLYSACCHARIDE
Lipopolysaccharides are unique, complex amphipathic macromolecules
situated in the outer membrane of the cell envelope of Gram-negative
bacteria (Mlihlrhdt & Golecki, 1975; Funahara & Nikaido, 1980).
Although sharing the same general composition, LPSs show distinct
heterogeneity in size within a bacterium (Munford et al, 1980). LPS is
composed of three genetically, biochemically and antigenically distinct
regions linked covalently together (Figure 2), (Wilkinson 1977;
Liideritz et al, 1982). The hydrophobic lipid A region of LPS is a
phosphorylated and extensively acylated glucosamine disaccharide
embedded in a continuum of proteins and phospholipids of the outer
membrane. Extending outwards from lipid A is the common oligo¬
saccharide core region. In smooth strains, a longer carbohydrate
polymer, the O-polysaccharide side chain extends outwards from the core





Figure 2. Scheaatic representation of a saooth lipopolysaccharide, showing the principal structural
coiponents.
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core and lipid A regions are relatively conserved compared with the
extreme structural variability observed among LPS O-side chains of
different Gram-negative bacteria. LPS carries a net negative charge
resulting in the strong negative surface charge of Gram-negative cells
(Sherbert & Lakshmi, 1973).
Lipid A
The lipid A moiety of LPS has the same fundamental structural elements
in all Gram-negative bacteria (Brade et al, 1988). These consist of a
bis-phosphorylated p-1, 6-linked D-glucosamine disaccharide substituted
with six or seven saturated fatty acids (Westphal et al, 1983; Nikaido
& Vaara, 1985). The fatty acids, usually hydrophobic (R)-3~hydroxy-
myristic acid, substitute 2, 2', 3 and 3' positions of the glucosamine
disaccharide in amide and ester linkages respectively (Brade et al,
1988). The chemical structures of lipid A from E. coli and Salmonella
minnesota are shown in Figure 3 (Rietschel et al, 1984a). In E. coli
lipid A, the acyl residues of the non-reducing glucosamine at positions
2' and 3' are esterified with lauric and myristic acid respectively.
These acyloxyacyl residues are typical structural markers of LPS (Brade
et al, 1988). The genus Salmonella contains the same elements as lipid
A of E. coli, but carries additional substituents (Wollenweber et al,
1982; Galanos et al, 1986). This lipid A carries phosphoryl-
ethanolamine on the CI phosphate and 4-deoxy-4-amino-L-arabinopyranose
on the C4' phosphate of the hydrophilic backbone, and the amide-linked
3-hydroxymyristic acid of the reducing glucosamine is substituted with
palmitic acid, forming a third acyloxyacyl residue. Comparative
studies of lipid A from many genera of Enterobacteriaceae have shown
that the lipid A structure appears to be closely related but not




Figure 3. Cheiical structure of the E. coli-iype lipid A (a) and the Sahonella-type lipid A (b).
The nuibers in circles show the nuiber of carbon atois in acyl chains. (Rietschel et al, 1984).
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structures concern: the number of carbon atoms in the hydrocarbon
chains; the type and distribution of acyloxyacyl residues, and the
additional substitution of phosphoryl residues (Brade et al, 1988).
The high degree of structural conservation shown between genera makes
lipid A the least variable component of LPS (Drewry et al, 1973;
Westphal et al, 1983; Galanos et al, 1984). It is now well established
that lipid A represents the endotoxic principle of LPS, being respon¬
sible for its pathophysiological effects (Galanos et al, 1985a;
Rietschel et al, 1987; Brade et al, 1988). The term endotoxin,
synonymous with LPS, was introduced in the 19th century to describe the
component of Gram-negative bacteria responsible for the patho-physio-
logical phenomena associated with Gram-negative infections (Rietschel
et al, 1984b; Suffredini et al, 1989). A number of structural
constituents required for the full expression of endotoxicity of lipid
A have been identified (Galanos et al, 1984; Homma et al, 1985;
Matsuura et al, 1985; Brade et al, 1987a). Small changes in the
structure of lipid A (native or synthetic) can lead to a marked
reduction in toxicity (Proctor et al, 1986; Kiener et al, 1988).
Core oligosaccharides
The core region consists of a hetero-oligosaccharide divided into inner
and outer subdomains. Structural analysis of the core oligosaccharides
has been achieved through studies of a number of rough mutant strains
from various organisms (0rskov et al, 1977; Westphal et al, 1983; Brade
et al, 1988). Rough (R)-form variants, so called because of their
colony morphology, represent bacteria lacking the O-side chain and
possibly parts of the core oligosaccharide as a result of biosynthetic
defects. Based on the sugar composition of the LPS isolated from
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various sub-mutants of R-form bacteria with incomplete core oligo¬
saccharides it is possible to construct a classification of LPS
submutants, termed chemotypes.
The chemotypes for R-submutant LPS of the Salmonella core-glycolipid
(CGL) are shown in Figure 4. The Ra mutant represents the full core
oligosaccharide with each subsequent mutant possessing progressively
shorter oligosaccharides substituted onto lipid A. The Re chemotype is
the smallest naturally occurring LPS mutant, possessing only the lipid
A and 3-deoxy-D-manno-2-octulosonate (KDO).
The inner core exhibits a high degree of structural conservation among
all Enterobacteriaciae (Eskenazy et al, 1977; Jansson et al, 1981;
Perez-Perez et al, 1986). It is composed of two unusual sugars,
heptose (mainly in the L-glycero-D-manno- and the D-glycero-D-manno-
configuration) and KDO which links the core polysaccharide to lipid A
via an acid labile bond (Wicken & Knox, 1980). In addition, charged
residues such as phosphate and ethanolamine are common constituents of
the inner core (Brade et al, 1988).
The KDO region of the LPS appears to be indispensable, since mutants
defective in the biosynthesis of the inner core region have never been
isolated (Hammond et al, 1984). The structural elucidation of the KDO
region could not be approached for a long time due to difficulties with
the chemistry of KDO (Brade et al, 1988), leading to controversy in its
structure. Liideritz et al (1966) proposed one KDO residue for the main
sugar chain, whilst Prehm et al (1975) later reported two KDO residues
in the main chain. The substitution of the inner KDO residue (next to
lipid A) by a third KDO residue was later described by Jansson et al
18





Figure 4. Rough Lipopolysaccharide Cheiotypes of Sahoaella.
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(1981). Finally, it is now thought that Re mutants (lipid A and KDO
alone) contain two KDO molecules in the a pyranoid ring form and 2-4
interlinked, hence only one KDO residue in the main sugar chain. In
mutants other than Re, the reducing KDO (KDO I) is substituted at
position 5 by a heptose and in position 4 of the terminal KDO by a
third KDO in a pyranosidic linkage (KDO III), (Brade & Rietschel, 1984;
Brade et al, 1985; 1986; 1987b; 1988). However, substitution with the
third KDO is often not present in stoichiometric amounts (Brade et al,
1988). Indeed, although the third KDO, the third heptose and several
phosphorylated substituents are thought to exist, the techniques used
to show their presence are indirect and subject to analytical artefacts
(Tacken et al, 1986; Raetz, 1990).
The outer core contains the frequently occurring hexoses, D-glucose, D-
galactose, and N-acetyl-D-glucosamine in different proportions and
sequential arrangements, accounting for the main differences between
the known core types (Figure 5) (Schmidt et al, 1970; Jansson et al,
1981; LUderitz et al, 1982; Westphal et al, 1983; Perez-Perez et al,
1986; Barclay, 1990). The linkage of the outer core to the O-side
chain is another variable between LPS (Jansson et al, 1981). Although
most of the structural variations in the core occurs in the outer
region, these are low compared to that of the O-side chain. Thus, in
Salmonella species only one core type exists and in E. coli only five
core types have been described (Hammerling et al, 1971; Prehm et al,
1976; Feige et al, 1977; Jansson et al, 1981; Westphal et al; 1983;
Brade et al, 1988).
The core of P. aeruginosa differs significantly from other described
LPSs (Day & Marceau-Day, 1982). In contrast to entero- bacterial LPS
20
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Figure 5, Lipopolysaccharide core oligosaccharides.
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which contains about four phosphate residues in the inner core region
and an additional two or three in the lipid A, LPSs from P. aeruginosa
may contain ten or more residues per molecule (Kropinski et al, 1979;
Wilkinson, 1983; Kropinski et al, 1985). The outer core of P.
aeruginosa typically contains D-glucose and D-galactosamine with the
addition of L-rhamnose and alanine (Wilkinson, 1983).
It has been proposed that rough mutant bacteria or their LPS induce
specific core or R antibodies since, as for O-polysaccharides, the
terminal sugar residues represent the immunodominant sugar (Brade et
al, 1988). However, in the host, natural exposure will only occur to
the complete unsubstituted core LPS (Ra chemotype) and core LPS
substituted with O-polysaccharide (smooth bacteria) (Barclay, 1990).
0-side chains
The 0-side chain component of LPS is a polysaccharide chain consisting
of repeating oligosaccharide subunits which extend outwards from the
cell surface in an irregular spiral shape. The side chains of most
enteric bacteria consist of a variable number of repeating tri-
pentasaccharides which can range from one to as many as forty units
(Williams, 1988). Such heterogeneity in the chain length of the 0-
specific polysaccharide can be demonstrated with the aid of sodium-
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). This
allows LPS molecules differing by one 0-antigen repeat to be separated
from each other (Goldman & Leive, 1980; Palva & Makela, 1980) permit¬
ting estimation of the extent of 0-antigen polymerization.
The number of repeating units can show considerable variation under
different physiological conditions (Chester & Meadow, 1975; McGroarty
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& Rivera, 1990). Such variation provides the bacterium with a means to
modify its surface properties and thereby its interaction with various
agents in the environment (Nikaido & Nakae, 1979; Munford et al, 1980;
Taylor, 1983).
Most repeating units are hetero-oligosaccharides, usually containing
short chain branches, although homo-oligosaccharides in the linear
chain formation have been shown to exist, including E. coli 08 and 09
(identical with those of Klebsiella 05 and 03 respectively) containing
2- and 3- linked mannose residues (Westphal et al, 1983; Jann & Jann,
1987). Salmonella typhimurium possesses a tetrasaccharide repeating
unit containing the 2-deoxy-hexoses (rhamnose & abequose) and the
hexoses galactose and mannose (Hammond et al, 1984). The 0-side chains
of many other salmonellae also contain galactose, mannose and rhamnose
often in an identical sequence, although their linkage may be either
the a or p configuration. In contrast to Salmonella and Klebsiella,
which produce only neutral O-specific polysaccharides, E. coli can also
express acidic O-specific polysaccharides (Jann & Jann, 1987). In most
LPS the acidic constituents are hexuronic acids, whilst the specific
neutral polysaccharide of E. coli often contain unusual amino sugars
and rhamnose.
Variation in both the composition and combinations of sugars in the
repeat unit, together with differences in the position and anoraeric
configuration of their glycosidic linkages, creates immense structural
diversity per unit structure of the 0-side chain (Barclay, 1990). Such
variability within this component of LPS is reflected in the ability to
classify strains of Gram-negative organisms by their 0-antigen,
resulting in a number of distinct O-serotypes. There are over 160
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serotypes in E. coli, over 60 types in Salmonella. Liu et al (1983)
proposed a scheme comprising 17 0-types for P. aeruginosa, although
three new major somatic antigens have recently been described (Liu &
Wang, 1990). The many modifications of O-antigens may help Gram-
negative bacteria to evade the immune system (Raetz, 1990) and their
presence has also been associated with resistance to serum complement
and virulence in many species of Gram-negative bacteria including E.
coli, Salmonella, Shigella (Taylor, 1983; Cross et al, 1986) and
Klebsiella (Williams et al, 1983; Tomas et al, 1986).
It has been demonstrated that the 0-antigen of different E. coli
serotypes show serological cross-reactivity indicating recognition of
similar epitopes in the different O-polysaccharide antigens (0rskov et
al, 1977; Pluschke et al, 1986). The commonest serogroups of E. coli
in septicaemic patients include 01, 02, 04, 06, 015, 018 (Eykyn et al,
1990; Gransden et al, 1990). E. coli 018, frequently associated with
neonatal infections contains several serologically related but not
identical O-antigens, including 018 ab and 018 ac. The most abundant
018 antigen of invasive E. coli is the 018 ac antigen (Gupta et al,
1984).
Compared to P. aeruginosa the overall capping frequency of entero¬
bacterial LPS (ie the percentage of core LPS constituents covered with
0-antigen) is high, leaving a lower percentage of core determinants
exposed at the cell surface (Kropinski et al, 1985). The percentage of
smooth type molecules in P. aeruginosa LPS has been reported at 8%
(Rivera et al, 1988) compared to 35% and 65% in S. typhimurium and E.
coli respectively (Goldman & Leive, 1980; Palva & Makela, 1980). The
LPS of other pathogenic bacteria, such as Neisseria gonorrhoeae and
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Haemophilus influenzae, which do not contain any O-antigen is often
termed lipooligosaccharide (LOS).
2.3 BIOSYNTHESIS OF LIPOPOLYSACCHARIDE
Advances in the determination of the mechanisms involved in the
synthesis of LPS have been greatly facilitated by the isolation of the
biosynthetic mutants blocked at various points of the assembly
sequence, and by the use of specific inhibitors (Hammond et al, 1984).
The mechanisms involved in the synthesis of the lipid A, core and 0-
side chain have been determined at both biochemical and genetic levels
(Osborn et al, 1972; 0rskov et al, 1977; Ishiguro et al, 1986;
Brahmbhatt et al, 1988).
Since very few mutants defective in lipid A have been described,
knowledge of the assembly sequence of the lipid A-KDO region is
incomplete. An important precursor in the biosynthesis of lipid A is
a diacylated glucosamine-l-phosphate, termed lipid X which accumulates
to high levels in some phosphatidylglycerol-deficient mutants of E.
coli (Nishijima et al, 1981; Nishijima & Raetz, 1981). Ray et al
(1984) demonstrated that by incubating 1 mM lipid X and 1 mM UDP-2, 3-
diacyl-GlcN with a crude cytosolic fraction of E. coli a new product
was formed with the characteristic p, 1-6 linkage of lipid A. The
identification of the high energy donor UDP-2, 3-diacyl-GlcN as a
natural product in living cells supported the evidence that lipid X was
a precursor of lipid A. KDO on the other hand is activated to CMP-KDO,
a sugar nucleotide that serves as the precursor of the KDO domain of
LPS. Incorporation of KDO into the lipid A precursor precedes the
incorporation of ester-linked straight chain fatty acids (Rick et al,
1977; Rick & Osborn, 1977). Although a full understanding of the
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biosynthetic pathway of lipid A is still incomplete, further informa¬
tion is being generated as the structural requirement for toxicity and
immunogenicity become clearer (Anderson et al, 1985; Coleman & Raetz,
1988; Brozek et al, 1989; Galloway & Raetz, 1990).
The R-core is sequentially assembled at the cell membrane by the
transfer of sugars, phosphate and ethanolamine to the lipid A-KDO
moiety. The mechanism by which the heptose units are added to the
fully acylated lipid A-KDO is obscure (Hammond et al, 1984). The
hexoses of the outer core are added, one residue at a time from UDP
derivatives which function as activated sugar donors (Osborn, 1969;
Rothfield & Romeo, 1971). The glycosyl transferases that generate the
outer core are peripheral membrane proteins requiring
phosphatidylethanolamine for activity (Osborn, 1969; Rothfield & Romeo,
1971; Hinckley et al, 1972; Raetz, 1990).
The O-side chain is synthesized independently of lipid A and core by a
series of cytoplasmic membrane bound enzymes (Jann & Jann, 1984). Its
repeating oligosaccharide unit is synthesized on a 55-carbon isoprenoid
carrier lipid (Osborn, 1969; Rothfield & Romeo, 1971). An important
feature of 0-antigen polymerization is that the newly generated
tetrasaccharide repeat is incorporated at the reducing end of the
growing chain (Raetz, 1990). Finally, an LPS ligase transfers 0-
antigen to the outer core independent of the length of the O-side
chain.
The mechanisms involved in the translocation and subsequent introduc¬
tion of a molecule as complex LPS into the outer membrane is still open
to debate, although is thought to occur through adhesions between the
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two membranes (Hammond et al, 1984; Raetz, 1990).
2.4 PROTEINS OF THE OUTER MEMBRANE
Of the three major classes of protein found in the outer membrane,
lipoproteins are the most abundant, accounting for approximately six
per cent of total cell protein (Hammond et al, 1984). Lipoproteins
play an important role in anchoring the outer membrane to the cell
wall, and in maintaining the structure and stability of the outer
membrane (Brass, 1986).
The term major outer membrane protein, refers to components present in
sufficient quantity to be readily detected by simple staining of
polyacrylamide gels. These include the pore proteins termed porins (in
E. coli K12, Omp F and Omp C; in S. typhimurium LT2, Omp F, Omp C, and
Omp D proteins) and Omp A proteins. The porins form relatively non¬
specific, water-filled pores spanning the outer membrane for the
passive entry by low molecular weight hydrophilic solutes present at
relatively high concentrations (around 106 M) (Nikaido & Nakae, 1979;
Nikaido & Vaara, 1985; Nakae, 1986). The porins also serve as
receptors for bacteriocins and bacteriophages (Lugtenberg & Van Alphen,
1983). The Omp A protein is associated with lipoprotein and plays a
role in conjugation and the stability of the outer membrane (Vaara &
Nikaido, 1984).
Some of the minor outer membrane proteins are constitutive but many are
inducible or derepressible and may, under appropriate environmental
conditions, reach levels with those of the major proteins. Many of the
minor proteins facilitate specific diffusion processes of solutes which
are too large to pass through the porins and which are present in low
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concentrations (down to 10 M). The process involves the binding of
substrate or a substrate chelator complex to these outer membrane
receptor proteins (Brass, 1986; Williams, 1988). An important example
of this is the uptake of ferric ions chelated to low molecular weight
iron chelating compounds (siderophores) via specific inducible outer
membrane receptor proteins (Neilands, 1981; 1982). This process plays
an integral role towards a bacterium's ability to multiply in host
tissues during infection.
2.5 EXOPOLYSACCHABIDE
Gram-negative bacteria growing in the natural environment or pathogens
causing bacteraemia, meningitis and urinary tract infections are
usually extensively covered by discrete exopolysaccharide capsules or
loosely attached slime layers (Williams, 1988). Capsules have evolved
distinctive structural and functional characteristics which are of
cardinal importance in the pathogenesis of infections such as
septicaemia. These include the protection of most organisms against
the non-specific host defence which is exerted in the preimmune phase
of infection by serum complement and phagocytes as described in Section
4.2.
Capsules are glycoconjugates composed primarily of monosaccharides
forming linear homopolymers of a single sugar, linear copolymers
composed of two or more monosaccharides, or multi-chained branched
polymers composed of at least five monosaccharides (Robbins, 1978;
Jennings, 1983; Silver & Vimr, 1990). Many capsules are acidic due to
the possession of carboxyl groups, either from acidic sugars such as
uronic acids or neuramic acid, or from non-sugar substituents such as
pyruvyl, acetyl and formyl groups (Poxton & Arbuthnott, 1990).
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The typing of capsules is largely based upon serological analysis of
the capsular antigen which has demonstrated the wide variety of
antigenic types produced by different strains of the same species
(Hammond et al, 1984). Serological studies on E. coli (Kauffmann &
Vahlne, 1945; 0rskov et al, 1977) demonstrated additional surface
antigens covering the cell wall O-antigens which were assumed to be
present in an extracellular envelope or capsule. They were termed K
antigens ("Kapselantigene"). A limited number of acidic K antigens
predominate among invasive E. coli (0rskov et al, 1977). Kl, K2, K3,
K5, K12 and K13 antigens accounting for the majority of all E. coli
isolates from the upper urinary tract (Kaijser et al, 1977) and Kl
comprising almost all of isolates from neonatal septicaemia (Schiffer
et al, 1976).
The capsular antigens of E. coli are acidic polysaccharides which can
be divided into two groups on the basis of chemical, physical and
microbiological characteristics. The high molecular weight
polysaccharides of group I have a relatively low charge density/low
electrophoretic mobility, contain hexuronic acids as the acidic
component, and are co-expressed essentially with only the 08 and 09
antigens at all growth temperatures (Jann & Jann, 1987). Structural
and serological studies have revealed that these polysaccharides may
occur on the E. coli surface as either a group I capsular
polysaccharide or as an acidic LPS, forming the cell wall 0-antigen
(0rskov et al, 1977; Jann & Jann, 1983; 1984). Capsules of Klebsiella
share many properties with the polysaccharides of this group, indicat¬
ing an inter-generic relationship similar to that described with the
respective O-antigens (Jann <& Jann, 1990).
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Whilst group I capsular polysaccharides are a relatively homogeneous
group, the capsular polysaccharides of group II, which are present on
most of the strains causing extraintestinal infections, show great
variations in composition and general structural features. The
majority are heteropolysaccharides containing more unusual acidic
compounds such as KDO, N-acetylneuraminic acid (NeuNAc), N-
acetylmannosaminuronic acid (ManNAcUA) or phosphate (Jann & Jann,
1987). Of the several capsular polysaccharides containing Neu NAc, two
are homopolysaccharides, differing only in linkage position. These Neu
NAc polymers, termed sialic acids, occur as the capsule of E. coli K1
(Dewitt & Rowe, 1961) and Neisseria meningitidis b (Rasper et al,
1973), both highly virulent organisms. The virulence of K1 E. coli is
thought to be based on the ability of the K1 capsule to mask underlying
structures on the bacterial cell that activate the antibody independent
alternative complement pathway (Horwitz & Silverstein, 1980), and its
poor immunogenicity (Cross, 1990) (see Section A.2).
Infections due to K1 capsulate E. coli produce significant morbidity
and mortality especially in neonates (McCracken & Mize, 1976; Cross et
al, 1984). The K1 capsule associates with only a relatively few
serotypes. Four 0-antigens (07, 016, 018 and 083) account for the
majority of K1 strains isolated from infected neonates (Cheasty et al,
1977; Korhonen et al, 1985), whilst Cross et al, (1984) established
that a large proportion of K1 positive E. coli isolated from blood and
cerebral spinal fluid were associated with the O-antigens of 01, 02,
012, 016 and 018ac. This association of specific capsules with only a
limited number of O-serogroups is believed to be evidence of the
existence of bacterial clones of common origin (0rskov et al, 1976;
1990). It has been proposed that many of these clones survived because
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of unique functional relationships between capsules, LPS and possibly
other determinants in that clone, allowing the bacterial clone to
compete and survive (Cross, 1990). The K1 antigen has been found to
undergo phase variation of O-acetylation of sialosyl residues, covalent
modifications which may undergo transition between acetylated and
unacetylated states (0rskov et al, 1979).
The mode of attachment of capsule to the cell surface is still largely
unanswered. However, the relatively recent finding of a lipid on the
reducing end of some E. coli capsular polysaccharide was thought to
suggest that they associate with the outer membrane through hydrophobic
interactions. It is thought that group I polysaccharides are bound to
core-lipid A, whilst the lipid end of group II capsular polysaccharides
was identified as a phosphatidic acid bound in a very labile linkage
(Jann & Jann 1987; 1990). In all group II polysaccharides which
contain KDO in their repeating unit, KDO is the reducing sugar (Schmidt
& Jann, 1982) whilst NeuNAc is the reducing end for the polysialyl
antigens of, for example, E. coli K1 (Gotschlich et al, 1981). Since
not all group II polysaccharides are lipid substituted Jann & Jann
(1990) proposed that the lipid-substituted polysaccharide fraction is
anchored in the bacterial outer membrane by hydrophobic interactions,
and the unsubstituted polysaccharide is retained by ionic and other
interactions.
2.6 FIMBRIAE
Fimbriae (pili) of Gram-negative bacteria are broadly classed as
mannose sensitive (MS), or mannose resistant (MR), depending upon
whether or not the adhesion is inhibited by D-mannose. Fimbriation is
a reversible trait most likely determined by chromosomal genes and
31
present up to 1,000 per bacterium (Hammond et al, 1984).
Fimbriae may assist in the attachment of organisms to and invasion of
various cell surfaces, an essential part of the establishment of many
bacterial infections. Work by Saukonen et al (1988) determined that
fimbriae aided the adherence of cells to vascular endothelium during
invasive infections, particularly septicaemia, therefore preventing the
removal of bacteria by phagocytosis. This could progress to local
tissue damage, and the release of mediators from the endothelial tissue
and the cellular immune system as part of the septic syndrome (Steadman
et al, 1988).
2.7 FLAGELLA
Flagella are protein, filamentous cell surface appendages responsible
for the mobility and chemotaxis of many bacteria (Doetsch & Sjoblad,
1980). Despite having key roles to play in some invasive infections,




ENVIRONMENTAL MODULATION OF THE GRAM-NEGATIVE CELL ENVELOPE
3.1 PLASTICITY OF THE BACTERIAL CELL ENVELOPE
The ability of an invading bacterium to adapt rapidly to the host
environment is widely recognized as a key determinant of virulence and
pathogenicity (Smith, 1990). The cell envelope of pathogenic bacteria
plays a pivotal role in this adaptive process, since it is involved in
promoting adhesion and colonization of host tissues, in the acquisition
of essential nutrients and in conferring resistance to host defences
and to antibiotics (Brown & Williams, 1985). Many environmental
variables, in particular, nutrient deprivation, growth rate, growth
temperature, and replication with,xa surface associated biofilm all
exert a marked effect in vivo upon the macroraolecular structure and
function of the cell envelope (Williams, 1988). It is this remarkable
plasticity of the bacterial cell envelope which confers a distinct
survival advantage to the organism as it moves from one environmental
niche to another within the host.
Cell envelope properties are ultimately determined by information
contained within the genome which also has the capacity to respond to
environmental changes (Harder & Dijkhuizen, 1983). This may occur in
principle by changes in genetic constitution, phase variation or
phenotypic adaptation. However, bacteria only express that part of
their genome enabling them to adapt functionally and structurally to
their immediate environment, and a wide variety of phenotypic responses
may be encountered within a specific genotype (Harder & Dijkhuizen,
1983; Williams, 1988; Miller et al, 1989). Phenotypic adaptation is
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characterized by a change in expression of one or more genes in
response to an environmental stimulus, without any alterations to the
DNA coding sequence (Clark, 1990). Although there are many examples of
environmental regulation of various gene products, it is only relative¬
ly recently that attention has focused on the identification and
characterization of the regulatory mechanisms associated with the
expression of virulence factors in the host environment (Finlay &
Falkow, 1989). Some pathogens, have been demonstrated to regulate the
production of various virulence determinants by common mechanisms which
are influenced by environmental factors (Betley et al, 1986; Miller et
al, 1989). The induction or repression of diverse and unlinked genes
are known to be co-ordinated by environmentally controlled global
regulatory networks (Gottesman, 1984), and appears to involve DNA
supercoiling and protein phosphorylation (Dorman et al, 1988; Bhriain
et al, 1989; Bourret et al, 1989).
The knowledge of the molecular mechanisms governing global regulation
of pathogenicity is integral to the understanding of bacterial
infectious processes (Miller et al, 1989). The virulence determinants
of Bordetella pertussis are all regulated by a single genetic locus,
vir, which is negatively regulated by temperatures of <37°C and
increased levels of nicotinic acid and MgSO^ (Weiss et al, 1983; Weiss
& Hewlett, 1986). Products of this locus function as a positive
inducer of many virulence genes, including those which encode filament-
cws haemagglutin , pertussis toxin, adenylate cyclase,
haemolysin, fimbria subunits, and dermonecrotic factors. This
regulatory mechanism is related to several two-component bacterial
regulatory systems which transcriptionally regulate several genes
(Finlay & Falkow, 1989). These systems similarly respond to environ-
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mental stimuli and control, for example, chemotaxis, phosphate
response, and osmotic response in E. coli and sporulation in Bacillus
subtilis (Nixon et al, 1986; Ronson et al, 1987; Miller et al, 1989).
3.2 THE IN VIVO ENVIRONMENT - NUTRIENT DEPRIVATION
The ability of microorganisms to adjust both structurally and func¬
tionally to changes in their environment is particularly applicable to
their behaviour in response to the most common of environmental
constraints, that of nutrient deprivation (Harder & Dijkhuizen, 1983).
Essential nutrients or environmental factors which are most critical in
influencing particular pathogens in vivo are relatively unknown, and
unstudied (Smith, 1990).
The most notable exception to the lack of knowledge is the comprehen¬
sive work on iron limitation. Iron is a crucial nutrient for most
bacteria, and its availability is severely restricted within the host
(Brown & Williams, 1985; Griffiths, 1987). The form and abundance of
iron compounds varies significantly within the mammalian host, but free
iron is rarely available (Clark, 1990). Most iron is stored
intracellularly, predominantly as haem, but also as a component of non-
haem proteins, or stored as ferritin. Extracellulary, iron is
generally complexed to high-affinity iron-binding glycoproteins,
transferrin and lactoferrin, which have association constants for iron
of about 10 (Aisen & Leibman, 1972). Iron availability is further
limited during infection by inhibitory iron absorption in the
gastrointestinal tract, a phenomenon known as "hypoferraemia"
(Weinberg, 1984). This state is mediated by interleukin-1 (IL-1),
induced by the exposure to endotoxin (Kluger & Bullen, 1987). The
early release of lactoferrin by leukocytes during degranulation and
35
phagocytosis during infection also reduces iron availability (Leffell
& Spitznagel, 1975; Wright & Gallin, 1979) and may be mediated
indirectly by IL-1 and tumour necrosis factor (TNF) (Goldblum et al,
1987; Kluger & Bullen, 1987; Koivuranta-Vara et al, 1987). Lactoferrin
can remove iron from transferrin and the iron-bound lactoferrin is
rapidly cleared by the reticuloendothelial system. Indeed, the rapid
fall of total iron seen in E. coli endotoxaemic and septicaemic pigs
was explained by this release of lactoferrin and the removal of iron-
bound lactoferrin (Gutteberg et al, 1989).
The limited availability of iron within serum was illustrated early on
by Schade & Caroline (1946). They showed that serum inhibited the
growth of Shigella dysenteriae, and the inhibition was specifically
reversed by the addition of iron. In experimental animals, iron
restriction can also be overcome by injection of iron compounds
(Bullen, 1981). The ability of the host to respond to infection by
restricting the availability of an essential nutrient, has been termed
"nutritional immunity" (Kochan, 1977).
Lack of nutrients other than iron which are thought to influence the
pathogen include carbon (Smith, 1977), magnesium (Broughton et al,
1968; Davey et al, 1985), phosphate (Vasil et al, 1985) and zinc
(Weinberg, 1978). Materials probably not limiting in vivo may equally
affect the virulence determinants of pathogens. Indeed, recognition
that certain nutrients may not be growth limiting in vivo on occasion,
may direct more attention to non-limiting substrates (Smith, 1990). A
given set of growth conditions are also not necessarily universal
within a host.
36
3.3 ENVIRONMENTAL EFFECTS ON THE EXPRESSION OF VIRULENCE FACTORS
The complex and constantly changing in vivo environment of bacterial
pathogens influences bacterial pathogenicity by affecting growth and
the production of virulence determinants (Smith, 1990). Lack of
essential nutrients for bacteria results in marked changes in biochem¬
istry and in envelope structure, characteristic of the specific
nutrient and with corresponding changes in envelope-associated
properties (Brown & Williams, 1985). Growth rate per-se also signifi¬
cantly influences envelope structure and function, with evidence
indicating that doubling times in vivo are usually relatively long.
However, slow multiplication does not necessarily mean that limiting
nutritional conditions exist (Smith, 1990). Host defences may restrict
growth rate as well as remove or destroy the pathogen.
Pathogenic bacteria overcome iron-restriction by expressing high
affinity iron-uptake systems, usually based on low molecular weight
iron-che1ating agents (Williams, 1988). These siderophores are capable
of removing iron from transferrin and lactoferrin, and transporting it
to the bacterium via specific iron-regulated OM receptor proteins
(Neilands, 1981; 1982) (Section 2.4). Several new OM receptor proteins
are synthesized by Gram-negative bacteria under iron-restricted
conditions. E. coli recovered directly from the peritoneum of lethally
infected pigs (Griffiths, 1983), and a mucoid P. aeruginosa strain from
the lungs of a cystic fibrosis (CF) patient (Brown et al, 1984) have
both expressed these high affinity iron uptake systems. Other nutrient
limitation specific proteins have been obtained for the OM of K.
pneumoniae during potassium, carbon, phosphate and sulphate restricted
conditions (Robinson & Tempest, 1973; Sterkenburg et al, 1984; Lodge et
al, 1986).
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LPS structure can be altered phenotypically in response to different
environmental factors. Growth rate and nutrient deprivation have been
reported to influence the structure of LPS in E. coli (Dodds et al,
1987). P. aeruginosa from CF patients frequently possess non typable,
R-LPS (Hancock et al, 1983), which lacks the normal O-side chain that
protects Gram-negative bacteria from the bactericidal effect of human
serum. These observations suggest that in chronic bronchopulmonary
infection with P. aeruginosa in CF, the organism undergoes an
environmental adaptation, marked by changes in somatic antigens and
serum sensitivity (Penketh et al, 1983). McGroarty & Rivera (1990)
demonstrated the alteration of size heterogeneity of P. aeruginosa PA01
serotype LPS under near growth limiting conditions, allowing exposure
of common antigen LPS. The ability of an opportunistic pathogen like
P. aeruginosa to modify the LPS structure, perhaps under the influence
of environmental factors (Day & Marceau-Day, 1982), may give the
organism a survival advantage and help it persist within the lung.
Exopolysaccharide production is also influenced by nutrient limitation,
growth rate and growth temperature (0rskov et al, 1984; Nfikaido &
Vaara, 1985; van Verseveld et al, 1985). The possibility that
environmental factors within CF bronchial secretions might induce or
switch on the production of alginate and hence influence the emergence
of mucoid P. aeruginosa has been proposed. Contributory factors
include the presence of dipalmitoyl-phosphatidylcholine, the major lung
surfactant (Govan, 1975); increased osmolarity (Berry et al, 1988;
Govan, 1990); effects of individual cations (Boyce & Miller, 1982);
nutrient limitation (Speert et al, 1990; Terry et al, 1991); selection
of phage (Govan, 1975) and antimicrobial pressure (Govan & Fyfe, 1978;
Deretic et al, 1986).
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Phenotypically induced alterations in the microbial cell surface affect
the susceptibility of the bacterium to antimicrobial agents. In P.
aeruginosa, magnesium deficiency resulted in the induction of OM
protein HI, and associated with increased resistance to polymyxins,
aminoglycosides, and ethylenediaminetetraacetic acid (EDTA) (Nicas &
Hancock, 1980). HI has been suggested to replace magnesium at LPS
divalent cation cross-bridging sites in the OM, the proposed target
sites for these antimicrobials (Nicas & Hancock, 1980; Hancock, 1984).
The rate of antibiotic-induced killing has also been shown to decrease
in strict proportion to the decrease in the rate of bacterial growth
(Tuomanen et al, 1986). The mechanism(s) involved, though poorly
understood, probably include such contributory factors as OM permeabil¬
ity changes; total cell concentrations or affinities of penicillin-
binding proteins, and cell wall synthesizing enzymes.
In addition to direct inhibitory effects, antibiotics at sub-minimum
inhibitory concentrations (sub-MICs) can significantly influence the
sensitivity of a pathogen to host defences, sometimes as a result of
influencing envelope structure (Williams, 1988; Darveau & Cunningham,
1990). The formation or expression of 0-side chains and the acidic
capsular polysaccharide of E. coli is affected by growth of the
organism in mecillinam (Taylor et al, 1982). The reduction in the
envelope polysaccharide components was thought to play a role in the
conversion of serum-resistant E. coli to serum susceptibility.
Similarly, growth of K. pneumoniae in the presence of cephalosporins
reduced capsule production (Kadurugamuwa et al, 1985b) an effect which
may increase the susceptibility of an organism to phagocytosis.
Antibiotic induced alterations to LPS and other surface structures also
frequently correlate with an increase in microbial resistance to
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antibiotic therapy (Legakis et al, 1989; Pagani et al 1990).
Since the genetic basis for virulence is only expressed completely
during growth in vivo, bacteria grown in most in vitro conditions are
likely to be incomplete in terms of the full expression of their
virulence determinants (Williams, 1988). Thus, a greater understanding
of the pathogenesis of disease requires knowledge of the environment at
the site of infection, allowing the use of in vitro growth conditions




Pathogenicity has been defined as the ability of microorganisms to
produce disease in susceptible hosts (Smith, 1977). A microbial
pathogen is now recognized as a highly adapted microorganism that may
cause disease, since its survival depends on a requirement for infec¬
tion (Falkow, 1990). Since disease is an inadvertent and unfavourable
outcome of a microbial infection, the usual outcome is sufficient
multiplication by a pathogen to secure its establishment within the
host or to bring about its successful transmission to a new susceptible
host (Finlay & Falkow, 1989; Falkow, 1990). Not all pathogens however,
have an equal chance of causing infection and disease (Finlay & Falkow,
1989). At one end of the spectrum are septicaemias caused by organisms
of high virulence such as S. pneumoniae, N. meningitidis, H. influenzae
type b and E. coli type K1 which can cause disease in a proportion of
non-immune individuals with intact host defence systems (Easmon, 1990).
In contrast are the septicaemias involving many organisms of lower
virulence which can infect compromised individuals and cause disease
but spares those with intact host defences. Indeed, probably any
microorganism possessing the capacity to survive in humans will
occasionally cause disease in compromised individuals and behave as an
opportunistic pathogen (Finlay & Falkow, 1989).
Minimal requirements for pathogenicity are: 1) ability to enter the
host; 2) survive and multiply in the host; 3) resist or avoid host
defences; 4) cause damage to the host (Smith, 1977; Hammond et al,
1984; Falkow, 1990). Microbial factors responsible for these processes
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are the determinants of pathogenicity or virulence factors, and include
both cell-associated and extracellular products (Smith, 1977).
Although microbial pathogenesis is diverse and multifactorial, common
themes of microbial pathogenesis have evolved in distinct bacterial
species because of their need to overcome common host and environmental
barriers (Falkow, 1990).
The interaction of microbial factors with host mediation systems
results in a profound array of pathophysiological sequelae (Ryan, 1985)
as shown in the related clinical conditions of septicaemia and septic
shock. Although a number of virulence factors participate in the
pathogenic process, bacterial endotoxic LPS has been implicated as the
major contributory factor to the development of septic shock (Morrison
& Ryan, 1987).
4.1 COLONIZATION AND MULTIPLICATION
The sequence of events which may ultimately lead to septic shock begins
with the nidus of infection consisting of an abscess, peritonitis,
pneumonitis, cellulitis, or another focus (Parrillo et al, 1990). It
is the ability of bacteria to adhere to and colonize mucosal surfaces
which is often the first major stage in the development of infection
(Williams & Tomas, 1990). Some microorganisms multiply at and remain
on the surface whilst others use attachment as the first essential step
before proceeding to deeper tissue or other locations such as the blood
stream (Finlay & Falkow, 1989).
Many microbes express several distinct and alternative means of cell
attachment, some of which may be expressed under different environ¬
mental and host conditions or perhaps at different host surfaces
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(Falkow, 1990). E. coli, for example, can express several distinct
types of fimbriae or adhesins encoded by distinct regions on the
chromosome and plasmids (Uhlin et al, 1985; Low et al, 1987). Many
species of Enterobacteriaceae possess the common pili or type 1
fimbriae which enables them to bind to D-mannosyl residues on
eukaryotic cells (Clegg & Gerlach, 1987). Although their role in the
pathogenesis of infection has been difficult to discern (Freter &
Jones, 1983), it is thought they play a significant role in E. coli
colonization of the urinary tract and in colonization of the large
bowel (Finlay & Falkow, 1989). Other cell surface macromolecules such
as LPS, capsule and outer membrane proteins could also contribute to
the adhesive process. Non-fimbrial adhesins have been shown to
surround bacterial cells like capsule (0rskov et al, 1985). Indeed,
Krbncke et al (1990a) demonstrated the coexpression of these adhesive
protein capsules with the K polysaccarides of two pathogenic E. coli
strains forming a composite capsule.
The host represents an environment of marginal conditions where
multiplication constitutes a formidable task for the microbe (West &
Apicella, 1985). Competition with the host for a number of essential
nutrients appears to be a major factor determining growth rate, with
iron assuming an integral role (Weinberg, 1978). To multiply in extra¬
cellular body fluids, Gram-negative pathogens must compete for iron
associated with host iron-binding glycoproteins, transferrin and
lactoferrin (Williams, 1988). A common feature of enterobacteria under
conditions of iron deprivation is the production of high molecular mass
outer membrane proteins (Williams & Tomas, 1990). These act as
receptors for the low molecular mass iron chelators (siderophores) such
as enterobactin and aerobactin, also produced under iron restricted
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conditions.
The negatively charged nature of the LPS molecule is also thought to be
responsible for the sequestration of positively charged ions and
molecules. These may be taken up and used in essential metabolic
processes, offering bacteria a distinct advantage during in vivo
growth.
4. 2 RESISTANCE TO HOST DEFENCES
The normal host defence mechanisms pose the greatest threat to the
survival of an invading pathogen. The maintenance of Gram-negative
bacteria within the host entails the evasion of a diverse array of
defences that include complement-mediated bacteriolysis, uptake and
killing by phagocytes as well as cell-mediated immune mechanisms
(Cross, 1990).
Bacterial capsules have long been associated with virulence properties
(White, 1938), although only relatively recently have the mechanisms
involved been elucidated. The capsules of many Gram-negative bacteria
have been shown to confer resistance to phagocytosis. Most capsular
polysaccharides are hydrophilic and confer a negative charge on the
bacterial cell, characteristics intrinsically antiphagocytic in their
effect (Moxon & Kroll, 1990). In the absence of factors which facili¬
tate contact between the bacterium and phagocytic cell and which modify
the hydrophilic bacterial surface, phagocytic ingestion of capsulate
organism is a very slow and inefficient process. This was highlighted
by Mehta et al (1988) who demonstrated that rough mutants of Gram-
negative bacilli, lacking either capsule or 0-antigen were more
hydrophobic than the smooth parent strains and more readily ingested.
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The K antigen also plays a crucial role in protecting the organism from
opsonophagocytosis (in the absence of specific antibodies) and comple¬
ment mediated lysis. Triggering the antibody-independent alternative
pathway depends on the association of C3b (the cleavage product of the
third complement component) and factor B to form C3bBb, a C3 convertase
which amplifies C3b. Activation of the alternative pathway is trig¬
gered by many surface-exposed polysaccharides such as LPS (Marcus et
al, 1971). The sialic acid polysaccharides of E. coli K1 and group B
streptococci, however, favour the inactivation of C3b (Stevens et al,
1978; Edwards et al, 1982). Their strategy is to exploit the competi¬
tion between factor B which promotes amplification, and factor H, a
major regulatory protein of the alternative pathway which terminates
it. This enhanced affinity of factor H for cell bound C3b leads to the
breakdown of the amplification loop. A similar mechanism of limiting
complement deposition has been described for capsules lacking sialic
acid (Cross, 1990).
Capsular polysaccharides may also provide virulence by steric mechani¬
sms. The K1 capsule of E. coli is thought to mask underlying struc¬
tures on the bacterial cell surface which activate the alternative
pathway (Horwitz & Silverstein, 1980). Alternatively, a capsule may
function by preventing the binding of opsonic antibody to its cell wall
antigen or prevent the recognition of opsonins by the phagocytes
(Easmon, 1990).
Many capsular polysaccharides are poor immunogens including the K1 and
K5 capsules of E. coli (Cross, 1990). The sialic acid of K1 and
desulpho-heparin of K5 mimic important host molecules of mammals (Vann
et al, 1981; Finne, 1982) allowing them to avoid immune recognition.
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Together with other means of resisting host defences it is not surpris¬
ing that Kl- and K5-encapsulated E. coli are the most common serotypes
found in extraintestinally invasive infections (Cross et al, 1984).
Other potential strategies of capsules include the shedding of capsule
from the bacterial surface to remove attached host factors, or for
nullifying the functional role of circulating host factors such as
type-specific antibodies (Moxon & Kroll, 1990). It is also proposed
that bacterial capsules may exert an effect on the cellular immune
response (Cross, 1990).
The LPS phenotype also assumes an important role in the resistance of
bacteria against host defences. The O-polysaccharide of some
phenotypes have been shown to prevent phagocytosis or complement
mediated lysis or both (Williams et al, 1983; 1986; Schiller, 1988).
In non-immune serum, rough mutants lacking 0-antigen are more readily
phagocytosed or lysed by complement than 0-antigen bearing strains. A
number of workers have also established that serum resistant strains
often possess longer O-polysaccharides than their serum sensitive
counterparts (Goldman et al, 1984; Ciurana & Tomas, 1987; Tomas et al,
1988). However, sugar composition and structure have also been
considered (Rozenberg-Arzka et al, 1986; Jiminez-Lucho et al, 1987).
While the exact mechanisms of resistance are unknown, it is speculated
that LPS prevents lysis by activating complement at a site distant from
the cell surface. Evidence of exogenous LPS protecting organisms from
the bactericidal activities of serum complement, perhaps by its
activation and depletion has also been reported (Tanamoto et al, 1984;
Vukajlovich, 1986).
The ability of a bacterium to resist host defence mechanisms is clearly
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emerging as a multifactorial phenomenon, involving both LPS, capsule
and other factors. Vermeulen et al (1988) showed that the LPS
phenotype or presence of a capsule by itself is insufficient to explain
a strain's sensitivity to serum bacteriolysis. A comparison of two E.
coli K1 strains of similar levels of K1 expression demonstrated that
the strain with R-LPS was killed quicker than its smooth equivalent.
Indeed, a close functional relationship is thought to exist between LPS
and capsular surface moieties in their roles as virulence determinants,
suggesting the existence of bacterial clones of common origin (0rskov
et al, 1976; 1990), (Section 2.5). For example, the K1 capsule is
significantly associated with LPS phenotypes (rough and part rough)
which are poorly able to resist serum bacteriolysis in the absence of
capsule (Gemski et al, 1980; Cross et al, 1984). However, K5 non-
capsulate mutants of smooth E. coli 06:K5 retain serum resistance
(Cross et al, 1986). A comparison of virulence of K1 and K5 capsulate
strains with non-capsulate mutants in a neonatal rat model of infection
showed significant differences in LD50 between K1 capsulate parent and
mutant not observed for the K5 capsulate parent and mutant (Kim et al,
1986). Thus, the roles of K1 and K5 capsules appear to be different,
and the phenotypes of the associated LPS to be an important variable.
4.3 PATHOPHYSIOLOGICAL CONSEQUENCES OF SEPTICAEMIA
LPS as a toxin
For more than a century many of the pathological sequelae of Gram-
negative sepsis have been known to be associated with a heat-stable
toxin bound to the cell wall. Structural analysis of endotoxin was
initiated by Boivin & Mesrobeanu (1933) who enriched the endotoxic
activity from bacterial cell walls. However, it was not until the
early nineteen fifties that Westphal & Llideritz (1954) started to
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investigate the chemical nature of endotoxin in greater detail, aiming
to purify and identify the fever-inducing principle, to determine its
chemical structure, and to understand its mechanism of action in higher
animals (Westphal & Liideritz, 1954).
The biologically active lipid A component of LPS is now well recognized
as the primary toxiphore. Evidence for the crucial role of lipid A in
LPS-mediated effects was highlighted when the biological activities of
both natural and synthetic preparations were found to be identical
(Galanos et al, 1985b). Although the polysaccharide portion lacks
intrinsic endotoxic activity it has a key role in modulating lipid A
activity by: rendering the toxic part of the molecule soluble, thereby
facilitating its biological interaction with host cells; optimizing the
size of micellar aggregates of LPS, and by masking key determinants on
the lipid that may be necessary to trigger specific biochemical
reactions (Morrison et al, 1985; Ryan, 1985). The endotoxic activity
of lipid A is thought not to be determined by a single substituent in
the sense of a "toxophore group" but by its unique overall conformation
(Brandenburg & Seydel, 1984; Rietschel et al, 1984a). Indeed, the
number of fatty acids within the lipid A, their position, perhaps their
chain length and the phosphate content appear to be essential determi¬
nants of LPS's endotoxicity (Kanegasaki et al, 1986; Cady et al, 1989;
Loppnow et al, 1989).
Although LPS induces acute pathophysiological manifestations reflecting
those seen during Gram-negative septicaemia (Ryan, 1985), its role in
infection lethality has often been questioned. Parant et al (1977)
demonstrated that endotoxin-resistant mice (C3H/HeJ) were highly
susceptible to lethal infection with Gram-negative microorganisms.
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However, despite the uncertainty regarding the proposal that LPS
represents the only pathological determinant in Gram-negative
bacteraemia, they remain important factors responsible for many of the
pathophysiological activities accompanying infection (Ryan, 1985).
Presentation of LPS in vivo
LPS activity is markedly influenced by its mode of presentation in vivo
during an infection where it may assume a number of biochemically or
physiochemically distinct forms (Pollack ef al, 1989). The toxicity of
LPS is expressed upon its release from the bacterial cell surface and
exposure of the lipid component, and not while it forms an integral
component of the outer membrane of intact organisms. Circulating
endotoxin probably never occurs as free LPS, but remains strongly
associated with an outer membrane protein component when it detaches
from the bacterial outer membrane (Hitchcock & Morrison, 1984; Poxton
et al, 1985; Killion & Morrison, 1986). Formation of these outer
membrane complexes imparts a significant increase in LPS toxicity
(Straus, 1987; Straus et al, 1988). Released LPS molecules from
organisms may also form micelles through hydrophobic interactions
between lipid A units.
LPS specifically interacts with a number of host components (Brade et
al, 1988). Of particular importance is the interaction of LPS with
serum lipoproteins, especially high density lipoprotein (HDLP), which
have been shown to bind rapidly to both circulating free LPS and that
contained in membrane fragments (Ulevitch & Johnston, 1978; Munford et
al, 1982; Munford & Dietschy, 1985). LPS-HDLP complexes have been
demonstrated to be much less active than unbound LPS in a number of
assays of biological activity (Ulevitch & Johnston, 1978; Warren et al,
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1986). Cavaillon and colleagues stated that in the process of binding
to LP, LPS may be rendered less toxic through a mechanism of decreased
ability to induce monocytes and macrophages to release cytokines
possibly due to an altered interaction at the cell surface (Cavaillon
et al, 1990). The significance of LPS-lipoprotein complexes was
highlighted when it was proposed they are the predominant form which
circulates in the bloodstream (Mathison & Ulevich, 1981).
The binding of LPS to HDLP is thought to be a critical event determin¬
ing the rate of removal of LPS from the plasma (Ulevitch et al, 1979).
LPS which do not bind to HDLP appear to leave the circulation rapidly,
whereas bound LPS have a prolonged half-life in plasma, and are taken
up slowly by tissues (Munford & Dietschy, 1985). The binding of LPS to
HDLP, however, appears to be of minor importance in animals having
homologous antibodies to LPS. Munford & Dietschy (1985) suggested that
antibodies to LPS inhibit LPS-HDLP binding, opsonize both LPS and
preformed LPS-HDLP complexes and increase their uptake by phagocytic
rich tissues such as the liver and spleen.
There is considerable evidence that the binding of LPS to lipoprotein
is altered in inflammatory serum. Lipopolysaccharide binding protein
(LBP), a trace protein that binds to lipid A may control the response
to LPS under physiological conditions by forming high affinity
complexes with LPS that bind to monocytes and macrophages (Schumann et
al, 1990).
The mediators of septicaemia
Although LPS initiates sepsis, it indirectly affects host tissues by
triggering a cascade of biological mediators. LPS is well recognized
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as a potent activator of both the humoral and cellular mediation
systems, inducing a wide spectrum of acute pathophysiological manifes¬
tations the same as those seen during Gram-negative septicaemia and
septic shock (Ryan, 1985). These include fever, hypotension, dissemi¬
nated intravascular coagulation (DIC), and irreversible shock (Morrison
& Ryan, 1987).
Whilst the precise cellular and molecular mechanisms whereby LPS
triggers these events have not been elucidated, mononuclear phagocytes
(monocytes and macrophages) appear to play a central role (Freudenburg
et al, 1986; Morrison & Ryan, 1987). LPS induces many responses from
macrophages, among which are the development of an enhanced respiratory
burst (Pabst & Johnston, 1980) and the secretion of inflammatory
mediators, including prostaglandins, colony-stimulating factors
(Thorens et al, 1987) interleukin-1 (IL-1) (Dinarello, 1984) and tumour
necrosis factor a (cachectin) (TNF) (Mannel et al, 1980). The func¬
tional inter-relationships of these mediators are complex, since some
of them modulate the synthesis or activities of others (Morrison &
Ryan, 1987). The fact that endotoxin could activate a series of
inflammatory mediators suggested one or more of these intermediators
was responsible for the lethality of LPS. Recent studies have focused
attention on such cytokines as IL-1 (Weinberg et al, 1988), IL-6 (Hack
et al, 1989; Waage et al, 1989), and TNF in particular.
Strong evidence suggests that TNF is a major endogenous toxin in the
pathogenesis of endotoxic shock. The central role of TNF as a mediator
of LPS-induced injury gained prominence when it was shown to reproduce
many of the pathological features of shock (McCutchan & Ziegler, 1983;
Remick et al, 1987; Mathison et al, 1988). Antibodies to TNF were also
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demonstrated to confer protection of mice from LPS (Beutler et al,
1985) and baboons in an E. coli challenge model (Tracey et al, 1987).
Anti-TNF antibodies reduced the IL-1 and IL-6 responses in this latter
study, suggesting an interdependence of these cytokines (Fong et al,
1989). Despite these findings, investigations by Neilson et al (1989),
Silva et al (1990a) demonstrated that TNF is necessary but not suffi¬
cient to cause death in septic shock, whilst Ciancio et al (1991)
suggest synergism between TNF and endotoxin (Rothstein & Schreiber,
1988) may be a major component in the pathophysiology of TNF and
endotoxin induced shock. Indeed, shock probably results from sequen¬
tial and synergistic interactions between TNF and a number of biologi¬
cal mediators (Neilson et al, 1989; Mdzes et al, 1991). Proposed
candidates include complement (McPhaden & Whaley, 1985), endorphins
(Faden & Holaday, 1980), arachidonic acid metabolites (Flohb & Giertz,
1987), and platelet activating factor (Braquet et al, 1987). The
development of endotoxic shock during Gram-negative septicaemia is
thought to occur after the generation of LPS-hyperresponsive
macrophages by a sublethal infection (Matsuura & Galanos, 1990).
The relative importance of various mediators is thought to vary with
different host responses or bacterial virulence factors including
differing patterns of mediator release (Silva et al, 1990a). Addit¬
ionally, individual cytokines may preferentially mediate different
aspects of LPS effects. For example, TNF might mediate lethality
(Freudenburg et al, 1986) or tissue injury (Beutler et al, 1985)
whereas IL-1 may activate lymphocytes (Dinarello, 1989).
The activation of the complement pathways represents another critical
event predisposing the host to septic shock (Goldstein, 1985; McPhaden
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& Whaley, 1985). Activated components of complement via the classical
and alternative pathways (Morrison & Kline, 1977; Cooper & Morrison,
1978) are potent agents for the stimulation of many of the cellular
systems involved in host responses to LPS (Morrison & Ulevitch, 1978).
The release of the anaphylatoxins C3a and C5a stimulates the release of
histamine which in turn can result in vasodilation. These molecules
therefore have the potential, if activated in sufficient quantity, to
produce hypotension.
Endotoxin produces marked effects on the coagulation system, and
septicaemia often results in DIC (Ryan, 1985). LPS can have
fibrinolytic effects through the action of tissue-plasminogen activator
and plasminogen-activator inhibitors, which can result in DIC. The
classic model of endotoxin-induced shock, the Shwartzman reaction,
first suggested that endotoxin perturbs the coagulation system. One of
the consequences of DIC, is a haemorrhagic state with profuse bleeding
from mucous membranes.
The undoubted detrimental reactions for the host are the result of the
over stimulation of host mediator production with an excess of
endotoxin (Brade et al, 1988). Thus, the release of large amounts of
various mediators into the bloodstream profoundly affect the peripheral
and pulmonary vascular system, whilst some affect the myocardium itself
(Parrillo et al, 1990). The vascular and myocardial abnormalities
combine to give a generalized cardiovascular insufficiency. Respira¬
tory and renal dysfunction may also be produced by the action of
endotoxin. Consequently, septicaemia is a common cause of the adult
respiratory distress syndrome (Kaplan et al, 1979; Fowler et al, 1983).
Progression to the later stages of septic shock during severe infec-
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tions is commonly characterized by unresponsive hypotension and organ
failure.
In contrast to the detailed knowledge on the potential target cells
responsive to LPS and the mediators produced by these cells in response
to LPS, the mechanisms by which LPS initiates host-cell responses is
poorly understood. The identification of relevant LPS receptors on
cells of the immune system reviewed by Morrison (1989) is integral to
the understanding of endotoxic pathophysiology. Schumann et al (1990)
proposed a model of LPS induced monocytic stimulation involving the
formation of high affinity complexes between LPS and LBP (Tobias et al,
1986; 1989). These subsequently interact with CD14, a monocytic
differentiation antigen possibly leading to the induction of appropri¬
ate transmembrane signals (Wright et al, 1990). The ligated CD14 may
directly trigger the synthesis of cytokines such as TNF, or indirectly
via the production of other proteins.
4.4 HOST RESPONSE TO ENDOTOXIN AND ITS BENEFITS
In vivo, LPS is detoxified by both intravascular antibody and comple¬
ment mediated mechanisms, and the phagocytic cells comprising the
reticuloendothelial system (Skarnes, 1985). Ultimately, most of the
LPS seems to be processed by the liver, initially by the liver
macrophages, the Kupffer cells. Whilst it is evident that some of the
biological activities of LPS are harmful to the host, others appear to
be beneficial (Morrison & Ryan, 1987; Brade et al, 1988). The
beneficial effects of endotoxin are thought to reflect physiological
activities of endotoxin being released from Gram-negative bacteria of
the gut flora.
54
LPS is a non-specific B-cell mitogen and has an immunological adjuvant
effect for other bacterial antigens. Sublethal Gram-negative infection
or LPS administration also induces an increased tolerance to larger
doses that usually precipitate a toxic or lethal response (McCuskey et
al, 1987; Vuopio-Varkila et al, 1988). The mechanism of early phase
tolerance developed by Greisman & Hornick (1973) is complex, involving
a direct endotoxin-cell interaction which inhibits synthesis and/or
release of endogenous pyrogen. Recent reports, however, suggest that
TNF and IL-1 productions are involved in the induction of early-phase
endotoxin tolerance (Fraker et al, 1988; Sheppard et al, 1989). The
ability to produce these, and possibly other mediators in response to
LPS may be an important defence mechanism. The protection observed
during late-phase tolerance correlates with the presence of serotype-
specific antibodies following an immune response to the O-antigen of
administered endotoxin (Johnston & Greisman, 1985).
The fine balance existing between an appropriate protective response
■ft
and over activation of the immune system is markedly influenced by
certain predisposing factors discussed in section 1.4. In an evol¬
utionary view of endotoxin, Legrand (1990) proposed that while LPS
serves a critical function for Gram-negative bacteria, animals use this
cell surface component as a signal for the endotoxin response system.
Although responses to endotoxin are commonly classified as being either
beneficial or toxic, some of the toxic effects include both protective
effects and those which are harmful when taken in excess. However, the
unequivocally harmful effects of endotoxin such as free radical damage,
DIC, hypotension and death results from this excessive activation of a
remarkably well adapted defence system.
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CHAPTER 5
TREATMENT OF SEPTICAEMIA AND ENDOTOXAEMIA
5.1 ANTIMICROBIAL THERAPY
The crucial stage in the clinical management of septicaemic patients
remains the identification of the responsible bacterial pathogen and
determination of its susceptibility to antimicrobial agents (Wood,
1990). Rapid institution of an empirical regimen that includes
appropriate therapy on clinical diagnosis of the causative organism(s)
has been associated with improved survival and decreased frequency of
shock (Kreger et al, 1980b; Bryan et al, 1983). Prior to identifying
the causative organism it is essential that broad-spectrum antibiotic
coverage be initiated (Kreger et al, 1980b; Parrillo et al, 1990). The
antimicrobial agents selected for initial therapy are tailored to the
individual patient after considering the presumed infecting organism,
its likely sensitivity pattern and host factors which may influence the
impact of infection on the individual, or the hazards of some agents
(Wood, 1990). Depending on the clinical response and results of blood
culture and sensitivity testing, these regimens may need to be revised.
Initial therapy is often based around the use of a combination of
antimicrobials that include an aminoglycoside with a penicillin or
second-generation cephalosporin plus metronidazole - if an anaerobic
sepsis is suspected (Smith, 1990; Wood, 1990). If previous antibiotics
have been given, or the patient is immunosuppressed, a third-generation
cephalosporin is frequently used (Geddes, 1988). Although the use of
combinations of antibiotics is widely adopted to cover a broad range of
potential pathogens, it is now possible to use single antibiotics
having broad-spectrum activity such as the 4-fluoroquinolones, notably
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ciprofloxacin (Smith, 1990). Despite the introduction of new
antimicrobial agents, those with a proven "track-record" continue to be
used by clinicians (Smith, 1990).
The frequent failure of antibiotics to ameliorate infections causing
septicaemia is in part explained by their ineffectiveness, against the
toxic effects mediated by endotoxins (Fomsgaard, 1990). Thus, although
antibiotics are of value during the initial bacteraemic stage, they are
ineffective later in the course of illness. Evidence has also revealed
that antibiotic therapy can encourage endotoxin release during therapy,
thereby aggravating the clinical symptoms of disease (Cohen &
McConnell, 1985; McConnell & Cohen, 1986). Studies have demonstrated
that the rate of liberation of endotoxin is different for antibiotics
of different classes, despite similar bactericidal activities (Shenep
& Mogan, 1984; Shenep et al, 1985b). Despite being unable to prevent
continued influx of bacteria into the bloodstream, bacteriostatic
antibiotics were however shown not to induce endotoxin release.
Indeed, Kreger et al (1980b) reported a higher survival rate in
patients treated with bacteriostatic antibiotics compared to those
treated with bactericidal agents. Further support for the detrimental
effects of antibiotics was highlighted by Shenep et al (1988) who
established a marked increase in both bacterial-bound and free
endotoxin levels in the plasma of patients with septicaemia during
antibiotic therapy.
Polymyxin B, a polycationic antibiotic which binds to LPS is known to
block many of its biological activities in vitro (Craig et al, 1974;
Spear & Teodorescu, 1984). It has also been shown to protect against
experimental models of endotoxaemia (Rifkind, 1967; Baldwin et al,
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1991) and septicaemia (Flynn et al, 1987), although its high toxicity
is thought to limit its therapeutic potential. The protective
mechanism afforded by polymyxin B against LPS-induced toxicity is
proposed to be the inhibition of TNF production (Stokes et al, 1989).
Despite important advances in the development of antimicrobial agents
septic shock remains a serious disease with high mortality. Since
clinical results from antimicrobial therapy appear to be maximized,
considerable interest lies in the development of therapeutic strategies
which neutralize or inhibit the key toxins and mediators of
septicaemia.
5.2 ANTI-ENDOTOXIN ANTIBODIES
Considering the central role of endotoxin in Gram-negative septicaemia,
and the success of immunotherapy in the treatment of other bacterial
diseases involving the release of toxins, it appears that antibodies to
LPS might be of some value in the treatment of septicaemia. Despite
important advances on the protective role of anti-LPS antibodies over
the last decade, the specificity and the type of anti-LPS antibody
required for protection, as well as the mechanism(s) of protection,
have not been completely defined (Ziegler, 1988).
Antibodies to serospecific determinants are thought to opsonize LPS and
whole bacteria, and to provide an additional bactericidal effect on
intact Gram-negative bacteria (Pennington & Menkes, 1981; Kauffmann et
al, 1986; Ziegler, 1988). Previous studies have demonstrated the
ability of polyclonal or monoclonal anti-O-polysaccharide antibody to
protect against experimental bacterial infections (Kaijser & Ahlstedt,
1977; Colwell et al, 1984; Dunn et al, 1985; Pluschke & Achtman, 1985;
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Zweerink et al, 1988). Active immunization of animals to produce high
levels of serospecific antibodies has also conferred protection (Young,
1972; Cryz, et al 1984; 1985).
Although O-antigen specific antibodies appear to be effective, it is
not feasible to produce a polyvalent antiserum against all potential
pathogens in human septic shock (0rskov et al, 1977; Ziegler, 1988).
However, since approximately 10 O-serotypes account for roughly 705& of
E. coli bacteraemic isolates (McCabe et al, 1978; Cross et al, 1984;
0rskov & 0rskov, 1985) the possibility has been raised of developing an
O-serospecific vaccine against this leading cause of nosocomial Gram-
negative septicaemia. Preliminary work by Cryz et al (1990) led to the
production of a non-toxic E. coli 018 O-polysaccharide (O-PS)-toxin A
and O-PS-Cholera toxin conjugate vaccines which afforded protection
against a challenge from the homologous strain when passively trans¬
ferred to mice. Their safety and immunogenicity in humans has also
been established, providing impetus for the development of further
conjugate vaccines against other important E. coli serotypes (Cryz et
al, 1991). Many high risk patients are immunocompromised in some
manner, and therefore not ideal candidates for active vaccination. A
more promising use of such vaccines includes the proposed preparation
of a hyperimmune gammaglobulin for intravenous use (IVIG) from the
plasma of immunized healthy donors (Cryz et al, 1991). The preparation
of such an IVIG needs to consider that the majority of nosocomial Gram-
negative septicaemias are caused by E. coli, P. aeruginosa and
Klebsiella species (McGowan et al, 1975; Bryan et al, 1983; Easmon,
1990). A polyvalent IVIG to these three pathogens would increase the
spectrum of activity thereby lending itself for use prophylactically or
perhaps immunotherapeutically. Multivalent P. aeruginosa O-polysaccha-
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ride conjugate vaccine and Klebsiella capsular polysaccharide vaccine
have already been prepared and shown to be safe and immunogenic in
humans (Granstrom et al, 1988; Cryz et al, 1989). The possibility of
combining these existing vaccines with an E. coli component is
particularly attractive and awaits future developments (Cryz et al,
1991).
Another approach to the development of a protective agent against
septicaemia includes the use of antibodies directed towards the
conserved regions of the LPS molecule, the core-glycolipid. It was
postulated that these common determinants might stimulate widely cross-
reactive antibodies to LPS which could inhibit its endotoxic activities
(Chedid et al, 1968). Great emphasis has been placed on characterizing
antisera against rough mutants lacking O-antigens, in particular the R
mutants of E. coli 0111:B4 (J5) and S. minnesota (R595), which express
only lipid A and a portion of the core oligosaccharide as their LPS
(McCabe et al, 1972; Fuller et al, 1973).
Polyclonal antiserum raised against rough mutant bacteria has been
shown to protect animals from a wide variety of Gram-negative bacteria
(Ziegler et al, 1973a & b; Young et al, 1975; Marks et al, 1982) and
endotoxins (Braude & Douglas, 1972; Braude et al, 1973; Davis et al,
1978). In addition, the discovery of naturally occurring antibodies to
endotoxin-core structures in animals, including man, led to a series of
retrospective studies in patients with Gram-negative bacteraemia.
These demonstrated that patients with high levels of anti-core antibody
at the time of presentation had a reduced incidence of septic shock and
lower mortality (McCabe et al, 1972; Pollack et al, 1983). Such
observations prompted clinical studies with antiserum obtained by
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immunizing volunteers with the rough mutant E. coli J5. Ziegler et al
(1982) commenced a double-blind, randomized, controlled trial of
polyclonal anti-J5 antiserum versus control, non-immune serum in
patients with established Gram-negative bacteraemia. Mortality was
reduced overall from 39% in control patients to 22% in recipients of
anti-J5 antiserum (pO.Oll). In the subgroup of patients with severe
shock, the results were even more convincing; 77% of control patients
died compared with 44% of the anti-J5 group (p0.003). A subsequent
clinical trial by Baumgartner et al (1985) successfully demonstrated
the protective prophylactic use of anti-J5 antiserum in high-risk
intensive-care patients.
The protective element of antisera against rough mutant bacteria has
been hypothesized to be cross-reactive anti-core-glycolipid antibodies
which neutralize the harmful effects of endotoxins. Indeed, many
believe its effects depend primarily upon IgM antibody neutralizing the
toxic properties of LPS, perhaps by steric hinderance, although
enhanced bacterial clearance may also play a part (Ziegler et al,
1973a; Young et al, 1975; Sakulramrung & Domingue, 1985). A number of
in vitro and in vivo studies have however failed to show these cross-
reactive and protective properties (Ng et al, 1976; Greisman et al,
1978; 1979; Gigliotti & Shenep, 1985; Trautmann & Hahn, 1985). Even in
studies showing protection, it has been difficult to demonstrate that
the antisera contain antibodies which cross-react with LPS from smooth
strains, and establish a close relationship between protection and the
levels of core-glycolipid antibodies (Ziegler et al, 1982; DeMaria et
al, 1988). This inability to measure the specific protective antibody
in polyclonal antiserum has resulted in uncertainty regarding its
protective mechanism (Baumgartner & Glauser, 1987; Baumgartner et al,
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1991). Much uncertainty also relates to the great variation in the
protective properties of pre-immune sera owing to the presence of
naturally occurring anti-LPS antibodies, and vaccination procedures
giving rise to considerably different titres.
The presence of high affinity antibodies to type specific immuno¬
dominant core LPS determinants are also thought to obscure cross-
reactive antibodies in antisera to rough mutants (Baumgartner et al,
1987). Since considerable amounts of immunogen-specific antibodies may
be stimulated by novel epitopes of R-submutant LPS it is possible the
cross-reactive anti-LPS activity in R-LPS-immune sera has been over¬
estimated (Baumgartner et al, 1987; Cross et al, 1989; Barclay, 1990).
In addition to the hypothesis attributing cross-protection of antisera
to antibodies, protection may be conferred by small amounts of contami¬
nating endotoxin, which might cause tolerance (Chong & Huston, 1987),
or polyclonal B-cell activation (Siber et al, 1985), or other non-
antibody proteins present in the antiserum (Brade & Brade, 1985).
Warren et al (1991) established the requirement of serum for the
optimal interaction between smooth (S)-LPS and IgG fractions from J5
antiserum. They suggested these results may explain discrepancies
shown in previous in vivo and in vitro studies. Concern has also been
raised over the suitability of the J5 mutant as an immunogen. The core
structure of E. coli J5 appears to be distinct from those of other
bacteria and exhibits greater heterogeneity, thus limiting the cross-
reactive potential of antibody raised against J5 (Fuller et al, 1973;
Appelmelk et al, 1986a). Antisera raised against rough mutants
continue to demonstrate protection (Baumgartner et al, 1987; Calandra
et al, 1988) although it is not feasible this form of antisera will
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ever become available on a large scale (Johns et al, 1983).
The potential use of naturally occurring anti-LPS antibodies in humans
as an immunotherapeutic agent has also been investigated. The import¬
ance of these antibodies in the defence against infections has long
been established by clinical studies relating the outcome of infection
in patients to titres of specific and, in particular, cross-reactive
antibodies prior to bacteraemia (McCabe et al, 1972; Pollack et al,
1983). A number of further complementary reports have established a
depression of antibodies to the LPS molecule in patients with Gram-
negative septic shock which, together with rising or constant
endotoxaemia are associated with early mortality (Nys et al, 1988;
Peter et al, 1979; Schedel, 1988). Barclay et al (1989) demonstrated
depression of intrinsic serum IgG antibody levels to structures in the
inner core region of LPS during shock, while those to the outer core or
O-polysaccharide region remained unaltered. Temporal variation in
levels of individual anti-LPS antibodies were also related to vari¬
ations in endotoxaemia, since depressions of certain anti-LPS anti¬
bodies occurred immediately before peaks of endotoxaemia, and recovery
of these anti-LPS antibody levels preceded fall in endotoxin.
Several reports have emphasized the importance of anti-lipid A (Cerra,
1987; Schedel, 1988) or Re-LPS and lipid A antibodies (Schellekens et
al, 1989) in septicaemia, whilst others suggest that cross-reactive IgG
antibodies to a variety of epitopes in the endotoxin are prevalent in
normal human sera and can be depressed during septicaemia (Barclay &
Scott, 1987; Wessels et al, 1988). Thus the passive administration of
antibodies of appropriate specificities during endotoxaemia may mediate
some clinical benefit by reducing the level or duration of endotoxaemia
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and its subsequent clinical effects.
The use of standard IVIG has been shown to prevent the acquisition of
bacterial infections in hypogammaglobulinaemic patients (Pirofsky,
1984). Although evidence exists for its potentially beneficial effect
in the treatment of septicaemic patients (Collins et al, 1986;
Baumgartner & Glauser, 1987; De Simone et al, 1988) there is insuffi¬
cient justification for its widespread use (Cohen, 1988; Dudley, 1990).
Indeed its prophylactic and therapeutic use in clinical trials showed
only marginal benefit (Duswald et al, 1980; Schmidt et al, 1984; Glinz
et al, 1985; Just et al, 1986).
An alternative approach has been the use of hyperimmune IVIG, that is,
plasma donors with especially high titres to core antigens. Screening
of blood donor populations has revealed the presence of a wide range of
anti-LPS antibody concentrations. The small number of individuals
showing very high titre anti-LPS antibodies may provide sera for
preparation of a therapeutic hyperimmune gammaglobulin (Appelmelk et
al, 1985; 1987; Barclay & Scott, 1987; Fomsgaard et al, 1987; Scott et
al, 1990). Antibodies to all LPS substructures are simultaneously
present in such sera, and screening for one antibody specificity also
selects sera containing anti-LPS of other specificities (Fomsgaard,
1990). A broad range of specific as well as cross-reactive anti-LPS
antibodies is therefore obtained by the pooling of selected sera.
Scott & Barclay (1990) observed multiple reactivity in individual high-
titred sera, predominantly attributable to one of two kinds of cross-
reactive families of anti-LPS core antibodies: those reactive with both
Re-LPS and Rc-LPS (anti-lipid A/KD0), or with Rc-LPS but not Re-LPS
(anti-heptose). Therapy with single anti-LPS sera portions is thought
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unlikely to possess an appropriate combination of antibody specifi¬
cities (Gaffin et al, 1985). Screening for anti-LPS antibodies also
prevents the problems of uneven antibody titres, and risks of vaccinat¬
ion.
The potential of hyperimmune IVIG has been demonstrated in a number of
trials. Gaffin et al, (1982) screened blood donors for natural
antibody to LPS by ELISA using a cocktail of 12 purified endotoxins.
Selected anti-LPS rich material was used in an open trial of septic
shock complicating obstetric conditions (Lachman et al, 1984). Results
indicated a reduction in mortality from 47% in the control group to 7%
in the treated group (P<0.01). The same group has also produced an
equine anti-endotoxin by immunizing horses with a pool of endotoxins,
which has subsequently been used in a variety of endotoxin implicated
conditions (Wells & Gaffin, 1987). Fomsgaard et al (1989) demonstrated
the antibody mediated neutralization of different biological effects in
vitro and the protection against lethal toxicity induced by either
purified LPS or Gram-negative infection. Protection was independent of
the specific anti-LPS titre, suggesting that protective antibodies were
a fraction of the total antibody present, possibly directed to less
exposed structures in the core-glycolipid region. The anti-LPS IgG was
used in a preliminary clinical trial (Fomsgaard, 1990). Intravenous
treatment of patients in septic shock was associated with a decrease in
serum concentrations of endotoxin and TNF, improvement of the clinical
condition, and a decrease in expected mortality from 80% to approxi¬
mately 50%. An additional report describes seven patients with Gram-
negative septicaemia who were given a commercial human IgG preparation
shown to have a high titre of antibody to lipid A (Marget et al, 1985).
Four patients survived and a follow up randomized, double blind study
65
also showed an improved outcome (Jaspers et al, 1987).
Continued investigation of the properties of naturally immune blood
donor sera is required for selection of appropriate hyperimmune anti-
LPS gammaglobulin for passive immunotherapy of septic shock. The
determinations of the exact specificity of the protective antibodies is
essential since it will permit the screening of appropriate blood
donors for clinical use as well as the production of effective
monoclonal antibodies (MAbs). However, this anti-LPS specificity may
be different for different LPSs and also for protection against
endotoxaemia and bacteraemia (Fomsgaard & Galanos, 1989; Fomsgaard,
1990). The protective mechanisms conferred by anti-LPS immunoglobulins
is equally uncertain. The possession of determinants against core and
surface structures may act by neutralizing both the toxic-groups
responsible for the pathophysiological effects of LPS and opsonization
and complement-mediated bacterial killing (Cohen, 1986). Scott &
Barclay (1990) established major opsonic activity of natural cross-
reactive IgG antibodies binding to the core of the LPS molecule for
both rough and smooth strains of Gram-negative bacteria. Such
antibodies may perform an important defence mechanism against infection
prior to the production of serospecific antibodies.
The relative protective abilities of antibody isotypes (IgG or IgM) is
still unresolved (Young et al, 1975; Ziegler et al, 1982; McCutchan &
Ziegler, 1983; Marget et al, 1985). This is of particular practical
significance since IVIG contains little or no IgM. Previous studies
have demonstrated a stronger association of protection with IgG
antibodies compared to IgM (Young et al, 1975; Fenwick et al, 1986).
Others have shown that sera from humans or animals deliberately
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immunized to produce antibodies to the S. miimesota Re LPS core are
cross-protective against bacteraemia and endotoxaemia when given
passively to animals, but that protection was provided by IgM and not
IgG (DeMaria et al, 1988; McCabe et al, 1988). However, naturally
immune IgG from selected blood donors may have a different range of
anti-LPS specificities and protective properties from 'Re-immune' IgG
or IgM (Barclay et al, 1989). Young et al (1989) suggested protection
seen with different isotypes may be related to the nature of the
experimental model. IgG antibodies may appear more protective where
infection has been initiated in peripheral tissue or the lung.
However, in models of acute bacteraemia, IgM antibodies may be more
effective on a molar basis because of their greater number of anti^e^n
binding sites. Results of recent and ongoing investigations with anti-
core-glycolipid antibodies are anticipated to relate antibody function
directly to specificity and isotype. This information will allow the
testing in carefully controlled clinical trials, the efficacies of
hyperimmune IVIG preparations and MAbs in the treatment of critically
ill patients (Baumgartner & Glauser, 1987).
The advent of MAb technology (Kohler & Milstein, 1975) opened up the
possibilities of commercial production of those immunotherapeutic
agents which overcome some of the drawbacks associated with polyclonal
antisera to LPS. The potential of MAb anti-LPS antibodies directed
towards the conserved regions of the core-glycolipid has been inten¬
sively investigated over the last decade for immunotherapy of
septicaemia. A number of studies have demonstrated broad cross-
reactivity of MAbs, indicating that commonly shared antigenic determi¬
nants are present in the LPS of many unrelated species (Mutharia et al,
1984," Nelles & Niswander, 1984; Teng et al, 1985; Kirkland et al, 1986;
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Miner et al, 1986; Bogard et al, 1987; Pollack et al, 1989). Most
widely cross-reactive MAbs react with the lipid A component of LPS, and
are considered the best candidates for cross-protective immunotherapeu-
tic reagents owing to their ability to inhibit the biological activ¬
ities of LPS (Mayoral & Dunn, 1990; Mehta et al, 1990; Cornelissen et
al, 1991).
The immunotherapeutic potential of these agents has been illustrated by
their ability to confer protection in a number of experimental
infection and endotoxaemia models (Dunn et al, 1985; Teng et al, 1985;
Coughlin et al, 1986; Dunn et al, 1986; Ziegler & Teng, 1986; Dunn et
al, 1988; Priest et al, 1989). Other cross-reactive MAbs have however
failed to protect against lethal infection, possibly due to their
inability to bind to inner-core and lipid A determinants on smooth
bacteria (Ward et al, 1988; Salles et al, 1989; Evans et al, 1990;
Mandine et al, 1990). Thus, the importance of anti-lipid A antibodies
in host defence may lie more in their ability to neutralize pathologi¬
cal effects of LPS, than in their ability to protect against bacterial
infection. The precise mechanism of inhibition of lipid A mediated
biological effects is unknown. Antibody may bind to the biologically
active site of lipid A, blocking its activity directly, or antibody may
bind to an epitope close to the active site of lipid A such that they
interfere sterically with the stimulation of target cells by lipid A
(Ward et al, 1988; Mehta et al, 1990). The binding of antibodies to
LPS may also cause a conformational change in the LPS molecule or
micelle thereby affecting the interaction of lipid A with receptor
eelIs.
The composition and number of long-chain fatty acids attached to lipid
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A backbone are critical determinants of toxicity (Brade et al, 1988),
suggesting the important role played by these hydrophobic elements of
lipid A in the mediation of cellular responses. Indeed, Cornelissen et
al (1991) demonstrated the neutralization of lipid A-mediated effects
in the presence of a MAb recognizing the hydrophobic elements of lipid
A. Failure of MAbs described by Chia et al (1989) to inhibit LPS-
induced secretion of TNF by macrophages may have been caused by their
specificity for the hydrophilic elements of lipid A.
Although a number of core-glycolipid MAbs have been produced, a great
deal of controversy exists regarding their epitope specificity, cross-
reactivity and immunoprotective potential. Much of this confusion is
related to the problems of immune sera, where the specificity of
antibodies has been inadequately defined (Barclay, 1990). Many MAbs
have been found to be specific for the immunodominant terminal epitopes
of their immunogen. If the immunogen is R submutant LPS the cross-
reactivity is often restricted to LPS of a similar chemotype (De Jongh-
Leuvenink et al, 1986; Brade et al, 1987b; Pollack et al, 1989).
Cross-reactivity is also limited by inter and intraspecies differences
in covalent core structures (Pollack et al, 1989). Lipid A, considered
the most conserved structural element of LPS, exhibits considerable
phylogenetic variation in polar head group substitution and fatty acid
composition (Rietschel et al, 1984b). Such variation can introduce
intrinsic structural microheterogeneity to the molecule, leading to
class related, but not identical lipid A chemical structures
(Schwartzer et al 1989).
Uncertainty regarding the specificity and cross-reactivity of MAbs is
also related to the lack of reliable and reproducible in vitro tech-
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niques for measuring reactivity of antibodies to heterologous Gram-
negative bacteria and LPS. A number of studies have demonstrated that
in addition to epitope specificity, cross-reactivity of MAbs is a
function of the physical state of bacteria or LPS used in an assay, and
the assay itself (Aydintug et al, 1989; Pollack et al, 1989; Heumann et
al, 1991). The putative cross-reactive and endotoxic properties of
many MAbs to the core-glycolipid are restricted by epitope concealment
by O-side chain and outer core sugars, preventing access to these
underlying determinants (Nelles & Niswander, 1984; Gigliotti & Shenep,
1985; Miner et al, 1986; Pollack et al, 1987).
Although the controversies concerning in vitro cross-reactivity of LPS
antibodies are not resolved, two large clinical trials using MAbs seem
to support the concept that anti-LPS antibodies may be protective in
clinical practice. The first used a murine IgM MAb designated as E5,
directed against the lipid A region of Gram-negative bacterial
endotoxin (Harkonen et al, 1987). The analysis of data suggests that
the difference in overall survival between the treated and untreated
groups were not significantly different (Bernard et al, 1989).
However, the MAb was possibly protective in patients who were not in
shock, and treatment was also shown to be beneficial in the resolution
of organ failures, regardless of the presence or absence of shock.
Murine MAbs have however been shown to be immunogenic in humans
(Schroff et al, 1985), prompting the production of either chimeric
(mixed mouse and human origin) and human MAbs for possible therapeutic
use.
The second trial used a human anti-lipid IgM MAb designated as HA-1A or
TH
Centoxin , produced from a cell line developed by Teng et al (1985).
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Results indicated that mortality in patients with Gram-negative
bacteraemia was reduced by 39% and in patients with septic shock by 42%
(Ziegler et al, 1991). The antibody also appeared to have a prophylac¬
tic effect in preventing the development of symptoms, if administered
early enough. However, those patients without positive blood culture
did not benefit from the administration of HA-1A. Additionally, the
properties of HA-1A are still not fully understood, and its mode of
action poorly defined. Overall, these findings illustrate the
potential of monoclonal antibody immunotherapy in clinical medicine and
supports the continued development of other, perhaps improved antib¬
odies .
5.3 OTHER STRATEGIES
Apart from the use of antimicrobials, early administration of appropri¬
ate supportive therapy is also required to influence progression of the
condition positively. The intensive-care of septicaemic patients
requires rapid therapeutic intervention with appropriate fluids and
vasopressors before hypotension becomes evident, together with other
cardiac, pulmonary and metabolic support (Wolf, 1982: Young, 1985;
Luce, 1987). Despite being useful adjuncts to other therapies, such
clinical management of septic shock is merely supportive to the host's
defences which must eventually effect a recovery. As the understanding
of the pathogenic mechanisms of the illness advances, a greater
awareness of the requirements for more effective resuscitation will
become apparent.
Avoiding septicaemia and taking measures to minimize the risk of
septicaemia are the easiest ways to lower mortality (Dipiro, 1990).
These include avoiding the over excessive use of antimicrobials and the
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use of invasive medical devices. A reduced frequency of septicaemia
has also been achieved for susceptible patients undergoing surgery
using the method of selective bowel decontamination (Alcock &
Ledingham, 1988; Schmeiser et al, 1988; Wiesner et al, 1988). This
strategy involves the use of oral antimicrobial agents which remove
opportunistic aerobic and facultatively anaerobic organisms from the
gut. However, the technique is ineffective against the threat of
septicaemia from exogenous sources or resistant organisms.
Since the macrophage product TNF appears to be one of the principal
mediators of endotoxin induced shock, there is considerable interest in
the prospect of the therapeutic use of anti-TNF MAbs against the
effects of septicaemia. An advantage of anti-TNF therapy is the
potential effectiveness against organisms other than Gram-negative
bacteria in the management of shock. Moreover, blocking TNF activity
may have uses in treating diseases other than septic shock. To date,
there has been uniform agreement on the efficacy of anti-TNF as
prophylaxis in experimental models of endotoxic shock (Beutler et al,
1985; Tracey et al, 1987; Mathison et al, 1988). Anti-TNF MAbs have
also been effective in infection models (Opal et al, 1990; Silva et al,
1990b), although a major concern is the apparent lack of protection if
antibody is administered after, rather than before bacterial challenge
(Silva et al, 1990b). The clinical use of anti-TNF antibodies in human
patients remains to be firmly established. However, successful phase
1 trials of such an agent have been reported (Exley et al, 1990).
Since TNF production is triggered by endotoxin itself, it is postulated
that the utility of combination therapy using anti-TNF and other
anticytokines with anti-LPS may be the most effective treatment (Cohen,
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1989). Anti-LPS MAbs could serve to inhibit the initial progression
caused by the septic insult, whilst inhibitors of mediator-induced
effects may further limit the deleterious host response. Although
cytokines such as TNF and IL-1 are important mediators of Gram-negative
shock a greater understanding of the septic shock pathogenic cascade is
still required. This may stimulate the development of effective
therapies interrupting key steps in the sequence, and reduce the high
mortality associated with this disease (Parrillo et al, 1990). Given
the complexity of the response to LPS it has also been postulated that
an antagonist of the initial interaction of LPS with macrophages would
have great therapeutic potential (Raetz, 1990). A recent study by
Morrison et al (1990) demonstrated the protection afforded by a MAb
against LPS receptors expressed on murine macrophages and lymphocytes.
The immunotherapeutic potential of this or related MAbs remains to be
determined. Inactive precursors and synthetic analogues of lipid A
have prevented the toxic effects of LPS (Danner et al, 1987; Golenbock
et al, 1987), whilst the non-toxic LPS of Rhodobacter capsulatus may
provide an attractive alternative in preventing the fatal effects of
septicaemia by competing with toxic LPSs (Loppnow et al, 1990).
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AIMS OF THE THESIS
Endotoxin, primarily the LPS component of Gram-negative bacterial outer
membrane, is one of the most important components responsible for the
development of endotoxic shock. The objective of this thesis was to
L.f=>.5 y
investigate the expression of E. coli.^under different environmental
conditions and the detection of specific LPSs with MAb probes.
The areas of research studied include:-
1) Characterization of anti-LPS MAbs in a number of assay systems
employing different LPS preparations for use as tools for studying
the expression and detection of LPS.
2) The use of MAbs in the development of a capture ELISA system for
the detection of E. coli LPS core and O-types. The underlying
objective of this study was to use MAbs for the detection of
specific LPS types in the serum of septic patients.
3) Investigation of the expression of LPS on bacteria grown in vitro,
under environmental conditions mimicking those of an infected
host, and on bacteria grown in vivo.
4) The effects of subinhibitory concentrations of various antibiotics
on the binding of anti-LPS MAbs to E. coli and the expression of







Bacterial strains and their source used in this thesis, are shown in
Table 2.
Maintenance of bacterial strains
Bacterial strains were maintained in a lyophilized form. Suspensions
of bacteria, prepared from bacterial cultures (Section 2.1) were
aseptically aliquoted into sterile glass ampoules and lyophilized
(Edwards Modylo freeze dryer, Edwards High Vacuum Ltd., Crawley,
Surrey).
Detection of K1 and K5 E. coli capsules
The detection or confirmation of K1 and K5 expression was performed by
the phage typing method described by Devine et al (1990). K1 and K5
specific bacteriophage (designated fKIGS and fK5DG) and their respect¬
ive propagating strains were obtained from Dr A P Roberts (Department
of Medical Microbiology, Charing Cross and Westminster Medical School,
London).
1.2 CHEMICALS, MEDIA AND REAGENTS
Chemicals
Unless otherwise stated, all chemicals were Analar grade (BDH Chemicals
Ltd., Poole, Dorset). All solutions were prepared in 'Milli-Q'
pyrogen-free ultra-pure water.
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Table 2. Bacterial Strains
Bacterial Strains Source
E. coli





018:Krf (isogenic mutant of
018:K1) Dr A S Cross (see below)
E. coli
Serotype strains 02:K? Dr A S Cross
04:K? Dept of Bacterial Diseases
06:K5 Div of Community Diseases
012:K? and Immunology
015:K? Walter Reed Army Institute of
016:K1 Research
018:K1 Washington DC USA
018:K1 (isogenic mutant of above)
E. coli
Clinical, blood 018:K5 (226)




Dr A P Gibb










Dr I W Sutherland
Institute of Cell & Molecular
Biology
King's Buildings Edinburgh
Dr N D Mehta
St Mary's Medical School
London
K. pneumoniae
Serotype strain Dr I W Sutherland (as above)
P. aeruginosa




a) Nutrient agar was Columbia agar base (Oxoid Ltd., Basingstoke,
Hants.).
b) Iso-sensitest agar (Oxoid)
a) and b) were prepared by the Medical Microbiology Media kitchen
according to manufacturers' instructions. Media was sterilised
by autoclaving at 15 psi for 15 min.
c) Nutrient broth was Gibco and prepared at the Blood Transfusion
Service Protein Fractionation Centre, Edinburgh. The medium was
sterilised by ultrafiltration.
d) Malka minimal medium was prepared as a modification of the medium
of Robert-Gero et a 1 (1970) as follows:
Solution A NAjHPO^TS.A mg ml"*), KI^PO^ (32.A mg ml *)
Solution B MgS0r7H20 (20.5 mg ml"1)
Solution C 20% w/v glucose
Solution D FeSO^-yHjO (1.83 mg ml *) in sterile distilled water
to which one drop of concentrated hydrochloric acid (HC1) was
added
Solution E (NH^)2S0A (50.0 mg ml"1)
All chemicals were from BDH. Solutions were prepared with sterile
distilled water and were filter sterilised. All solutions except C
were stored over chloroform. To prepare 1 litre of MALKA, 20 ml A, 20
ml B, 20 ml C, 1 ml D and 20 ml E were added to 919 ml sterile
distilled water. Modifications of this medium were prepared by the
addition of either a 10%, 5%, 1% or 0% volume of the magnesium salt
(Solution B) used for the standard minimal medium.
e) Nitrogen deficient/high carbon medium was prepared following the
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method of Sutherland & Wilkinson (1965) containing: 1 g yeast
extract (Oxoid); 1 g casamino acids (Difco technical grade); 10 g
Na2HP04; 3 g KH2P0^; 0.2 g MgS0r7H20; 11 g KjSO,; 1 g NaCl; 0.01 g
CaCl2; and 0.01 g FeSO^. The volume was made up to 1 litre with
sterile distilled water and autoclaved. To this, 20% w/v filter-
sterilised glucose solution was added to give a final concentration
of 2% glucose w/v.
f) Iron depleted medium was prepared by the addition of 150 pmol. L 1
2,2' dipyridyl (Sigma Chemical Co., Poole, Dorset) to Gibco
nutrient broth. Modifications to this medium used in growth
experiments are described in the results.
g) Magnesium/iron depleted medium was prepared by the addition of 150
pmol. L* 2,2' dipyridyl to a modification of the Malka minimal
medium containing 1% of the normal magnesium salt concentration.
h) Sheep serum was obtained from the Moredun Research Institute,
Gilmerton Road, Edinburgh. Serum was filter sterilised (0.45 pm
pore size) and stored at -20°C. Heat-inactivated serum was
prepared by heating at 56°C for 60 min and stored as above.
Lipopolysaccharides
A number of lipopolysaccharides were prepared as described below.
Serum Human serum containing low concentrations of core-glycolipid
antibodies for spiking with LPS was obtained from blood donors at the
Blood Transfusion Centre, Edinburgh.
Antibiotics
The p-lactam, Ampicillin (Beecham Research Laboratories, Brentford,
England); Chloramphenicol (Parke-Davis & Co., Hounslow, London); the
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quinolone Ciprofloxacin (Bayer UK, Hayward's Heath, West Sussex), and
the aminoglycoside Gentamicin (Parke-Davis & Co.) were used. Anti¬
biotic solutions were prepared according to the manufacturers'
instructions immediately before each experiment.
Monoclonal antibodies
All MAbs were obtained from fusions carried out in the Department of
Surgery, University Medical School, Edinburgh. MAbs were prepared by
fusing spleen cells from immune BALB/c mice with NS-0 myeloma cells by
standard techniques (Kipps & Hertzenberg, 1986). The reactivity of the
MAbs was determined by a LPS-polymyxin enzyme linked immunosorbent
assay (ELISA), as described by Scott & Barclay (1987). A summary of
the MAbs used and their immunogen(s) is presented in Table 3.
Supernatant fluids of hybridoma cell cultures grown in RPMI 1640
supplemented with 5% v/v fetal calf serum in 150 cm flasks were used
throughout unless specified. Cell cultures were grown to maximum cell
density and harvested at 50% cell viability. These hybridomas gave
yields of approximately 50 pg/ml.
Mouse MAbs were isotyped using a mouse monoclonal antibody isotyping
kit (RPN29) (Amersham International pic, Amersham, Bucks).
1.3 EQUIPMENT
Equipment and apparatus used in the experimental studies are described
in the relevant section of the text. Manufacturers' addresses are only
cited once.
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Table 3. Monoclonal Antibodies
Fusion MAb Immunogen Isotype
27 27.150.3 Cyclic: P. aeruginosa PAC605; IgG2a
27.193.3 E. coli Rl, R2, R3, R4, K12 IgM
Heat-killed bacteria
30 30.4.2.8 E. coli J5 Lipid A IgM
on cytoden beads
then J5 and Re595 LPS booster
40 40.18.7.1 E. coli R3 IgG3
Heat-killed bacteria
43 43. 3. 4.8 E. coli 018 rough IgG3




184 184.2.5.5 E. coli 018:K1 IgG
Heat-killed bacteria





2.1 CULTURE OF BACTERIA
All bacteria were cultured at 37°C in air. Bacteria were streaked onto
nutrient agar from lyophilized maintenance cultures, resuspended in a
small volume of nutrient broth. Subculture of bacteria onto fresh
plate media was performed fortnightly for up to three subcultures.
Thereafter, fresh cultures were prepared from maintenance cultures.
Bacteria were inoculated into 10 ml liquid medium to prepare a starter
culture prior to dispensing a 1% inoculum into larger volumes for
further growth. All liquid cultures were incubated in an orbital
incubator (Gallenkamp, Widnes, Lanes.) at 120-150 rpm. Cultures were
grown to early stationary phase and purity determined by Gram-staining.
2.2 MEASUREMENT OF BACTERIAL CONCENTRATIONS
Total counts Whole cell counts performed in a haemocytometer (Thoma,
Hawks 1ey, Eng1and).
Viable counts Serial ten-fold dilutions of bacteria were prepared in
sterile phosphate-buffered saline (PBS) (50 mM phosphate buffer, pH7.4,
containing 0.15 M NaCl) and volumes of 100 pi were plated on nutrient
agar plates. Plates were incubated at 37°C for up to 24 h and numbers
of colonies established using a colony counter (Gallenkamp,
Loughborough, Leics.).
Measurement by absorbance Measurements of absorbance (A) were made at
525 nm (spectrophotometer, Unicam, Cambridge, England). PBS was used
as a blank and as a diluent for absorbance measurements. A standard
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curve of log bacterial numbers (as determined by viable counts) against
Aj2j was constructed. An absorbance of 0.5 at 525 nm represented
0 _1
approximately 1x10 cells ml .
2.3 MINIMUM INHIBITORY CONCENTRATIONS
The minimum inhibitory concentration (MIC) of each antibiotic was
determined for each strain by the agar dilution method on iso-sensitest
agar in twofold dilutions. A multipoint inoculator (Mast Laboratories
Ltd., Liverpool, England) delivered a standard inoculum from bacterial
suspensions adjusted spectrophotomically, containing approximately lxlO*1
cells ml *.
2.4 ABSORPTION OF SERUM WITH WHOLE CELLS
Heat-inactivated sheep serum was subjected to a series of absorptions
with either identical or unrelated E. coli whole cells to those being
cultured in the absorbed serum. Cultures of washed bacteria were
resuspended to a density of 1x10^ cells ml *. Bacterial suspensions (1
ml) were harvested by centrifugation at 3,000 g for 5 min. After
removal of supernatant, bacteria were resuspended in 10 ml of serum,
incubated for 15 min at room temperature, and recentrifuged. The
supernatant was then added to another pellet of cells and the process
repeated. This step was repeated at least three times for each
absorbing cell type to ensure maximal absorption of antibodies by
bacteria. Samples of absorbed and unabsorbed serum were compared in
growth study experiments.
2.5 PREPARATION OF SMOOTH LIPOPOLYSACCHARIDES
Extraction of LPS from organisms expressing the S-LPS phenotype was
based on the aqueous phenol method of Westphal & Liideritz (1954).
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Eight, 2 litre flasks containing 1 litre of medium were inoculated with
a 1% volume of overnight starter culture grown in the equivalent
medium. The flasks were incubated in an orbital incubator (120 rpm) at
37°C overnight. Cells were harvested by centrifugation at 15,000 g
using a KSB continuous flow system (Dupont UK Ltd., Stevenage, Herts.),
before washing twice in PBS with centrifugation (Sorvall RC-5B
refrigerated superspeed centrifuge, Dupont) at 10,000 g for 10 min.
The bacterial pellet was frozen at -20°C, lyophilized and weighed.
A finely divided lyophilized bacterial mass was resuspended to a
concentration of 5% w/v in distilled water and heated to 67°C in a
water bath. Meanwhile, 90% w/v aqueous phenol was prepared by
dissolving 90 g of phenol (BDH) in 10 ml of distilled water at 45°C,
before making the volume up to 100 ml with distilled water. A volume
of phenol equal to that of the bacterial suspension was heated to 67°C
in a water bath. The prewarmed bacterial suspension and phenol
solution were mixed and stirred at 67°C for 15 min. The mixture was
transferred to 50 ml centrifuge tubes and cooled in ice to allow
separation of the phenol and aqueous phases. The tubes were then
centrifuged at 10,000 g for 15 min to complete separation of the
phases. The upper aqueous phase containing the LPS was carefully
removed and the extraction procedure repeated on the lower phenol
phase. The pooled aqueous phases were transferred to dialysis tubing
(Medical International Ltd., London) (washed and boiled for 10 min in
distilled water) and dialysed against running tapwater overnight, until
the smell of phenol was no longer detectable. The solution was
centrifuged for 15 min at 10,000 g to remove any insoluble deposit.
The dialysed extract was then concentrated by rotary evaporation (Buchi
Rotavapor-RElll, Switzerland) to approximately one-fifth of its
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original volume. This was proceeded by ultracentrifugation (Sorvall
ultracentrifuge - 0TD65B, Dupont) of the solution at 100,000 g for 3 h.
The resultant gelatinous pellet was resuspended in distilled water with
the aid of a syringe fitted with a 23-gauge needle and recentrifuged.
The final pellet was suspended in a small volume of pyrogen-free water,
lyophilized and weighed. The LPS was stored at -20°C until required.
2.6 PREPARATION OF ROUGH LIPOPOLYSACCHARIDES
Bacteria were cultured and lyophilized as described for S-LPS preparat¬
ions. The aqueous phenol, chloroform, petroleum ether (PCP) method of
Galanos et al (1969) incorporating the diethyl ether precipitation of
LPS described by Qureshi et al (1982), was used to prepare LPS
expressing the R-LPS phenotype.
The extraction solvent (PCP) consisted of 90% phenol (Section 2.5),
chloroform and petroleum spirit (40°-60°C boiling point) in the
proportions 2:5:8 by volume. Lyophilized bacteria were resuspended in
PCP at approximately 25% w/v, stirred for 2 min below 20°C, followed by
centrifugation at 10,000 g for 15 min. The supernate was filtered
through Whatman No 1 filter paper into a round bottomed flask. The
centrifuged pellet was re-extracted by the same procedure, and the
filtered supernates pooled. Chloroform and petroleum were removed from
the supernate by rotary evaporation.
LPS was precipitated by the addition of six volumes of diethyl
ether/acetone (1:5 by volume) to one volume of phenol solution. After
standing for 1 h the LPS was sedimented by centrifugation at 5,000 g
for 10 min. The pellet was washed three times in diethyl
ether/acetone. The final pellet was dried under vacuum until the smell
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of ether/acetone was no longer detectable, and resuspended in 5 ml of
distilled water with the aid of a syringe fitted with a 23-gauge
needle. LPS was recovered by ultracentrifugation at 100,000 g for 4 h.
Finally, the LPS was taken up in a minimum amount of pyrogen-free water
and stored at -20°C until used.
2.7 DEIONIZATION OF LIPOPOLYSACCHARIDE BY ELECTRODIALYSIS
Deionization of LPS was based on the method described by Galanos &
Liideritz (1975) using apparatus developed by ISCO, Nebraska, USA. LPS
was suspended in pyrogen-free water (5-10 mg ml"*) and placed in a
three-chambered electro-dialysis cell, before adding distilled water to
the two electrode chambers. A voltage of up to 500 V was maintained
across the cell. The contents of the chambers was replaced several
times over 3-4 h when the pH in the cathodic chamber rose. The
precipitated acid form of the LPS (deionized) was recovered from the
anodic side of the cell and suspended in pyrogen-free water. Deionized
LPS was solubilized by neutralization with sodium hydroxide.
2.8 PROTEINASE K DIGESTION OF BACTERIA FOR THE PREPARATION
OF LIPOPOLYSACCHARIDES
The proteinase K digestion of bacteria with both R- and S-LPS types
(Hitchcock & Brown, 1983) was used to prepare LPS for analysis by PAGE
and immunoblotting. Bacterial cultures were harvested by
centrifugation and washed twice in PBS. The density of washed bacteria
was adjusted to an of between 0.5 and 0.6 as measured spectro-
photomically. Bacterial suspension (1-5 ml) was transferred to an
Eppendorf tube (Elkay) and the bacteria sedimented by micro-
centrifugation at 10,000 g for 3 min. The pellet was resuspended in 50
pi of single strength PAGE sample buffer (see Section 2.10) and heated
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at 100°C for 10 min. On cooling, 10 pi of sample buffer containing 25
/ig of proteinase K (Sigma protease Type XI) (2.5 mg ml ^ in sample
buffer) was added followed by incubation in a 60°C water bath for 60
min. Samples were stored at -20°C.
2.9 PREPARATION OF OUTER MEMBRANE PROTEINS
Bacterial cultures were harvested by centrifugation at 10,000 g for 10
min. Cells were washed twice in PBS and centrifuged as above. The
bacterial pellet was resuspended in 13.5 ml distilled water followed by
the addition of Sarkosyl (7% w/v solution of sodium N-lauroyl
sarcosinate (Sigma)) at 0.7% w/v. Samples were sonicated (Microson,
Ultrasonic Cell Disruptor, Heat Systems-Ultrasonics Inc., NY, USA) for
six 1 min bursts with intervals of 30 s at an amplitude of 6-10 pm on
iced water. Whole cells were removed by centrifugation at 6,000 g for
10 min. The suspension was centrifuged at 50,000 g for 1 h and
insoluble outer membrane was harvested and washed once in 5 ml of
distilled water by centrifugation at 50,000 g at 4°C for 1 h. The
pellet was resuspended in 0.5 ml of distilled water by repeated
aspiration into a syringe through a 26-gauge needle. The suspension
was stored at -20°C.
2.10 PREPARATION OF SAMPLES FOR POLYACRYLAMIDE GEL ELECTROPHORESIS
Sample buffer (pH6.8) contained 0.0625 M Tris (BDH) at pH6.8 in which
2.0% w/v SDS (BDH Specially Pure), 10% v/v glycerol (BDH), 1% v/v 2-
mercaptoethanol (BDH) and 0.001% bromophenol blue (BDH) were present.
Double strength sample buffer (pH6.8) was made as above with concentra¬
tions of all constituents doubled.
Lipopolysaccharides Proteinase K digests were prepared as described
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above and samples were loaded onto the gels at 10 pi per track for
silver staining, or 20 pi for immunoblotting.
Protein samples The protein concentration of OMPs and purified MAbs
were determined by the method of Lowry et al (1951). Samples contain¬
ing 25 pg protein were mixed with an equal volume of double strength
sample buffer and were denatured by heating in a water bath at 100°C
for 2 min.
2.11 POLYACRYLAMIDE GEL ELECTROPHORESIS
PAGE was performed on acrylamide slab gels with the buffer system of
Laemmli (1970). PAGE of proteinase K samples for subsequent silver
staining and immunoblotting was carried out with SDS-free gel buffers
(Pyle & Schill, 1985). The following buffers and solutions were used
in PAGE:
a) Separating gel buffer (double strength, pH8.8) consisted of 0.75 M
Tris-HCl at pH8.8 to which 0.2% w/v SDS was added. (SDS omitted
for SDS-free buffer).
b) Stacking gel buffer (double strength, pH6.8) consisted of 0.25 M
Tris-HCl at pH6.8 to which 0.2% w/v SDS was added (SDS omitted for
SDS-free buffer).
c) Acrylamide stock solutions (40% w/v) contained 100 g acrylamide
(BDH Electrophoresis Grade) and 2.7 g methylene bis acrylamide (BDH
Electrophoresis Grade) made up to 250 ml with distilled water.
d) Electrode buffer (pH8.3) consisted of 0.025 M Tris (BDH), 0.192 M
glycine (BDH Chromatographically Homogenous) and 0.1% w/v SDS
(BDH).
Non-gradient gels
The separating gel was prepared as described in Table 4, with
87
Table 4. Preparation of polyacrylamide gels.
Volume (ml) to give acrylamide
concentration of:
Reagent
5% 12% 14% 20% 4%
Separating gel Stacking gel
Distilled water 4.7 5.2 3.45 1.3 3.5
Separating buffer 6.6 17.5 17.5 8.6
Stacking buffer 5.0
Acrylamide solution
(40% w/v) 1.6 10.5 12.25 1.0
Acrylamide solution
(50% w/v) 6.9
TEMED 0.01 0.05 0.05 0.012 0.02
Ammonium persulphate
(15mg/ml) 0.32 1.75 1.75 0.41 0.5
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deaeration under vacuum prior to addition of TEMED (NNN'N'-
tetramethyl-l,2-diamino ethane (BDH Electran) and ammonium
persulphate (BDH). The gel solution was poured between glass
plates (160 mm x 125 mm x 1.5 mm) previously wiped clean with
methanol and sealed with molten vaseline. The gel was overlayed
with water saturated butan-2-ol (BDH) and allowed to set. After
removal of butan-2-ol, the stacking gel (prepared in a similar
manner) (Table A), was poured onto the separating gel. A comb was
inserted and the gel allowed to set. On removing the comb, the gel
was secured within an electrophoresis tank (hand built by Mr J
Duffus, Dept of Medical Microbiology, University Medical School,
Edinburgh) and electrode buffer added.
Gradient gels
Prepared as described above, except for the separating gel which
was composed of a gradient of between 5% and 20% from top to
bottom. The gradient was established using a gradient mixer.
Samples, prepared as described above, were loaded into the wells of the
stacking gel. These were electrophoresed through the stacking get at
a constant 60 V and through the separating gel at a constant 150 V
until the dye front had run 8 cm. Electrophoresis was proceeded by
staining or immunoblotting.
2.12 SILVER STAINING OF POLYACRYLAMIDE GELS FOR LIPOPOLYSACCHARIDE
The LPS separating gels were stained with silver by the method of Tsai
& Frasch (1982), modified by Hancock and Poxton (1988). The following
reagents and solutions were used in the silver staining procedure:
a) Fixative consisted of 7% w/v acetic acid (BDH General Purpose) and
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25% propan-2-ol (BDH General Purpose).
b) Oxidizing solution contained 1.05 g periodic acid (BDH General
Purpose) in 150 ml of distilled water to which 4 ml of fixative was
added.
c) Ammoniacal silver nitrate solution was made up by mixing 1.4 ml
ammonia solution (BDH General Purpose) with 21 ml of 0.36% w/v
sodium hydroxide (BDH) and the slow addition of 4 ml silver nitrate
(BDH) accompanied by vigorous agitation. The solution was made up
to 100 ml with distilled water.
d) Developing solution consisted of 0.019% v/v formaldehyde (BDH)
solution containing 0.005% w/v citric acid (BDH).
The gel was placed in fixative overnight followed by oxidation in
freshly prepared periodic acid for 5 min. After frequent washing over
a 4 h period in distilled water, fresh ammoniacal silver nitrate
solution was added for 15 min. Following at least four washes in
distilled water over 40 min, gels were transferred to freshly made
developing solution. On development the gel was washed repeatedly in
large volumes of distilled water. The gel was stored in the dark.
(All reaction steps were shaken following fixation).
2.13 COOMASSIE BLUE STAINING OF POLYACRYLAMIDE GELS FOR PROTEIN
The Coomassie blue stain described by Hancock & Poxton (1988) was used.
Solutions were made up in distilled water and included:
a) Solution 1-2% v/v propan-2-ol (BDH General Purpose), 10% v/v
acetic acid (BDH General Purpose) and 0.05% w/v Coomassie brilliant
blue R-250 (BDH).
b) Solution 2 - 10% v/v propan-2-ol, 10% v/v acetic acid and 0.005%
w/v Coomassie blue.
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c) Solution 3 - 10% v/v acetic acid and 0.0025% w/v Coomassie blue.
d) Solution 4 - 40% v/v methanol (BDH General Purpose) and 10% v/v
acetic acid.
e) Solution 5 - 10% v/v acetic acid.
The gel was placed in Solution 1 overnight and then sequentially
through Solutions 2-5, each for 30-60 min at room temperature with
gentle shaking throughout.
2.14 IMMUNOBLOTTING
This was based on the method of Towbin et al (1979) as described by
Hancock & Poxton (1988). LPS components separated in PAGE were
transferred to nitrocellulose (NIC) paper (pore size 0.2 pm)
(Schleicher & Schuell, Dassel, Germany) for immunochemical analysis.
The following reagents and solutions were used:
a) Electrode transfer buffer (pH8.3) - contained 12 g TRIS (BDH
General Purpose), 57.68 g glycine (BDH Chromatographically
Homogeneous) in 4 litres distilled water and 1 litre methanol (BDH
General Purpose).
b) Tris buffered saline (pH7.5) (TBS) - contained 4.84 g Tris (BDH),
58.48 g NaCl (BDH) and 2 litres distilled water.
c) Tween-Tris-buffered saline (pH7.5) (TTBS) - as for TBS, containing
0.025% v/v Tween 20 (Sigma).
d) Blocking solution - as for TBS containing 3% w/v gelatin (Bio-Rad
EIA Purity Grade, Bio-Rad Laboratories Ltd., Watford, Herts.).
e) Antibody/conjugate diluent - as for TBS containing 1% w/v gelatin
(Bio-Rad).
f) Horseradish peroxidase (HRP) colour solution - contained 30 mg HRP
colour reagent (Bio-Rad EIA Purity Grade) dissolved in 10 ml
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methanol (BDH), to which 50 ml TBS containing 60 pi hydrogen
peroxide (30% w/v BDH General Purpose) was added.
Electrophoretic transfer of antigens from polyacrylamide gels to
nitrocellulose
The gel was removed from the PAGE apparatus and placed in the
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Scotchbite pad cassette of the blotting apparatus (hand made by Mr J
Duffus, Dept. Medical Microbiology, University Medical School,
Edinburgh). The gel was covered with a sheet of NIC presoaked in
transfer buffer before closing the cassette, sandwiching the gel and
NIC paper between the two pads. The assembled cassette was then placed
into the immunoblotting tank containing transfer buffer, ensuring the
gel was placed towards the cathode and the NIC towards the anode. A
constant current of AO mA was applied overnight at 4°C.
Immunological staining of antigens
After transfer, the NIC was removed and washed in TBS for 10 min before
placing in blocking solution for 30-45 min. The blocked NIC was
transferred into antibody buffer containing a 1:10 dilution of MAb
(shown to give optimum staining). The NIC was rinsed briefly in
distilled water and washed for two 10 min periods in TTBS, followed by
incubating with a HRP-conjugated secondary antibody (diluted 1:500 in
antibody diluent) for 1 h. Conjugates used included an anti-mouse IgG
(ICN Biomedicals, High Wycombe, Bucks.) and an anti-mouse IgG/M/A
(Zymed Laboratories Inc., San Francisco, California, USA). The NIC was
rinsed in distilled water and washed in TTBS as above. Binding of
antibody to separated antigenic determinants was visualized by addition
of freshly prepared HRP colour development reagent to the NIC. The
reaction was stopped when appropriate by washing the membrane in
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several changes of distilled water. The blot was dried and stored in
the dark. (After the blocking step, gentle shaking was used
throughout).
2.15 IMMUNOELECTRON MICROSCOPY
Immunoelectron microscopy was performed by a modification of the method
described by Hancock & Poxton (1988). Bacterial cultures were
harvested and washed twice in 0.01 M sodium cacodylate buffer, pH7.2.
Cells were fixed in cacodylate buffer containing 2% w/v paraformalde¬
hyde (prepared by heating the 2% solution to 60°C, allowing it to cool,
adding 1 M NaOH dropwise until clearing occurs, and then adjusting to
pH7.2 by addition of 1 M HC1) and 0.1% v/v glutaraldehyde for 1 h at
4°C. After washing in cacodylate buffer, cells were dehydrated twice
in graded alcohols and finally rinsed twice in 100% ethanol that had
been dried by filtering through sodium sulphate. Samples were embedded
in London Resin white and dried at 60°C for 18 h. Thin sections were
cut in an ultramicrotome, and placed on nickel grids.
The immunoassay was carried out at room temperature by placing
sequentially in:
a) 1% w/v bovine serum albumin (BSA) in PBS, pH7.2, for 15 min to act
as a blocking agent.
b) Antibody solution containing a 1:10 dilution of MAb in antibody
diluent (see ELISA methodology Section 2.19) for 2 h.
c) 0.1% BSA w/v in 20 mM TBS, pH8.2, to act as a holding buffer prior
to washing under a succession of drops of approximately 8 ml TBS
from a burette.
d) 1% w/v BSA-TBS for 15 min to act as a blocking buffer.
e) 1:20 dilution 15 nm gold conjugated anti-mouse IgG/IgM (Janssen
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Life Sciences, Olen, Belgium) for 1 h.
f) 0.1%, w/v BSA-TBS holding buffer prior to washing in the same
buffer, followed by distilled water as above.
Immunogold thin sections were viewed with a Hitachi 12A electron
microscope at 75 KV.
2.16 WHOLE CELL ELECTRON MICROSCOPY
Simple negative staining was performed using the method described by
Hancock & Poxton (1988). Bacteria were harvested from broth, washed
once in PBS and resuspended to a milky turbidity in 1% w/v ammonium
acetate. Equal volumes of suspension and 2% v/v phosphotungstic acid
(neutralized to pH7 with sodium hydroxide) were mixed on the surface of
a glass slide. Formvar-coated 400 mesh copper grids were floated on a
drop of the specimen for 30 s before removing excess fluid by lightly
blotting with filter paper (Whatman No 1). Grids were placed in a
desiccator for several min before viewing with the electron microscope.
Grids were examined for capsule presence and relative thickness.
2.17 FLOW CYTOMETRY
Washed cultures of bacteria were resuspended to an A^j of between 0.5
8 ~1and 0.6, equivalent to approximately 1x10 cells ml . Suspensions (1
ml) were microcentrifuged at 10,000 g for 2 min and the pellets
resuspended in 1 ml of MAb culture supernates, diluted 1:10 in dilution
buffer (see ELISA methodology, Section 2.19), and incubated for 60 min
at 37°C. Samples were washed twice in PBS and 0.5 ml sheep FITC-
conjugated anti-mouse IgG or IgM (ICN Biomedicals) (diluted 1:100 in
dilution buffer) was added, and incubated for 60 min at 37°C.
Following further washings in PBS, the pellet was resuspended in 1 ml
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PBS containing 0.5% formaldehyde.
Prepared samples were diluted 1:50 in PBS, and the fluorescence of
stained bacteria quantified using an EPICS *C* (Coulter Electronics)
flow cytometer equipped with a 5 watt argon ion laser, operating at 500
mW and exciting at 488 nm. Cells were passed through the beam at
approximately 500 s"1 from a standard 76 pm flow cell tip. Background
noise and clumps of cells were excluded by a gate on the log forward
angle light scatter. Cells stained with FITC conjugate, but no primary
antibody, provided a background staining level, set at 1% ± 0.5% by
adjusting the voltage applied to the green fluorescence log (GFL)
photomultiplier tube. A total of 50,000 cells were analysed from each
sample and the percentage of cells exhibiting positive staining GFL was
calculated by the EPICS 'Stat Pack' programme.
Cell sorting
Viable bacterial cells were sorted in the flow cytometer on the basis
of differential MAb binding (fluorescence). The instrument was
sterilised with 50% ethanol. Bacteria were prepared as previously
described but omitting the fixation step. The light scatter gain was
set at maximum, a horizontal gate set to exclude debris, and vertical
fluorescence gates set to separate cell populations of interest.
Sorted bacteria were collected in nutrient broth and subcultured on
nutrient agar medium. Single clones were picked, expanded, and
reanalysed by flow cytometry.
2.18 IN VIVO ANIMAL MODELS
All animal manipulations were performed by Mr J Verth and colleagues
(Animal House, University Medical School, Edinburgh) or Dr I R Poxton
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(Dept of Medical Microbiology, University Medical School, Edinburgh).
Chamber Implantation
Chambers were constructed and implanted in the mouse peritoneal cavity
based on the method described by Patrick et al (1984). Chambers were
made from 1 cm lengths of 1 ml polypropylene syringe barrels. Two
holes were made towards each end of the chamber with a red-hot 25-gauge
needle. After autoclaving (15 psi for 15 min), the ends of the
chambers were sealed with autoclaved (10 psi for 10 min) 0.22 pm
membrane filters (Millipore, Bedford, M.A. USA) using UHU glue (Beecham
UHU, Brentford, Middlesex). The E. coli culture used to inoculate the
chambers was grown overnight in nutrient broth, harvested, washed and
diluted in physiological saline to give a chamber inoculum of approxi-
5 -1
mately 1x10 cells ml . The chambers were filled through the holes with
bacterial suspensions. The two holes were sealed with UHU glue and the
chambers transferred to bijou bottles containing saline. The C57B16
male mice were anaesthetized by intraperitoneal injection of Avertin
(prepared by dissolving 0.315 g tribromoethyl alcohol in 0.25 ml iso-
amyl alcohol in a water bath at 37°C followed by the addition of 10 ml
physiological saline) at 0.2 ml/10 g body weight. Two chambers were
implanted into each animal through a small longitudinal incision in the
abdomen. The chambers were removed after the required incubation
period (see Results) before harvesting the cells by centrifugation and
washing twice in PBS. The numbers of viable bacteria in each chamber
were determined. Samples were finally prepared for analysis using
techniques described elsewhere in this section.
The mucin-haematin septicaemia model
The infection model was a modification of the method described by
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Appelmelk et al (1986b). Mucin and haematin reagents were prepared as
follows:
a) Mucin, 24% w/v was prepared by suspending 2.A g mucin (porcine
stomach mucin, type II,, Sigma) in 7 ml PBS adjusting to pH7.4 with
1 M NaOH. Volume was made up to 10 ml with PBS, and material
sterilised by autoclaving (10 psi for 10 min).
b) Haematin HC1, 0.234% w/v, was prepared by dissolving 23.4 mg
haematin HC1 (BDH) in 2 ml 0.05 M NaOH. Approximately 6 ml PBS was
added, adjusting to pH7.4 with 1 M HC1. The volume was made up to
10 ml with PBS. The solution was filter sterilised through 0.2 pm
pore size membrane filters (Millipore).
Equal volumes of the mucin and haematin preparations were mixed and
stored at 4°C. Overnight cultures of E. coli were harvested by
centrifugation and washed twice in PBS. Bacterial concentration was
adjusted to a total cell count of approximately 200 cells ml . The
mucin-haematin suspension was diluted with an equal volume of cell
suspension, and 0.5 ml inoculated into the peritoneum of C57B16 male
mice. Retrospective viable cell counts of inocula samples were
determined.
Mice were bled via the vena cava up to 24 h after inoculation, and the
blood transferred to sterile universals containing 20 units of heparin.
Bacteria were recovered from blood components using Sepracell-MN
(Sepratech Corporation, Oklahoma City, USA). Equal volumes of anti-
coagulated blood and Sepracell-MN were mixed gently in a centrifuge
tube. Samples were centrifuged for 20 min at 1,500 g to sediment red
blood cells. The first 20% of the supernatant, containing bacteria and
blood mononuclear cells was mixed with four volumes of PBS-BSA (0.1%
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w/v) and centrifuged at 300 g for 10 min to remove mononuclear cells.
Bacteria were recovered from the supernatant by centrifugation at 3,000
g and prepared for analysis.
2.19 ENZYME LINKED IMMUNOSORBENT ASSAY
Polystyrene microplate 8-well strips (Immuno module Polysorp F8, Nunc,
Inter Med, Kampstrip, Roskilde, Denmark) were used in all ELISA
experiments. Frame-modules were used to hold strips, forming a
'plate'. Mini-sorb tubes (Nunc) were used for making antigen and
antibody dilutions. The following diluents and buffers were used for
various ELISA procedures:
a) Coating buffer (pH9.6) consisted of 0.05 M carbonate/bicarbonate
buffer (6.2g L ^ NajCO^HjO and 4.2g L~^ NaHCO^) and 0.05% w/v sodium
azide (Sigma).
b) Post-coat buffer consisted of PBS (pH7.2) containing 5% v/v BSA
(ICN Biomedicals) and 0.05% w/v sodium azide.
c) Wash buffer consisted of PBS (pH7.2) containing 0.05% v/v Tween-20
(Sigma) and 0.05% w/v sodium azide.
d) Dilution buffer consisted of PBS (pH7.2) containing 0.05% v/v
Tween-20, 4% w/v polyethylene glycol 6,000 (Sigma) and 0.05% w/v
sodium azide.
ELISA coating procedures
a) Coating with whole bacteria
ELISA strips were coated with 100 pi per well of washed bacteria,
7 -1
resuspended to a density of 2x10 cells ml (measured spectrophotometri-
cally) in coating buffer. Coating was promoted by centrifugation at
630 g for 4 rain and leaving overnight at room temperature. Plates were
washed four times (Ultrawash 1, Dynatech Laboratories Ltd.,
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Billingshurst, Sussex) in wash buffer, before post coating at 100 pi
per well overnight at room temperature. After further washing, plates
were rinsed in distilled water and stored at -20°C until used.
b) Coating with heat killed or sonicated whole cells
7 -1
Washed bacteria were resuspended to a density of 2x10 cells ml in
dilution buffer and either heat killed at 100°C for 15 min or sonicated
for six, 1 min bursts with 30 s intervals. Preparations were added at
100 pi per well. Following overnight incubation at room temperature,
the procedure was as described for whole cell coating.
c) Coating with LPS-polymyxin complex (Scott & Barclay, 1987)
Stock solutions of LPS and polymyxin were made up in distilled water
and were sonicated for 30 s prior to mixing. Complexes were formed by
adding polymyxin B sulphate (Sigma) at a concentration of 0.2 mM with
LPS at a concentration of 0.1 mM. LPS-polymyxin complexes were
sonicated for a further 30 s and then stirred for 30 min. The mixture
was transferred to cellulose dialysis tubing with a 2,000 molecular
weight cut off (Spectrum Medical Industries Inc., Los Angeles, USA) and
dialysed overnight at 4°C against distilled water (containing 0.05% w/v
sodium azide) to remove excess, unbound polymyxin. Complexes were
stored in mini-sorb tubes at -20°C until required. Molarity of E. coli
R- and S-LPS was determined from the estimated molecular weights of LPS
as determined by Morrison & Jacobs (1976):
LPS TYPE MOLECULAR WEIGHT
Wild type smooth 15,000
Ra and Rb type A,500
Rc type 4,150
Rd and Re type 3,100
Microwell strips were coated with complexes at 100 pi per well after
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diluting 1:50 in coating buffer. Cocktails of different LPS-polymyxin
complexes (see Results) were constituted by mixing equal volumes of the
relevant complexes. Incubation, washing and post-coating were carried
out as described for LPS whole cell coating.
d) Coating with proteinase K digested cell extracts
Cultures of bacteria were harvested and washed twice in PBS before
0
resuspending to an A^j of 1.0 (equivalent to approximately 1x10 cells
ml *) in 0.0625 M Tris-HCl pH6.8. Suspensions were heated at 100°C for
10 min. On cooling, proteinase K (Sigma) (2.5 mg mlin Tris-HCl,
pH6.8) was added, followed by incubation in a 60°C water bath for 60
min. In preliminary experiments, the addition of several volumes of
the proteinase stock solution were investigated. A volume of 10 pi
(containing 25 pg of proteinase K) per 1.5 ml cell suspension was found
to digest the cells efficiently, whilst minimizing the amount of added
enzyme. Following digestion, samples were centrifuged at 10,000 g for
5 min to remove any undigested whole cells or large cell-fragments.
Digested extracts were then heated at 100°C for 5 min (found to
eliminate any residual proteinase K activity).
LPS containing samples were coated to microplates after complexing with
polymyxin B sulphate. Complexes were formed by mixing (30 min at room
temperature) equal volumes of presonicated 1 mM polymyxin and protein¬
ase K digested sample. The mixture was dialyzed as above to remove
excess, unbound polymyxin. In preliminary experiments, coating
microwell strips with LPS-polymyxin complexes, doubly diluted in
coating buffer from 1:2 to 1:128 were investigated. A coating dilution
of 1:16 was shown to give optimal sensitivity, yielding maximal
difference in optical density (0D) between coated wells and background
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controls. Following overnight coating at room temperature, the
procedure was as described for whole cell coating.
ELISA experimental procedures
a) Standard procedure to quantify anti-LPS MAb binding
MAb supernatant fluids were diluted in dilution buffer and added to
coated microplates at 100 (Ul per well in triplicate. Plates were
incubated at 37 C for 90 min before washing four times with wash
buffer. Urease-conjugated sheep anti-mouse 1 g (Sera Lab Ltd., Crawley
Down, Sussex) was diluted 1:500 in diluent, added at 100 /Ul per well
and plates incubated for a further 90 min at 37 C. Plates were washed
four times and rinsed with distilled water before urease substrate
(Sera Lab) was added at 100 jul per well. Plates were incubated for 60
min at room temperature and reactions stopped by adding IX w/v
thimerosal in distilled water (20 yl per well). The OD of wells was
read at 590 nm using an Anthos reader 2001 (Denley Instruments Ltd.,
Bi 11ingshurst, Sussex). Final results were expressed after subtraction
of the OD of negative control wells (coated with BSA post coat only)
for each MAb.
b) Suspension ELISA
The ability of selected MAbs to bind to a suspension of intact whole
cells in ELISA was investigated. Initial stages of the assay were
performed in microtubes. Nutrient broth grown bacterial cultures were
harvested and washed twice in PBS with centrifugation at 3,000 g for 5
min. Pellets of approximately 2x10 cells were resuspended in 1 ml of
each MAb dilution. Tubes were incubated at 37°C for 90 min with
occasional shaking, before centrifugation as above. The supernatant
was discarded and bacterial pellets washed twice in ELISA wash buffer
101
with centrifugation. Urease-conjugated sheep anti-mouse Ig was diluted
1:500, added at 1 ml per tube and incubated for a further 90 min at
37°C. Bacteria were recovered by centrifugation, before washing twice
in both wash buffer and distilled water. Samples were added to
microtitre plates at 100 pi per well (representing the equivalent cell
coating concentration of the standard ELISA coating procedure).
Coating was promoted by centrifugation at 630 g for 10 min before
removing supernatant from wells. Urease substrate was added at 100 pi
per well, and plates incubated for 60 min at room temperature before
reading at 590 nra.
c) Serial absorption of MAbs on whole bacteria
MAbs were absorbed serially by bacteria of S. typhimurium in ascending
order of LPS core size: lipid A, Re, Rc and Ra. Lipid A bacteria were
prepared by acid hydrolysis of the S. typhimurium Re mutant by
incubating at 100°C in 1% v/v acetic acid for 1 h. MAb supernate (1
ml), diluted 1:10 in dilution buffer, was added to a 1.5 ml Eppendorf
8 ~1
tube containing sedimented, washed bacteria at 1x10 cells ml .
Bacteria were resuspended in the MAb solution, incubated for 15 min at
room temperature and centrifuged at 10,000 g for 5 min using a micro¬
centrifuge. The supernatant was then added to another pellet of cells
and the process repeated. This step was repeated three times for each
absorbing bacterial strain to ensure maximal absorption of antibodies
by bacteria. A sample of MAb solution was removed after absorption by
each bacterial strain in the serial sequence for ELISA tests. The
ELISA procedure was as previously described.
d) Inhibition of ELISA
Anti-LPS MAb, diluted as appropriate in dilution buffer, was added to
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an equal volume of each dilution of various inhibitor preparations (as
specified in the Results). Samples were preincubated at 37°C for 30
min with occasional shaking before adding to the ELISA. Modifications
of this method are as outlined in the Results.
2.20 PURIFICATION OF MONOCLONAL ANTIBODIES
Selected MAbs were purified for use in the LPS detection assay system
only.
Concentration of MAbs from bulk growths
Culture supernatant from bulk growth (1 litre) of MAb producing clones
was centrifuged at 10,000 g for 10 min to remove cellular debris. The
MAb supernates were concentrated 20-fold by a Minitan tangential-flow
system (Millipore), employing Minitan pore filters (Millipore) with a
molecular weight cut-off of 30,000. The system was purged with 0.1 M
sodium hydroxide (BDH), copious amounts of pyrogen-free water and
primed with a small quantity of RPMI (Gibco, Paisley, Renfrewshire)
between each concentration. Activity of MAbs was checked by ELISA.
Ammonium sulphate precipitation of immunoglobulins
A modification of the method described by Hardy (1986) was used.
Immunoglobulin was precipitated by the addition of crystalline ammonium
sulphate (Sigma Grade III) to the concentrated solution containing MAb
to give 50% saturation (equivalent to a final concentration of 0.313 g
ml ^). Thus 3.13 g of ammonium sulphate was slowly added to 10 ml of
MAb preparation with stirring, and allowed to dissolve. The precipi¬
tate was stirred for 2 h at room temperature before harvesting by
centrifugation at 10,000 g for 60 min at 4°C. The pellet was resuspen-
ded in 10 ml of 0.1 M NaHCO^ (BDH) before repeating the precipitation
103
procedure as above. The ammonium sulphate was removed by dialysis for
20 h at 4°C with stirring, against at least three changes of 0.1 M
NaHCOj buffer containing 0.05% w/v sodium azide (Sigma). Activity of
the MAbs was checked by ELISA.
Cartridge chromatography
VU
Ammonium sulphate precipitated MAbs were further purified using MemSep
chromatography cartridges (Millipore). All buffers used for the
elution of MAb containing solutions were prepared with Milli-Q* ultra
pure water and filtered through Sterivex^-GS 0.22 pm filter units
(Millipore).
Protein-A IgG MAbs were purified using a Protein-A MemSep^" 1010
affinity membrane chromatography cartridge. The MAb sample was
prepared by diluting 1:2 in sample loading buffer containing 0.05
M Tris-HCl, 0.1 M NaCl, pH8 followed by filtration through a MiIlex*
-GV unit (Millipore). The cartridge was initially equilibrated by
passing through >45 ml of loading buffer. After loading with the
prepared MAb solution using a peristaltic pump, the sample was
recirculated several times at a flow rate of 3.6 ml min The
cartridge was rinsed with loading buffer until the Ajjq of the
effluent was at baseline. MAb was desorbed by passing 0.1 M
glycine-HCl, pH2.5 through the system, and A2gQ monitored until it
returned to baseline. Eluted MAb was neutralized with 5% v/v 1 M
Tris (BDH) before dialyzing against at least three changes of 0.1
M NaHCOj (BDH) containing 0.05% w/v sodium azide (Sigma). Fractions
were checked by ELISA for MAb activity.
DEAE IgM MAbs were purified using a DEAE Mem-Sep 1010 ion
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exchange membrane chromatography cartridge. MAb samples were
diluted 1:2 in sample loading buffer containing 0.02 M Tris-HCl, pH8
followed by filtration through Millex* -GV units (Millipore).
Prepared MAb solution was loaded on to the DEAE using a peristaltic
pump, and recirculated several times at a flow rate of 3.6 ml min"^.
The cartridge was rinsed with loading buffer until the A28q of the
effluent reached baseline. Protein components were desorbed using
a step-wise elution protocol based on increasing the NaCl concen¬
tration from 0.1 M to 1 M in 0.05 M increments. Individual
fractions were collected and analysed by ELISA for MAb activity.
The MAb containing fraction (eluting between 0.15 and 0.2 M NaCl)
was dialyzed against at least three changes of 0.1 M NaHCO^ (BDH)
containing 0.05X w/v sodium azide (Sigma).
2.21 BIOTINYLATION OF MONOCLONAL ANTIBODIES
Biotinylation of MAbs was based on the method described by Guesdon et
al (1979). Aminohexanoyl-biotin-N-hydroxysuccinimide ester (AH-BNHS)
(Zymed) was used to bind biotin covalently to the MAbs. The protein
concentration of purified MAbs was determined by the method of Lowry et
al (1951). Calculations of quantities of reagents were based on a
value of 90 free amino groups per gamma globulin molecule as reported
by Habeeb (1966). Various molar ratios (1:1, 2:1, 4:1) of AH-BNHS and
free amino groups of IgG and IgM MAb molecules were prepared to
determine the optimal binding ratio. To react a 1:1 molar ratio of AH-
BNHS with the free amino groups of IgG MAb, 27.5 pi of AH-BNHS (10
mg/ml dissolved in dimethylformamide BDH) was added to 1 ml of MAb (1
mg ml ' in 0.1 M NaHCO^). To react a 1:1 molar ratio of AH-BNHS with the
free amino groups of IgM MAb, 22.7 pi of AH-BNHS (10 mg ml *) was added
to 1 ml of MAb (1 mg/ml in 0.1 M NaHCOp. Reactions were performed in
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Reacti-vials (Pierce Chemical Co., Rockford, Illinois, USA) and were
gently stirred for 2 h at room temperature. The reaction mixture was
dialyzed for 24 h at 4°C with stirring, against several changes of PBS
(pH7.2) containing 0.05% w/v sodium azide (Sigma). After dialysis, an
equal volume of glycerol (Sigma) was added and the biotinylated MAbs
(bio-MAbs) stored at -20°C. The bio-MAbs were analysed by ELISA.
2.22 STREPTAVIDIN-BIOTIN ELISA SYSTEMS
Prepared bio-MAbs were used in a comparison of a streptavidin-biotin
enzyme non-amplification ELISA system, with an amplification system
incorporating streptavidin-biotin-enzyme complexes. Buffers, reagents
and methodologies used in these ELISA studies were as previously
described unless otherwise indicated.
Enzyme-labelled reagents The following enzyme-labelled reagents
were used at some stage in the development of the LPS-detection
assay: i) streptavidin alkaline phosphatase (SAP) (Zymed) diluted
1:1000 in dilution buffer (Section 2.19); ii) biotinylated alkaline
phosphatase-streptavidin (BAPS) complex made up by the addition of
10 pi biotinylated alkaline phosphatase (1 mg ml *) (Zymed) and 20
pi streptavidin (1 mg ml *) (Zymed) to 5 ml dilution buffer (PBS,
pH7.2, containing 0.05% v/v Tween 20 (Sigma).
Substrate Substrate for the alkaline phosphatase labelled reagents
was prepared by dissolving one p-nitrophenyl phosphate tablet (Sigma
104 phosphatase substrate tablets) per 5 ml of substrate dilution
buffer, pH9.8 (containing 0.05 M sodium carbonate/bicarbonate, 0.002
M magnesium chloride).
Bio-MAbs were serially diluted (or as appropriate) in diluent and added
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to antigen coated microwell strips at 100 pi per well. In some of the
investigations (chequerboard titratrions) strips were coated with a
series of different antigen concentrations. Plates were incubated for
90 min at 37°C and then washed. Enzyme labelled reagents were added at
100 pi per well and plates incubated for a further 90 min prior to
washing. Substrate was added (100 pi per well) and plates incubated
for 60 min at room temperature before the 0D was read at 405 run.
2.23 MONOCLONAL ANTIBODY COMPETITION STUDIES
An ELISA competition assay was used to compare the antigen binding
sites of different MAbs. Buffers, reagents and methodologies were as
previously described. A serial dilution of unlabel led MAb (capable of
saturating the binding site at the lowest dilution) was prepared in
dilution buffer and added to antigen coated microwell strips at 100 pi
per well. Following incubation at 37°C for 90 min, serially diluted
bio-MAb (the same as or different from the unlabel led MAb) was added to
the unlabel led MAb at 100 pi per well in a chequerboard formation.
MAbs were mixed by shaking and incubated for 90 min at 37°C, before
washing and adding 100 pi per well alkaline phosphatase conjugated
streptavidin (1:1000). Following incubation for a further 90 min at
37°C, plates were washed and substrate added at 100 pi per well.
Plates were incubated at room temperature for 60 min before the 0D was
read at 405 nm.
2.24 CAPTURE ELISA
An LPS capture ELISA, employing different combinations of various MAbs,
was developed with the aim of detecting either all E. coli core types
or specific core and 0-serotypes in solution. Solutions, reagents and
basic methodologies were as previously described.
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The wells of microwell strips were coated with MAb, diluted as
appropriate (see Results) in coating buffer. Plates were coated
overnight at room temperature before washing, post-coating and storing
as previously described. A series of dilutions of purified E. coli LPS
and heat-killed cells were made in dilution buffer and added at 200 pi
per well. Plates were incubated overnight at room temperature. Bio-
Mab, diluted as appropriate (see Results) was added at 100 pi per well
and plates incubated at 37°C for 90 min before washing. Alkaline
phosphatase conjugated streptavidin was added at 100 pi per well and
plates incubated for 90 min at 37°C. After further washing, alkaline
phosphatase substrate was added at 100 pi per well. The 0D of wells
was read at 405 nm following incubation for 60 min at room temperature.
The above method was used for detection of LPS in spiked serum samples.
Serum was treated in various ways prior to the assay, as described in
the Results. Samples were added at 200 pi per MAb coated well. The




CHARACTERIZATION OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES
All MAbs used in this thesis were obtained from fusions carried out in
the Dept Surgery, University of Edinburgh, as outlined in the Materials
and Methods. The selection of MAbs for use in these studies was based
on predetermined reactivity patterns against an extensive panel of both
R- and S-LPSs in a LPS-polymyxin extended incubation ELISA (Scott &
Barclay, 1987) (see Appendix). Selected MAbs were further character¬
ized in a number of assay systems employing different LPS preparations.
1.1 BINDING OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES AGAINST
HEAT-KILLED BACTERIA IN ELISA.
The binding activities of eleven MAb supernates against heat-killed
bacteria are shown in Figures 6-16. ELISA antigens included a broad
panel of Gram-negative E. coli and non-E. coli species expressing 0-
antigen S-LPS and core R-LPS. MAbs 184.2.5.5 (Figure 15) and 185.1.2.2
(Figure 16) reacted exclusively against the E. coli serotypes 018 and
06 respectively. Binding of MAb 184.2.5.5 to the rough mutant of E.
coli 018 reflected the presence of some leaking 0-antigen.
MAbs 27.150.3 (Figure 6), 43.11.5.1 (Figure 12) and 43.27.11.2 (Figure
13) were all fully cross-reactive with E. coli core types (R1-R4 and
K12) and all E. coli serotypes. These MAbs showed a weak, if any,
response to the R- and S-LPS strains of S. typhimurium, whilst only
43.27.11.2 recorded some, although weak reactivity against bacterias P.
aeruginosa and K. pneumoniae. Overall, MAb 27.150.3 produced the
strongest reactions against the panel of antigens, whilst MAb
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Figure 6. ELISA activity of HAh 27.150.3 against whole, heat-killed E. coli and non-i". coli rough
and smooth cell types.
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Figure 7. ELISA activity of IU 27.193.3 against whole, heat-killed S. coli and non-J. coli rough
and saooth cell types.
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Figure 8. ELISA activity of HAb 30.4.2.8 against whole, heat-killed E. coli and non-£. coli rough
and smooth cell types.
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Figure 9. ELIS& activity of HAb 40.18.7.1 against whole, heat-killed E. coli and non-f. coli rough
and siooth cell types.
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Figure 10. ELISA activity of SAh 43.3.4.8 against whole, heat-killed E. coli and non-f. coli rough
and siooth cell types.
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Figure 11. ELISA activity of MAI 43.5.1.4 against whole, heat-killed E. coli and non-f. coli rough
and saooth cell types.
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Figure 12. ELISA activity of SAh 43.11.5.1 against whole, heat-killed S. coli and non-f. coli rough
and siooth cell types.
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Figure 13. ELISA activity of HAb 43.27.11.2 against whole, heat-killed S. coli and non-J. coli rough
and siooth cell types.
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Figure 14. ELISA activity of HAh 43.35.1.4 against whole, heat-killed E. call and non-f. coli rough
and saooth cell types.
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Figure 15. ELISA activity of BAb 184.2.5.5 against whole, heat-killed S. coli and non-f. coli rough
and smooth cell types.
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Figure 16. ELISA activity of MAb 185.1.2.2 against whole, heat-killed E. coli and non-i". ro/i rough
and saooth cell types.
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43.27.11.2 produced the weakest. MAb 43.11.5.1 reacted strongly (OD
>1.0) against most E. coli antigens, although its binding to E. coli R3
and the R3 core of serotype 015 was significantly lower compared to
other rough and smooth E. coli strains.
MAb 27.193.3 demonstrated preferential binding to the E. coli R3 core
type and the R3 core of serotype 015 (Figure 7). Lower responses were
also produced with most other heat-killed cell preparations including
P. aeruginosa and K. pneumoniae. Selective binding was also observed
for MAb 40.18.7.1 which preferentially bound to Salmonella, E. coli R2
core type and the R2 core of serotype 012 (Figure 9). Weaker reactiv¬
ity was shown against E. coli core types R2, K12 and serotypes 02, 04.
MAbs 43.3.4.8, 43.5.1.4 and 43.35.1.4 reacted almost exclusively with
the E. coli R1 core type and those E. coli serotypes possessing the R1
core (Figures 10, 11 and 14). However, weak reactions against the
rough cells of either, or both, R4 and K12, were shown for MAbs
43.3.4.8 and 43.35.1.4.
MAb 30.4.2.8 showed a strong affinity for the two E. coli 018 serotype
strains (Figure 8). Weaker responses were also recorded against most
other E. coli strains and the Gram-negative bacteria of P. aeruginosa,
K. pneumoniae and the two S. typhimurium strains.
1.2 IMMUNOBLOT ANALYSIS OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL
ANTIBODIES
The ELISA studies against heat-killed bacterial preparations demon¬
strated the wide range in cross-reactivities of the MAbs, from serotype
specific to broadly cross-reactive antibodies. To confirm and
investigate further the LPS binding site of each of the MAbs, immuno-
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blot analysis was performed against LPS from proteinase K digests of
equivalent R- and S-LPS cell types to those used in ELISA. The silver
stained PAGE profiles of LPS and corresponding immunoblots of eleven
MAbs are shown in Figures 17-22.
The silver stained LPS profiles of smooth strains (Figure 17a) exhibit
the characteristic ladder pattern, each step up representing LPS
substituted with a progressively increasing number of O-polysaccharide
repeating oligosaccharide units. These were missing from the rough
mutants. The immunoblot of the equivalent LPS profiles against MAb
27.150.3 (Figure 17b) demonstrated binding of the antibody to both core
LPS substituted with O-antigenic side chains, and low molecular mass
unsubstituted core material. The MAb was fully cross-reactive against
all E. coli and Salmonella LPS preparations, but not reactive against
the smooth strains of P. aeruginosa and K. pneumoniae.
Immunoblots of MAbs 27.193.3 and 30.A.2.8 are shown in Figure 18. A
positive reactive band corresponding to the unsubstituted core LPS of
the R-LPS mutants of E. coli R3 (Track 7) was observed for MAb 27.193.3
(Figure 18a). A weak response was also shown against the unsubstituted
core LPS band of E. coli serotype 015 (possessing a R3 core type)
(Track 14). The MAb was unreactive against all other LPS preparations.
The high molecular mass band observed against many samples in this, and
other immunoblots, is thought to represent a non-specific reaction
against the proteinase K digest enzyme. In ELISA studies MAb 27.193.3
demonstrated a wider reactivity pattern against heat-killed cell
preparations, although it showed preferential binding to E. coli R3 and
015. MAb 30.4.2.8 reacted against the ladder-like 0-antigen bearing
LPS bands of the two smooth E. coli 018 strains, and against small
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Figure 17. a) Silver stained LPS profiles of proteinase I whole cell digests of 18 E. coli and non-£.
coli cell types separated by PA6E (14% w/v aerylaaide). b) Iaaunoblot of the equivalent proteinase
I whole cell digests separated by PAGE (14% w/v acrylaaide) followed by transfer to IIC paper and
probed with HAb 27.150.3 (supernatant 1:10). Track 1, P. aeruginosa Oil (S-LPS); Track 2, J.
pnewniae (S-LPS); Track 3, S. tjphinuriut R1542, Ra (R-LPS); Track 4, S. typhinuriua (S-LPS);
Tracks 5-9, E. coli Rl, R2, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04,




Figure 18. Iuunoblots of proteinase I whole cell digests of 18 E. coli and non-f. coli cell types
separated by PAGE (14k w/v acrylaiide) followed by transfer to IIC paper and probed with RAbs a)
27.193.3 and b) 30.4.2.8 (supernatant 1:10). Track 1, P. Aeruginosa Oil (S-LPS); Track 2, /.
pneuMcaiae (S-LPS); Track 3, S. typhiiuriullMl, Ka (R-LPS); Track 4, S. typhiauriua (S-LPS); Tracks
5-9, E. coli 11, R2, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04, 06, 012,
015, 016, 018:11 and 018:11- (S-LPSs) and Track 18, E. coli 018:Irf (R-LPS).
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Figure 19. Iuunoblots of proteinase I whole cell digests of 18 E. coli and dob-j. coli cell types
separated by PAGE (141 w/v acrylanide) followed by transfer to IIC paper and probed with HAbs a)
40.18.7.1 and b) 43.3.4.8 (supernatant 1:10). Track 1, P. aeragiaosa Oil (S-LPS); Track 2, I.
pntuioniae (S-LPS); Track 3, S. tjphtnriMlllkl, Ra (R-LPS); Track 4, S. tfphinrioa (S-LPS); Tracks
5-9, S. coli 11, R2, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04, 06, 012,
015, 016, 018:11 and 018:11- (S-LPSs) and Track 18, E. «//018:Irf (R-LPS).
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Figure 20. Iiiunoblots of proteinase I whole cell digests of 18 E. coli and non-J. coli cell types
separated by PAGE (141 w/v acrylaiide) followed by transfer to IIC paper and probed with HAbs a)
43.5.1.4 and b) 43.11.5.1 (supernatant 1:10) Track 1, P. aeruginosa Oil (S-LPS); Track 2, I.
pneuMonia (S-LPS); Track 3, S. typhiMuriuMllMl, Ra (R-LPS); Track 4, S. tjphiauriuM (S-LPS); Tracks
5-9, E. coli Rl, R2, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04, 06, 012,





Figure 21, Iuunoblots of proteinase I whole cell digests of 18 E. coli and non-J\ coli cell types
separated by PAGE (141 w/v acrylaiide) followed by transfer to IIC paper and probed with HAbs a)
43.27.11.2 and b) 43.35.1.4 (supernatant 1:10). Track 1, P. aeruginosa Oil (S-LPS); Track 2, I.
paeutoniae (S-LPS); Track 3, S. typhitoriua R1542, Ra (R-LPS); Track 4, S. typhiauriui (S-LPS);
Tracks 5-9, E. colill, R2, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04,
06, 012, 015, 016, 018:11 and 018:11- (S-LPSs) and Track 18, E. coli 018:Irf (R-LPS).
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Figure 22. Iuunoblots of proteinase I whole cell digests of 18 E. coli and non-£. coli cell types
separated by PAGE (14* w/v aerylaaide) followed by transfer to MC paper and probed with HAbs a)
184.2.5.5 and b) 185.1.2,2 (supernatant 1:10). Track 1, P. aerogonosa Oil (S-LPS); Track 2, I.
pneuMoniae (S-LPS); Track 3, S. typhiiuriuillMl, 8a (R-LPS); Track 4, S. tjphiaoriuM (S-LPS); Tracks
5-9, E. coli 81, 82, R3, R4 and 112 (R-LPSs); Tracks 10-17, E. coli serotype strains 02, 04, 06, 012,
015, 016, 018:11 and 018:11- (S-LPSs) and Track 18, E. co//018:Irf (R-LPS).
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amounts of high molecular mass O-antigen leaking from the rough mutant
of 018 (Tracks 16-18) (Figure 18b). Whilst showing preferential
binding to the two E. coli 018 serotypes, ELISA studies again demon¬
strated a broader reactivity against other LPSs.
MAb 40.18.7.1 reacted against the unsubstituted core LPS of the R-LPS
mutant of R2 (Track 6) and very weakly against the unsubstituted core
LPS region of E. coli serotype 012 (possessing a R2 core type) (Track
13) (Figure 19a). The MAb was also reactive against the full core R-
LPS mutant (Ra) of S. typhimurium R1542, although the band is barely
visible above the background on the photograph shown.
The immunoblots of MAbs 43.3.4.8, 43.5.1.4, 43.11.5.1, 43.27.11.2 and
43.5.1.4 are shown in Figures 19, 20 and 21. All MAbs reacted against
the low molecular mass core-glycolipid band, corresponding to the
unsubstituted LPS of both rough and smooth E. coli strains possessing
the R1 core structure. The strongest reactions in all these immuno¬
blots were against the core R-LPS mutants of E. coli R1 and 018:Krf
(Tracks 5 and 18), whilst MAbs 43.3.4.8 (Figure 19b) and 43.11.5.1
(Figure 20b) produced the strongest overall reactions against both R-
and S-LPSs. ELISA activities of these MAbs (especially 43.11.5.1 and
43.27.11.2) again demonstrated greater cross-reactivity than that shown
in immunoblots.
The specificities of MAbs 184.2.5.5 and 185.1.2.2 for the O-serotypes
of E. coli 018 and E. coli 06 respectively, was confirmed by immuno-
blotting. MAb 184.2.5.5 reacted strongly against the O-antigen bearing
molecular mass bands of both E. coli 018 strains and the high molecular
mass O-antigen leaking from the rough mutant of 018 (Tracks 16-18)
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Figure 23. Iuunoblots of proteinase I whole cell digests of 4 E. coli strains probed with MAbs
184.2.5.5 (a); 43.27.11.2 (b) and 27.150.3 (c) (supernatant 1:10). Track 1, 018:11 (S-LPS); Track
2, 018:Il~ (S-LPS); Track 3, 018:Krf (R-LPS) and Track 4, 06:15 (S-LPS).
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(Figure 22a). MAb 185.1.2.2 reacted strongly against the corresponding
O-antigen bearing molecular mass bands of E. coli 06 (Figure 22b).
Immunoblots probed with three MAbs described above are shown in Figure
23 as a direct comparison of their binding specificities. Serotype
specific MAb 184.2.5.5 reacted with only substituted core material
bearing O-antigen LPS (Figure 23a). Of the two anti-core MAbs,
43.27.11.2 bound only to the fast migrating species that corresponded
to the unsubstituted core-glycolipid, whilst 27.150.3 reacted with both
the low molecular mass band of unsubstituted core LPS and substituted
core material of higher molecular mass bands (Figure 23b and c).
1.3 FLOW CYTOMETRIC ANALYSIS OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL
ANTIBODIES AGAINST WHOLE BACTERIA
Table 5 shows the binding activities of anti-LPS MAbs against whole
cells in suspension by flow cytometry. Results are presented as
percentage values, which refer to the proportion of cells exhibiting
positive fluorescence above a background staining level set at 1% ±
0.5%. The serotype specific MAbs of 184.2.5.5 and 185.1.2.2 showed
strong positive fluorescence (>50%) against the O-antigens of E. coli
018 and 06 respectively. No reactivity was observed with whole cells
of all other Gram-negative cells.
The specificities of those MAbs reactive against core-glycolipid LPS
were confirmed by results of flow cytometry. Those MAbs previously
shown to preferentially bind to selective E. coli core R-LPSs, also
demonstrated strong affinity against their respective homologous whole
cells (for example, MAbs 27.193.3, 40.18.7.1 and 43.3.4.8). However,
with the exception of 0-serotype reactive MAbs, MAbs either demon-
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Table 5. Flow cytometric analysis of 11 anti-LPS MAbs binding to rough
and smooth whole cells of E. coli, and S. typhimuriwn R15A2.
Percentage values represent the mean positive fluorescence of bacteria
above background levels.
Percentage of cells showing positive fluorescence
E. coli core type E. coli O-serotype S. typhimurium
MAb R1 R2 R3 RA K12 06 012 015 018 R15A:
27.150.3 31 27 15 18 27 ND 3 0 2 10
27.193.3 0 18 A8 1A 19 ND 0 12 0 13
30.A.2.8 21 18 8 30 22 ND 0 0 56 11
AO.18.7.1 21 52 5 13 29 ND 12 0 0 A5
A3.3.A.8 76 0 0 16 0 ND 0 0 3A 0
A3.5.1.A 69 0 0 0 0 ND 0 0 28 0
A3.11.5.1 66 63 3 3A 31 ND 9 0 15 7
A3.27.11.2 65 35 3 2A 29 ND 0 0 3 9
A3.35.1.A 72 0 0 12 0 ND 0 0 20 0
18A.2.5.5 0 0 0 0 0 0 0 0 75 0
185.1.2.2 0 0 0 0 0 69 0 0 0 0
ND = not done
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Table 6. Flow cytometric analysis of anti-LPS MAb binding to E. coli
018:K1 : effect of boiling bacteria.
Percentage of cells showing
positive fluorescence *
MAb Unboiled Boiled **
27.150.3 3 (±2) 39 ( ±4)
43.3.4.8 28 (±6) 57 (±11)
43.11.5.1 18 (±5) 71 ( ±9)
43.27.11.2 5 (±2) 46 ( ±8)
184.2.5.5 74 (±8) 71 (±12)
185.1.2.2 0 0
* Each FC value represents the mean (±SD) from three separate
experiments.
** Bacteria were boiled for 15 min before incubation with MAb and
staining with FITC-labelled secondary antibody.
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strated no reactivity or weak reactivity against smooth E. coli strains
(most showing labelling of <20%). Those MAbs reacting against
selective smooth whole cells at levels of >20% included MAbs 43.3.4.8
and 43.5.1.4. MAb 27.150.3, shown previously to be cross-reactive in
ELISA and immunoblotting studies was again reactive against all E. coli
core types, although weak labelling (<10%) was associated with smooth
E. coli strains.
The failure of anti-core-glycolipid MAbs to react strongly against
intact bacteria suggests an inability of these MAbs to recognize
clearly their respective epitopes on smooth, wild type bacteria. The
effect of boiling bacteria for 15 min on recognition by selected MAbs
was investigated by subjecting boiled and unboiled E. coli 018:K1 to
flow cytometric analysis. MAbs reactive against core LPS demonstrated
significant increases in binding to boiled compared to unboiled
bacteria (Table 6). Samples probed with the negative control MAb
185.1.2.2 (specific for E. coli 06 serotype) produced no detectable
positive fluorescence. E. coli 018 serotype specific MAb, 184.2.5.5,
exhibited equally high levels of binding to boiled and unboiled
bacteria.
1.4 SEQUENTIAL ABSORPTIONS OF MONOCLONAL ANTIBODIES BY WHOLE BACTERIA
OF SALMONELLA LIPOPOLYSACCHARIDE CHEMOTYPES
The binding specificities of those MAbs reactive against the core-
glycolipid component of the LPS molecule were further studied by
sequential absorption with whole bacteria of S. typhimurium chemotypes
(Ra, Rc, Re) and lipid A (Figures 24 and 25). The residual ELISA
reactivity of each MAb after each absorption stage was measured against
selected purified LPS. The percentage residual ELISA reactivity of the
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% 43-3-4-8 O 43-3-5-1
A 43-11.5-1 A 43-27-11-2
□ 43-35-1-4
Figure 24. Serial absorption of 5 HAbs with different cheiotypes of rough 5. typhiiuriuM bacteria,
used sequentially in an ascending order of LPS size. Residual ELISA reactivity to E. coli R1 (R-LPS)
















T 1 , ,
Non Lipid A Re Rc Ra
Absorbing bacteria
MAb 40.18.7.1
J-i 1 1 r
Non Lipid A Re Rc
Absorbing bacteria
Figure 25. Serial absorption of 4 BAbs with different cheiotypes of rough S. typhiiariiiM whole
bacteria, used sequentially in an ascending order of LPS size, Residual ELISA reactivity to E. coli
SI (R-LPS) (for BAb 27.150.3); E. coli M (R-LPS) (for BAb 27.193.3); E. coli 018 (S-LPS) (for MAb
30.4.2.8), and E. coli R2 (R-LPS) (for BAb 40.18.7.1) at each stage of absorption are expressed as
a percentage of the reactivity of unabsorbed BAb.
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five MAbs from fusion A3 after each absorption are shown in Figure 2A.
MAb A3.27.11.2 was absorbed out on Re bacteria while MAb A3.11.5.1 was
primarily absorbed out on Rc bacteria. All other MAbs from this set
showed only minor reductions in ELISA reactivity, even at the end of
the absorption sequence with the complete Ra core.
The percentage residual ELISA reactivity of four other MAbs after each
absorption are shown in Figure 25. Significant reductions in residual
ELISA reactivity occurred for MAbs 27.150.3 and AO.18.7.1 following the
Rc absorption stage. MAb 27.193.3 was readily absorbed on the lipid A
acid hydrolysed bacteria of S. typhimurium 1102 Re. Serial absorption
of MAb 30.A.2.8 showed incomplete absorption by lipid A to 56% residual
ELISA reactivity. After absorption with Re bacteria, reactivity
stabilized at AA% for the remainder of the absorption sequence.
1.5 DEVELOPMENT OF A PROTEINASE K EXTRACTED LIPOPOLYSACCHARIDE ELISA
The reactivities of individual MAbs were shown to differ between
immunoblotting and ELISA studies. Although some MAbs demonstrated
restrictive specificity against proteinase K extracted LPS in immuno-
blots, they appeared more cross-reactive against heat-killed cells in
ELISA. An ELISA employing proteinase K extracted LPS was developed to
compare the binding activities of MAbs in this assay with reactivities
against similarly prepared antigens in immunoblotting. Details of the
digestion of cells and coating to microplates are described in
Materials and Methods.
In preliminary experiments the amount of proteinase K enzyme required
to digest a heat-killed suspension of cells, set to an A^j of 1.0, was
investigated. A minimum volume of 10 pi proteinase K solution (2.5 mg
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Figure 26. Silver stained LPS profiles of proteinase I whole cell digests (prepared by a modification
of the conventional proteinase I digestion method for coating ELISA aicroplates) of 9 E. colii- and
S-LPS strains separated by PAGE (14* w/v acrylatide). Tracks 1-4, E. coli 81, E2, S3, R4 (R-LPSs),
Tracks 5-8, E. coli serotypes 06, 015, 016 and 018 (S-LPSs) and Track 9, E. coli 018:Irf (R-LPS).
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ml *) per 1.5 ml cell suspension was found to digest the cells effect¬
ively. Digested samples from several R- and S-LPS E. coli strains were
analysed on silver stained gels, loaded with AO pi of an equal volume
of digested sample and double-strength sample buffer (Figure 26).
Samples were shown to contain LPS as the only major macromolecular
component revealed by silver staining. Smooth strains demonstrated
their characteristic ladder pattern, whilst rough strains contained a
low molecular mass band corresponding to unsubstituted core LPS. A
qualitative comparison of the staining intensity of known concentra¬
tions of purified LPS with dilutions of proteinase K extracted LPS
indicated that 20 pi of proteinase K LPS was equivalent to approximate¬
ly 5 pg of purified LPS.
Scott & Barclay (1987) complexed LPS with the cationic polypeptide
polymyxin B to attain stable binding of purified R-LPS to microplates,
for the detection of natural antibodies in human sera to R-LPS. In an
attempt to develop a stable, reproducible ELISA employing proteinase K
extracted LPS, samples were complexed with polymyxin by a similar
method as described in Materials and Methods (Page 99).
Optimization of coating of LPS-polymyxin complexes for ELISA
Microplates were coated with doubling dilutions of polymyxin-018 (S-
LPS) or R1 (R-LPS) complexes from 1:5 to 1:80. Two anti-LPS MAbs, an
018-antigen specific MAb 184.2.5.5 and an anti-core specific MAb
27.150.3 were titrated against the R- and S-LPS respectively (Figure
27). The maximum response at each MAb dilution was generally obtained
at a coating complex dilution of 1:10 for both S- and R-LPS. Positive
reactions were detectable for both 1:10 and 1:20 complex dilutions at
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Figure 27. ELISA activity of 2 anti-LPS HAbs against doubling dilutions of coated proteinase I
extracted LPS polynyxin complexes.
a) Anti-core specific MAb 27.150,3 against E. coli 81 extracted LPS
b) Anti-018 specific MAb 184.2.5.5 against E. coli 018 extracted LPS
Each value represents the mean optical density value of triplicate readings.
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BSA concentration (v/v)
Figure 28. ELISA activity of anti-core specific MAb 27.150.3 against proteinase I extracted E. coli
R1 LPS, postcoated with 0-10% v/v bovine serua albuain (BSA). Each histograa bar represents the lean
optical density value of triplicate readings.
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Optimization of post-coating concentrations of BSA
Microplates coated with 1:10 dilutions of R1 LPS-polymyxin complex were
post-coated with varying concentrations of BSA in PBS (IX, 2%, 3%, 4X,
5%, 10X w/v). Cross-reactive, anti-core specific MAb 27.150.3 was
titrated against each of the R1 coated plates, post-coated with the
different BSA concentrations (Figure 28). Each MAb dilution showed
increasing 0D with increasing BSA post-coat concentration up to 4X,
above which there was no significant increase. Since a 5% w/v BSA
concentration had been used for all other ELISA coating procedures this
was also used for post-coating microplates coated with proteinase K
extracted LPS.
Reproducibility of proteinase K extracted LPS-polymyxin complex coating
and LPS coating alone
Proteinase K extracted LPS-polymyxin complexes and uncomplexed LPS from
both rough and smooth bacterial strains were each coated to microplates
on three separate occasions to assess the reproducibility of the
coating procedure in ELISA (Figure 29). Mean ELISA OD values for E.
coli 018-serotype specific MAb 184.2.5.5 against the corresponding S-
LPS were similar at each MAb dilution for both complexed and
uncomplexed LPS (Figure 29a and b). However, the reproducibility of
these OD values as measured by standard deviation (SD) was greater for
microplates coated with complexed LPS at each MAb dilution. Micro¬
plates coated with R-LPS-polymyxin complexes and probed with anti-core
MAb 27.150.3 had higher mean OD values and lower SD values at each MAb
dilution than microplates coated with LPS alone (Figure 29c and d).
The SD of both complexed and uncomplexed R-LPS preparations were higher
than equivalent S-LPS preparations.
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Figure 29. Comparison of ELISA activity of licroplates coated with proteinase X extracted LPS
coiplexed with either polymyxin (a 4 c) or no polymyxin (h 4 d) and probed with an anti-LPS HAb.
a 4 b represent HAb 184.2.5.5 against E. coli 018:11 (S-LPS)
c 4 d represent HAb 27.150.3 against E. coli 11 (R-LPS)
Bars represent the SB of triplicate experiients on iicroplates coated on 3 separate occasions.
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Inhibition of ELISA reactivity of anti-LPS monoclonal antibodies by
five different LPS preparations
Whole bacterial cells, purified LPS (coraplexed and uncomplexed) and
proteinase K extracted LPS (complexed and uncomplexed) were compared
for their ability to inhibit the ELISA reactivity of anti-LPS MAbs.
Purified LPS was prepared in a doubling dilution series from an
original concentration of 0.1 mM for use as an inhibitor. Doubling
dilutions of proteinase K extracted LPS were prepared from an approxi¬
mate LPS concentration of 0.1 mM. Whole cells were prepared in a ten-
0 -1
fold dilution series from 1x10 cells ml . All inhibitor dilutions were
mixed with an equal volume of MAb (diluted 1:40 in dilution buffer) and
preincubated at 37°C for 30 min before adding to ELISA.
Figure 30a and b represent ELISA inhibition by five LPS containing
preparations of 0-antigen specific MAb 184.2.5.5 against microplates
coated with either purified LPS-polymyxin complex (a) or proteinase K
extracted LPS-polymyxin complex (b). Figure 31a and b represent ELISA
inhibition by five LPS containing preparations of core-specific MAb
27.150.3 against microplates coated as above for (a) and (b). Inhibi¬
tion of ELISA reactivity occurred with all LPS preparations, residual
ELISA activity being inversely proportional to inhibitor concentration
in most cases. In general, the weakest inhibitor of ELISA reactivity
was the whole cell preparation, whilst the most efficient inhibitor was
the purified LPS-polymyxin complex. The inhibitory activities of
proteinase K extracted LPS preparations were comparable to the corre¬
sponding purified LPS preparations. Residual ELISA reactivity of MAb
184.2.5.5 (Figure 30) after inhibition with either purified or
proteinase K extracted LPS (complexed or uncomplexed) was higher
against coated purified LPS (a) than proteinase K extracted LPS (b).
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% LPS O LPS-polymyxin
A Proteinase K Proteinase K extracted
extracted LPS LPS-polymyxin
□ Whole cells
Figure 30. Inhibition of ELISA reactivity of 018, 0-antigen specific MAb 184.2.5.5 (diluted 1:40)
against purified E. coli 018 LPS and proteinase I extracted E. coli 018 LPS (b) with: whole cells
(ten-fold dilution series froa 1x10 cells al ); purified LPS or purified LPS coiplexed with polyayxin
(doubling dilutions froa an original concentration of 0.1 #1), and proteinase I extracted LPS or
proteinase I extracted LPS coaplexed with polyayxin (doubling dilutions froa an original concentration
of approxiaately 0.1 aH). Residual ELISA reactivity in the presence of inhibitor is expressed as a
percentage of reactivity with no inhibitor (the 1001 value, represented by the dotted line).
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Figure 31. Inhibition of ELISA reactivity of core-specific MAb 27.150.3 (diluted 1:40) against
purified E. colill LPS (^) and proteinase I extracted E. coli R1 LPS (b) with: whole cells (ten-fold
dilution series frow 1x10 cells al ; purified LPS or purified LPS cowplexed with polyiyxin (doubling
dilutions froa an original concentration of 0.1 al) and proteinase £ extracted LPS or proteinase I
extracted LPS coaplexed with polymyxin (doubling dilutions froa an original concentration of
approxiiately 0.1 al). Residual ELISA reactivity in the presence of inhibitor is expressed as a
percentage of reactivity with no inhibitor (the 100% value, represented by the dotted line).
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The equivalent comparison for MAb 27.150.3 (Figure 31) showed that
residual ELISA reactivity was similar for microplates coated with
purified LPS (a) or proteinase K extracted LPS (b).
1.6 BINDING OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES AGAINST
PROTEINASE K EXTRACTED LIPOPOLYSACCHARIDE IN ELISA
The ELISA binding activities of MAbs against proteinase K whole cell
digests of equivalent bacterial antigens used in the heat-killed
bacterial ELISA are shown in Figures 32-40. Optical density readings
for MAbs against the different LPS samples tended to be higher compared
to the responses of the MAbs with heat-killed cell antigens. This may
reflect differences in the amount of LPS antigen added to the wells of
the ELISA microplates, the coating efficiency of the different
preparations or the presentation of the LPS antigens.
The reactivity patterns of individual MAbs against the proteinase K
extracted LPS preparations reflected results of the heat-killed ELISA
(Figures 6-16), rather than those of immunoblotting studies (Figures
17-22). This was highlighted by MAbs 43.11.5.1 (Figure 38) and
43.27.11.2 (Figure 39) which cross-reacted against E. coli R- and S-LPS
antigens in ELISA, and reacted almost exclusively with the E. coli R1
core in immunoblots. MAbs 184.2.5.5 and 185.1.2.2 again demonstrated
specificity for E. coli serotypes 018 and 06 respectively (data not
shown).
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Figure 32. ELISA activity of HAh 27.150.3 against proteinase I whole cell digests of E. coli and non-
E. coli rough and saooth cell types.
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Figure 33. ELISA activity of HAb 27.193.3 against proteinase K whole cell digests of S. coli and non-
S. coli rough and siooth cell types.
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Figure 34. ELISA activity of HAb 30.4.2.8 against proteinase I whole cell digests of E. coli and non-
E. coli rough and siooth cell types.
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Figure 35. ELISA activity of HAh 40.18.7.1 against proteinase I whole cell digests of S. coli and
non-f. coli rough and siooth cell types.
151
PROTEINASE K EXTRACTED LPS MAb 43-3'4-8
P. aeruginosa Oil
K. pneumoniae


















Net OD (590 nm)
Reciprocal MAb dilution □10 90
Figure 36. ELISA activity of HAb 43.3.4.8 against proteinase I whole cell digests of E. coli and non-
E. coli rough and siooth cell types,
152
PROTEINASE K EXTRACTED LPS MAb43-5-14
P. aeruginosa oil
K. pneumoniae

















Net OD (590 nm)
Reciprocal MAb dilution | |10 90
Figure 37. ELISA activity of HAh 43.5.1.4 against proteinase I whole cell digests of E. coli and non-
E. coli rough and siooth cell types.
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Figure 38. ELISA activity of KAb 43.11.5.1 against proteinase I whole cell digests of E. coli and
non-I. coli rough and smooth cell types.
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Figure 39. ELISA activity of HAb 43.27.11.2 against proteinase I whole cell digests of E. coli and
non-i". coli rough and 3iooth cell types.
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Figure 40. ELISA activity of MAb 43.35.1.4 against proteinase I whole cell digests of E. coli and
non-f. coli rough and ssooth cell types,
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CHAPTER 2
DEVELOPMENT OF A CAPTURE ELISA FOR THE DETECTION OF ESCHERICHIA COLI
LIPOPOLYSACCHARIDE IN SOLUTION
The aim of this study was to use MAbs in a capture ELISA system for the
detection of E. coli LPS in solution. Several MAbs were selected (on
the basis of their specificities as illustrated in Chapter 1) for the
detection of E. coli core types Rl-RA, specific E. coli core types of
either R1 or R3, and E. coli 018 0-antigen. The assays were developed
with the ultimate aim of detecting LPS in the serum of septic patients.
Selected MAbs included:
MAb Preferential Specificity Isotype
27.150.3 E. coli core cross-reactive IgG2a
27.193.3 E. coli R3 core IgM
30.A.2.8 E. coli 018 0-antigen IgM
AO.18.7.1 E. coli R2 core IgG3
A3.3.A.8 E. coli R1 core IgG3
A3.11.5.1 E. coli core cross-reactive IgG2a/IgM
A3.27.11.2 E. coli core cross-reactive IgG3
2.1 PURIFICATION OF MONOCLONAL ANTIBODY PREPARATIONS
Bulk growth supernates of selected MAbs were concentrated twenty-fold
using a tangential-flow filtration system. The presence of antibody in
the retentate and absence in the filtrate was checked by ELISA. The
immunoglobulins in each concentrate were further purified by ammonium
sulphate precipitation. The presence of antibody in the final
preparation was confirmed by titrating in ELISA. Equal volumes of MAb
preparations before and after ammonium sulphate precipitation were






Figure 41. a) Cootassie blue stained profiles of proteins found in concentrated supernatants
containing HAb before and after auoniut sulphate precipitation, separated by SDS-PAGE (12* n/v
acrylanide). Track 1, 27.150.3 (before); Track 2, 27,150,3 (after); Track 3, 40.18.7.1 (before);
Track 4, 40.18.7,1 (after); Track 5, 43.3.4.8 (before); Track 6, 43.3.4.8 (after); Track 7, 43.11.5.1
(before); Track 8, 43.11.5.1 (after); Track 9, 43.27.11.2 (before); Track 10, 43.27.11.2 (after);
Track 11, 27.193.3 (before); Track 12, 27.193,3 (after); Track I3„ 30,4.2.8 (before); Track 14,
30.4.2.8 (after), b) Silver stained profiles of proteins found in huaan serun.
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41a. Ammonium sulphate precipitation of the MAb preparations resulted
in a substantial reduction in the number of contaminating proteins
including albumin and transferrin. Bands representing MAb components
were relatively weak compared to bands obtained for more abundant
immunoglobulins found in normal human serum (Figure Alb).
Ammonium sulphate precipitated MAbs were further purified by either
protein-A affinity chromatography (IgG) or DEAE ion exchange chromatog¬
raphy (IgM). Since 'MAb' 43.11.5.1 contained both IgG2a and IgM
isotypes, it appears that this MAb is actually the product of two
hybridomas. The IgG2a was purified and separated from the IgM by
protein-A chromatography and the IgM purified by DEAE affinity
chromatography. The reactivity of each MAb was checked in ELISA. The
specificity of the IgG component was shown to be identical to the
original concentrated supernate preparation and used for all subsequent
detection studies. The specificity of the IgM component was similar to
the concentrated supernate preparation, although it showed weaker
reactivity against individual LPS preparations.
Purified MAb samples (prepared for electrophoresis in the presence of
2-mercaptoethanol) were separated by SDS-PAGE and stained with
Coomassie blue as shown in Figure 42. Molecular masses of separated
heavy and light chains of IgG and IgM antibodies were estimated from a
calibration curve of log molecular mass of protein standards against Rf
(the distance moved by a standard protein through the separating gel,
divided by the distance moved by bromophenol blue marker). The light
chains of IgG and IgM antibodies had a calculated molecular mass of
23,000, whilst the heavy chains had calculated molecular masses of





Figure 42. Cooaassie blue stained profiles of purified Mb preparations separated by SDS-PAGE (121
■/v acrylaiide). Track 1, 27.150.3 (Ig62a); Track 2, 40.18.7.1 (Ig63); Track 3, 43.3.4.8 (Ig63);
Track 4, 43.11.5.1 (IgG2a); Track 5, 43.27.11.2 (IgG3); Track 6, 27.193.3 (IgH); Track 7, 30.4.2.8
(IgH). Molecular lasses of protein standards are indicated.
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values were similar to those documented by Parham (1986). All purified
MAb preparations still contained a non-MAb protein of approximately
66,000 molecular mass. Trace amounts of this protein were present in
IgG preparations as revealed by staining intensity, whilst an equal
amount to the heavy chain of IgM antibodies was present in IgM
preparations.
2.2 BIOTIN LABELLING OF MONOCLONAL ANTIBODIES
The degree of biotinylation of mouse MAbs yielding the highest
reactivity was determined by reacting various ratios of biotin to free
amino groups of MAbs. The different ratios of biotinylated MAbs were
tested in ELISA against individual cocktails of E. coli R- and S-LPS.
The results of representative IgG and IgM MAbs are illustrated in
Figure A3. All OD readings were expressed after subtraction of the
relevant background control.
Conjugation of MAb A3.3.A.8 and 27.193.3 with 1:1 and 2:1 biotin:
MAb/amino acid ratios appeared to produce the most usable reagents in
each case. The A:1 ratio gave the lowest OD readings for each dilution
of MAb, whilst the 1:1 ratio gave the maximal. As the dilution of each
biotinylated MAb increased, OD readings for wells with R-LPS were
usually higher than those obtained for wells coated with S-LPS. Since
both MAbs recognize unsubstituted core-glycolipid LPS, the increased
sensitivity with R-LPS may be due to the presence of more available
core LPS than in S-LPS. The masking effect of 0-antigen side chains is
also likely to influence epitope recognition. The equivalent results
for other MAbs gave similar results to those presented for A3.3.A.8 and
27.193.3.
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Figure 43. Reactivity in ELISA of HAbs 43.3.4.8 (a 4 b) and 27,193.3 (c 4 d) coupled with different
ratios of biotin. Reactions against a cocktail of saooth (a 4 c) and rough (b 4 d) E. coli LPS were
aeasured. The OD values obtained with streptavidin-alkaline phosphatase (SAP) were aeasured at 405
nn.
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2.3 BIOTIN-STREPTAVIDIN AMPLIFICATION ELISA SYSTEMS
The sensitivity of two different conjugate systems for bio-MAbs against
E. coli S-LPS and R-LPS were compared. The conjugate systems included:
i) alkaline phosphatase biotin-streptavidin (the amplification system)
and ii) alkaline phosphatase labelled streptavidin.
The results obtained for representative bio-MAbs (1:1) 43.3.4.8 and
27.193.3 with the different conjugate systems are shown in Figure 44.
The conjugate system employing alkaline phosphatase labelled biotin-
streptavidin complex produced the highest OD values for each respective
dilution of bio-MAb (43.3.4.8 or 27.193.3) against either E. coli R-
and S-LPS. Greater sensitivity of the conjugates against E. coli R-LPS
was also observed.
2.4 MONOCLONAL ANTIBODY COMPETITION STUDIES
The antigen binding sites of the seven core LPS specific MAbs were
compared by adding various combinations of MAbs (one labelled with
biotin and one unlabelled) to wells of microtitre plates coated with
purified R- or S-LPS. Plates were coated with single LPS types to
which unlabelled inhibitor MAbs were known to bind preferentially.
Coating with individual, rather than cocktails of LPS gave a clearer
indication of MAbs competing for close or overlapping epitopes.
To assess the relatedness of MAb binding sites, a standard curve was
established by titrating one MAb against itself, ie, the same antibody
was used as both the label and the inhibitor (self-inhibition). The
capacity of the unlabelled inhibitor to inhibit the binding of other
bio-MAbs was also titrated. All MAb dilutions were made from labelled
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Figure 44. Coaparison of the sensitivity of enzyie iaaunoassays with bio-HAhs 43.3.4.8 (a 4 b) and
27.193.3 (c 4 d) against a cocktail of saootb (a 4 c) and rough (b 4 d) E. coll LPS. The two
conjugate systeas included: i) alkaline phosphatase labelled biotin streptavidin coaplex (BAPS) and
ii) alkaline phosphatase labelled 3treptavidin (SAP). The OD values were aeasured at 405 na.
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bio-MAbs were titrated against doubling dilutions of unlabel led
inhibitor: the results for bio-MAbs A3.3.A.8 (diluted 1:160), A3.11.5.1
(diluted 1:80), A3.27.11.2 (diluted 1:A0) 27.150.3 (diluted 1:160),
27.193.3 (diluted 1:160), AO.18.7.1 (diluted 1:80) and 30.A.2.8
(diluted 1:160) are shown.
The results were plotted as shown in Figures A5-A8 and the concentra¬
tion of inhibitor required for 50% inhibition of binding of labelled
MAbs was compared. A labelled MAb was considered not to compete for
the same binding site as the unlabelled inhibitor if the dilution of
inhibitor, at the 50% inhibition level was at least one dilution less
(ie, inhibitor more concentrated) than required for self-inhibition.
In addition, a comparison of self inhibition curves with those
representing other combinations of MAbs gave an indication of the
relative proximity of MAb binding sites. The degree of inhibition will
be dependent on whether or not MAbs share similar binding sites, and
the amount of steric hindrance.
MAbs 27.193.3 (Figure A7a) and 30.A.2.8 (Figure A8a) were least capable
of inhibiting the binding of all other labelled MAbs. MAbs A3.3.A.8,
A3.11.5.1 and A3.27.11.2, previously shown to preferentially bind E.
coli JR1 core, all appeared to bind to different sites. Those MAb
combinations showing the greatest inhibition included MAbs 27.150.3,
AO.18.7.1 and A3.11.5.1. Although previous results established quite
different binding specificities, their respective binding sites are
perhaps similarly located on the core antigen.
2.5 CAPTURE ELISA FOR DETECTION OF E. COLI LIPOPOLYSACCHAFIDE
Capture ELISA systems were developed for the detection of E. coli LPS
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Reciprocal dilution of MAb inhibitor (43.3.4.8)
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Reciprocal dilution of MAb inhibitor (43.11.5.1)
Figure 45. MAb coapetition assay neasured by ELISA (OD 405 na) with S-LPS froi E. coli II as coating
antigen. Doubling dilutions of MAb 43.3.4.3 (a) and MAb 43.11.5.1, (b) inhibitors were run against
biotin labelled competing MAbs. The OD values obtained in the presence of inhibitor were calculated
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Figure 46. HAb competition assay measured by GLISA (OD 405 ni) with R-LPS from E. coli R1 as coating
antigen. Doubling dilutions of HAb 43.27.11.2 (a) and HAb 27,150.3 (b) inhibitors were run against
biotin labelled competing HAbs. The OD values obtained in the presence of inhibitor were calculated
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Reciprocal dilution of MAb inhibitor (AO.18.7.1)
Figure 47, HAb competition assay measured by GLISA (OD 405 not) with R-LPS from E. coli R3 (a) or R2
(b) as coating antigens. Doubling dilutions of HAb 27,193.3 (a) and HAb 40.18.7.1 (b) inhibitors were
run against biotin labelled competing HAbs. The OD values obtained in the presence of inhibitor were




Reciprocal dilution of MAb inhibitor (30.4.2.8)
Figure 48. HAJb competition assay aeasured by ELISA (OD 405 an) with S-LPS fro« E. cali 018 as coating
antigen. Doubling dilutions of MAb 30.4.2.8 inhibitor were run against biotin labelled competing
MAbs. The OD values obtained in the presence of inhibitor were calculated as a percentage of OD
values obtained without inhibitor, ie, percentage inhibition.
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in solution. Systems developed included the detection of E. coli core
types R1-R4, the specific core types of either R1 or R3 and E. coli 018
0-antigen. The amounts of coating and conjugate antibodies for each
system were determined by chequerboard titrations. Initial investiga¬
tions compared both the biotin-streptavidin amplification system and
the alkaline phosphatase streptavidin system. The sensitivity of each
system was similar. Although 0D readings were generally higher for the
amplification system, background signals were also significantly higher
compared to the non-amplified system. The incubation of added antigens
for various periods of time (1 h, 2 h, A h and overnight) were also
investigated; an overnight incubation gave the highest sensitivity for
each detection system and was used in all subsequent experiments.
The detection of ten-fold dilutions of E. coli LPS and heat-killed
cells, incorporating the non-amplification system are shown in Figures
49-52. A sample was considered positive for antigen if it yielded an
0D value which was 3 SDs greater than the mean of background controls.
Detection of E. coli R1-R4 core types
The system developed incorporated the two most cross-reactive, highest
affinity MAbs characterized above: 27.150.3 and 43.11.5.1 which compete
for different binding sites. MAb 27.150.3 was used as the coating/
capture antibody at 1:200 (approximately 5 fg ml *) and 43.11.5.1 used
as the biotinylated antibody (1:1 biotinylation) at 1:100 (approx¬
imately 10 fg ml"1). The E. coli core types of R1-R4 LPS were all
detected by this system (Figure 49a). The sensitivity of the assay was
between 0.01-10 ng ml 1 E. coli LPS (0.01 ng ml 1 for Rl, 0.1 ng ml 1 for
R2, R4 and 018, and 10 ng ml 1 for R3). The assay limits of detection









Figure 49. Sensitivity of capture ELISA incorporating an alkaline phosphatase labelled streptavidin
systea for the detection of a) E. coli R1-R4 LPS and b) E. coli R1-R4 heat-killed cell preparations.
The E. coli LPS and heat-killed cell preparations included: E. coli core types Rl, R2, R3 and R4 (R-
LPS), and E. coli 013 (S-LPS). Concentrations aarked with an asterisk indicate the first value
significantly greater than negative control values (>3 SDS of control aean).
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equivalent ml * (Figure 49b).
Other combinations of MAbs were also investigated for the detection of
E. coli core types R1-R4. These included (i) using the same cross-
reactive MAb as both capture and detector antibody, and (ii) the use of
a cocktail of core specific MAbs as capture, and a cross-reactive MAb
as detector. Although some of these MAb combinations demonstrated
comparable, if not greater sensitivity for particular core types
compared to the system described above, background signals were high in
all cases.
Detection of E. coli R1 core type
The specific detection of E. coli R1 LPS was achieved using MAb
43.3.4.8 which reacts almost exclusively with the R1 core, and the
cross-reactive MAb 43.11.5.1. Both MAbs were shown not to compete for
similar binding sites. MAb 43.3.4.8 was used as the coating/capture
antibody at 1:100 (approximately 10 pg ml ') and 43.11.5.1 was used as
the biotinylated antibody (1:1 biotinylation) at 1:100 (approximately
10 pg ml ^). The sensitivity of the assay was 0.01 ng ml ^ for the
detection of E. coli R1 (R-LPS) and 0.1 ng ml ' for the R1 containing
core of E. coli 018 (S-LPS) (Figure 50a). Other E. coli core types
were not detected in the assay. The sensitivity of the assay for the
detection of E. coli R1 (R-LPS) and 018 (S-LPS) heat-killed cell
a 5 _i
preparations was 10 and 10 cells equivalent ml respectively (Figure
50b).
Detection of E. coli R3 core type
MAb 27.193.3 was used as both the capture/coating antibody and













































Figure 50. Sensitivity of capture ELISA incorporating an alkaline phosphatase labelled streptavidin
system for the detection of a) E. coli 81 LPS and b) E. coli 81 heat-killed cell preparations. The
E. coli LPS and heat-killed cell preparations included: E. coli core types 81, 82, 83 and 84 (8-LPS),
and E. coli 018 (S-LPS). Concentrations larked with an asterisk indicate the first value
significantly greater than negative control values (>3 SDS of control #ean).
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E. coli R3 LPS. Both capture and conjugate antibodies were used at
1:200 (approximately 5 pg ml 1). The sensitivity of the assay was 0.01
ng ml * for the detection of E. coli R3 (R-LPS) and 0.1 ng ml ^ for the
R3 containing core of E. coli 015 (S-LPS) (Figure 51a). The assay also
k (\ -1
detected a minimum of 10 and 10 cells equivalent ml of the heat-
killed cell preparations of E. coli R3 (R-LPS) and 015 (S-LPS)
respectively (Figure 51b). The assay was unable to detect all other E.
coli core types apart from Rl, which was detected at only the highest
concentration of the LPS and heat-killed cell preparations.
Detection of E. coli 018 Q-antigen
The specific detection of E. coli 018 0-antigen used MAb 30.A.2.8 as
both the capture/coating antibody and biotinylated antibody (1:1
biotinylation). Both capture and conjugate antibodies were used at
1:100 (approximately 10 pg ml *). The sensitivity of the assay was 0.01
ng ml * for the detection of LPS from E. coli 018 (S-LPS) (Figure 52a)
3 -i
and 10 cells equivalent ml for the detection of E. coli 018 heat-
killed cell preparation (Figure 52b). Positive values were also
obtained with Rl and 015 antigen preparations at the highest concentra¬
tions only.
Detection of LPS in spiked serum
The capture ELISA systems were also applied for the detection of E.
coli LPS in spiked human serum samples, known to contain low levels of
core-glycolipid antibodies. Preliminary studies established high
backgrounds and low sensitivity with normal untreated serum. Various
methods were investigated in an attempt to improve assay sensitivity






Figure 51. Sensitivity of capture ELISA incorporating an alkaline phosphatase labelled streptavidin
systei for the detection of a) E. coli R3 LPS and (b) E. coli R3 heat-killed cell preparations. The
E. coli LPS and heat-killed cell preparations included: E. coli core types 81, R2, R3 and R4 (R-LPS),
and E. coli 015 (S-LPS). Concentrations narked with an asterisk indicate the first value
significantly greater than negative control values (>3 SDS of control lean).
Heat-Killed Whole
Cell Antigens
IF IP IP 10* i?










Figure 52. Sensitivity of capture ELISA incorporating an alkaline phosphatase labelled streptavidin
systei for the detection of a) E. coli 018 LPS and b) E. coli 018 heat-killed cell preparations. The
E. coli LPS and heat-killed cell preparations included: E. coli core types 81 and 82 (8-LPS), and E.
coli 012, 015 and 018 (S-LPS). Concentrations larked with an asterisk indicate the first value
significantly greater than negative control values (>3 SDS of control #ean).
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(i) Spiked samples were diluted 1:4 with pyrogen-free 0.15 M NaCl
and incubated for 30 min in a 60°C water bath (Roth et al, 1990).
(ii) Spiked samples were diluted 1:5 in pyrogen-free water and
heated for either 30 min at 56°C or 3 min at 100°C.
(iii) Spiked samples were treated by an alkaline denaturation
method described by (Limet et al, 1988). Samples were diluted 1:4
in 0.1 M NaOH and heated for 30 min at 70°C. The mixture was then
neutralized (pH 8.5) by one volume of 0.8 M boric acid.
(iv) Spiked samples were diluted 1:2 in pyrogen-free water and
the LPS extracted using phenol. Equal volumes of prewarmed (67°C)
sample and phenol solution (90 w/v) were mixed and stirred at 67°C
for 15 min. The mixture was cooled in ice until phase separation
occurred before contrifuging at 5,000 g for 15 min to complete the
process. The upper acqueous phase containing the LPS was
transferred to dialysis tubing and dialysed against running water
overnight to remove phenol.
All treated samples were diluted 1:2 in ELISA diluent and added at 200
pi per MAb coated well.
The effects of the above serum treatments on the sensitivity of the
capture ELISA for the specific detection of E. coli R1 (capture/coating
MAb 43.3.4.8, biotinylated MAb 43.11.5.1) are shown in Table 7. The
sensitivity of the assay for the detection of LPS in spiked serum was
at its optimum following dilution of serum four-fold with 0.15 M NaCl
and heating for 30 min at 60°C (mean 4 ± 5.2 ng ml ), and after the
phenol extraction method (mean 36.7 ± 55 ng ml '). The sensitivity of
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Table 7. The sensitivity of a capture ELISA assay for the detection of
E. coli R1 LPS in spiked serum after various treatments.
Detection of E. coli R1 in spiked serum
Treatment Mean sensitivity (ng ml'1) (ASP)*
Control (+ve):
LPS diluted in ELISA diluent 0.04 (0.052)
Control (-ve):
LPS diluted in untreated serum 400 (519.6)
Spiked serum diluted 1:4 with
0.15 M NaCl, heated 30 min at 60°C 4 (5.2)
Spiked serum diluted 1:5 with 1^0
and heated for:
i) 30 min at 56°C 70 (52)
ii) 3 min at 100°C 700 (520)
Spiked serum diluted 1:4 with
0.1 N NaOH, heated 30 min at
70°C and neutralized (pH 8.5)
with 0.8 M boric acid 70 (52)
Phenol extraction: spiked serum
diluted 1:2 with H^O, mixed with
equal volume of phenol (90% w/v).
Aqueous phase removed and dialysed. 36.7 (55)
* Each value represents the mean (±SD) from three separate
experiments.
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the assay for LPS diluted in ELISA diluent was 0.04 ± 0.052 ng ml *.
The use of capture ELISAs employing other MAb combinations for the




MONOCLONAL ANTIBODIES AS PROBES FOR DETECTING LIPOPOLYSACCHARIDE
EXPRESSION ON ESCHERICHIA COLI FROM DIFFERENT GROWTH CONDITIONS
The purpose of this work was to use MAbs as probes to investigate the
expression of LPS on E. coli strains, grown under a variety of nutrient
conditions in batch culture which mimicked some of the in vivo
environmental conditions of an infected host. A nitrogen deficient/
high carbon medium was also used to promote capsule production
(Sutherland & Wilkinson, 1965). The presence and absence of capsule on
selected E. coli strains was confirmed by phage typing and whole cell
electron microscopy (Figure 53). Growth under nitrogen deficient/high
carbon conditions appeared to improve the expression of the E. coli K1
capsule (approximately 250 nm thick compared to 125 nm under nutrient
broth conditions).
The expression of LPS on bacteria grown in vivo was also investigated.
3.1 SILVER STAINING AND IMMUNOBLOT ANALYSIS OF LIPOPOLYSACCHARIDES
FROM BACTERIA GROWN IN VITRO
Figures 54-65 include silver stained LPS PAGE profiles and their
corresponding immunoblots from four E. coli strains grown under
different growth conditions. The three smooth strains showed the
characteristic ladder pattern, each step up representing LPS substi¬
tuted with a progressively increasing number of O-polysaccharide
repeating oligosaccharide units. These were missing from the rough
mutant. The effect of each growth condition on the expression of LPS
was compared with nutrient broth.
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Figure 53. Electron micrographs of negatively stained whole cells of E. coli 018:11 grown in nutrient
broth Ja) and nitrogen deficient/high carbon aediun (b). c) represents the non-capsulate lutant
018:11 grown in nutrient broth. Bars, 1 pi.
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Silver stained LPS profiles of proteinase K digested whole cells grown
in nutrient broth, iron depleted and nitrogen deficient/high carbon
media, are shown in Figure 54. LPS from iron depleted cells show only
minor changes against the LPS from nutrient broth grown cells, whilst
cells grown in a nitrogen deficient/high carbon medium showed an
increased expression of both raid-range and high molecular mass bands.
Immunoblotting of transblotted gels against 018, 0-antigen specific MAb
184.2.5.5 (Figure 55a) demonstrates greater expression of ©-poly¬
saccharide as well as an overall increase in its chain length for cells
grown under nitrogen deficiency. Probing with 27.150.3, an anti-core
MAb, reactive against both substituted and unsubstituted core material
showed no significant differences between growth conditions (Figure
55b). The same LPS samples were separated by either a non-gradient 14%
acrylamide gel or a gradient 5-20% acrylamide gel and immunoblotted
against anti-core MAb 43.27.11.2. Figure 56a demonstrates the
reactivity of the MAb against unsubstituted core material and the high
molecular mass substituted core material leaking from the rough mutant
of E. coli 018. Marginally stronger reactivity was observed against E.
coli strains prepared under iron depletion. The gradient gel (Figure
56b) improved the resolution of the low molecular mass LPS bands. MAb
43.27.11.2 was shown to be reactive in most cases against at least
three low molecular mass bands of both R- and S-LPS strains. Reactiv¬
ity against E. coli strains grown under iron depletion was significant¬
ly greater than nutrient broth or nitrogen deficient/high carbon
conditions.
E. coli strains were grown in iron depleted media containing different
concentrations of the iron-chelator 2,2' dipyridyl (25, 50, 100, 150
and 200 pmol. L*). The effect of increasing the iron-chelator
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Figure 54. Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
separated by PME 14* w/v acrylaiide). Tracks 1-4, 5-8 and 9-12 represent 4 E. coli strains (018:11,
018:11 , 018:Irf and 06:1^) grown to early stationary phase in nutrient broth, an iron depleted aediui
(containing 150 piol. L 2,2' dipyridyl) and a nitrogen deficient/high carbon wediua respectively.
183
1 2 3 4 5 6 7 8 910 11 12
b
1 2 3 4 56 7 8 910 1112
Figure 55. Iaaunoblots of proteinase I whole cell digests of E. coli strains separated by PAGE (14*
w/v acrylaaide) followed by transfer to IIC paper and probed with a) an 018 O-antigen specific HAb,
184.2.5.5 and b)_ a core-specific MAb, 27.150.3 Tracks 1-4, 5-8 and 9-12 represent 4 E. coli strains
(018:11, 018:11 , 018:Irf and 05:15) g^own to early stationary phase in nutrient broth, an iron




Figure 56. Imunoblots of proteinase I whole cell digests of E. coli strains separated by PAGE ( a)
14% w/y acrylaaide and b) 5-20% w/v acrylaaide gradient) followed by transfer to MIC paper and probed
with a_core-specific MAb, 43.27.11.2. Tracks 1-4, 5-8 and 9-12 represent 4 E. coli strains (018:11,
018:11 , 018:Irf and 06:1^5) grown to early stationary phase in nutrient broth, an iron depleted aediua
(containing 150 fiiaol, L 2,2' dipyridyl) and a nitrogen deficient/high carbon aedium respectively.
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concentration on the growth of E. coli strain 018:K1 is shown in Figure
57. The lag phase increased, growth rate decreased and final cell
concentration as measured by absorbance decreased with an increase in
iron-chelator concentration. Figure 58 represents silver stained PAGE
profiles of LPS and their corresponding immunoblots from four E. coli
strains grown to early stationary phase under conditions described
above. An increase in iron-chelator concentration was associated with
a decreased expression of 0-antigen bearing molecular mass bands of S-
LPS, as illustrated by silver stained profiles (Figure 58a) and the
immunoblot against 018, 0-antigen specific MAb 184.2.5.5 (Figure 58c).
Probing with a core-specific MAb, 43.27.11.2 showed increased reactiv¬
ity against S-LPS strains grown in the presence of 150 and 200 pmol L ^
2,2' dipyridyl compared to the lower concentrations of 25, 50 and 100
pmol L* (Figure 58b).
Modifications of Malka minimal medium containing 1% and zero volume of
the magnesium salt used for the standard medium (magnesium depleted
[0.17 mmol. L '] and deficient growth media respectively) were used for
the growth of E. coli strains. Silver stained LPS profiles of four
magnesium deficient and depleted E. coli strains showed a significant
increase in the expression of unsubstituted core-glycolipid material
and other low molecular mass bands compared to growth in nutrient broth
(Figure 59). Immunoblotting with core-specific MAb 27.150.3 further
highlighted this pronounced increase in core LPS (Figure 60a), whilst
probing with MAb 184.2.5.5 showed similar expression of 0-antigen for
both nutrient broth and magnesium depleted conditions (Figure 60b).
The silver stained LPS profiles of E. coli strains grown under
magnesium/iron depleted conditions showed an increased expression of
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Figure 57. Growth of E. coli 018:11 in iron depleted media containing 25, 50, 100, 150 and 200 gmol.
L 2,2' dipyridyl as determined by measurement of absorbance of bacterial suspension at 525 nm.
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Figure 58. a) Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
separated by PAGE (14? w/v acrylaiide). (b 4 c) Imiunoblots following transfer of LPS to HIC paper
and probing with b) a core-specific HAb 43.27.11.2 and c) an 018 O-antigen specif SAb, 184.2.5.5.
Tracks, 1-5, 6-10, 11-15 and 16-20 represent E. coli strains 018:11, 018:11 , 018:Irf and 06:15
respectively. Each strain was grown to early stationary phase in iron depleted aedia containing 25,
50, 100, 150 and 200 paol. L 2,2' dipyridyl.
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Figure 59. Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
separated by PAGE (141 w/v acrylaaide). Tracks 1-4, 5-8 and 9-12 represent 4 E. coli strains (018:11,
018:11 , 018:Irf and 06:15) grown to early stationary phase in nutrient broth and a nagnesiua
deficient or depleted aediua (containing either zero or 1% voluae of the aagnesiua salt used for the
Halka ainiaal aediua) respectively.
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Figure 60. Immunoblots of proteinase K whole cell digests of S. coli strains separated by PAGE (14%
w/v acrylaiide) followed by transfer to NIC paper and probed with a) a core-specific HAb, 27.150.3
and b) an 018 O-antigen specific MAb 184.2.5.5. Tracks 1-4, 5-8 and 9-12 represent 4 S. coli strains
(018:11, 018:11 , 018:Xrf and 06:15) grown to early stationary phase in nutrient broth and a aagnesiui
deficient or depleted medium (containing either zero or 1% volume of the magnesium salt used for the
Haika minimal medium) respectively.
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low molecular mass unsubstituted core material (Figure 61a). The
corresponding immunoblot against anti-core MAb, A3.27.11.2 further
demonstrated the heightened expression of core LPS (Figure 61b).
Growth in heat-inactivated sheep serum resulted in greater expression
of both the fast migrating core region, and the high molecular mass, 0-
antigen bearing molecular species of the smooth strains, compared to
growth in nutrient broth (Figure 62a). Immunoblot analysis with MAb
184.2.5.5 again illustrates an increased expression of 0-antigen
(Figure 62b). Immunoblot analysis with anti-core MAbs 27.150.3 and
43.27.11.2 demonstrates increased expression of predominantly rough
form LPS grown in serum (Figure 63a & b).
The growth curves of E. coli strains 018:K1 and 018:K1 cultured in
nutrient broth, heat-inactivated sheep serum and untreated sheep serum
are presented in Figure 64. Both organisms divided more rapidly in
heat-inactivated sheep serum than untreated sheep serum. The growth
curves for organisms grown in heat-inactivated sheep serum were similar
to those obtained for growth in nutrient broth.
Silver stained LPS PAGE profiles of nutrient broth, heat-inactivated
sheep serum and untreated sheep serum culture samples (removed at
hourly intervals), are shown in Figure 65 for both E. coli 018:K1 a)
and 018:K1 b). Greater expression of unsubstituted core and 0-antigen
bearing bands with increasing incubation time was observed for both
organisms grown under the different nutrient conditions. The express¬
ion of core and 0-antigen after each period of incubation was greater
for organisms grown in heat-inactivated sheep serum and untreated sheep
serum than the equivalent samples grown in nutrient broth.
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Figure 61. a) Silver stained LPS profiles of proteinase K whole cell digests of E. coli strains
separated by PAGE (14t w/v acrylaiide). b) Ismunoblot following transfer of LPS to NIC paper and
probing with a core-specific NAb, 43.27.11.2 Tracks 1-4 and 5-8 represent 4 E. coli strains (018:11,




Figure 62. a) Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
separated by PAGE (14% w/v acrylaiide). b) Iaaunoblot following transfer of LPS to SIC paper and
probing with an 018 0-antigen specific HAb, 184.2.5.5 Tracks 1-4 and 5-8 represent 4 E. coli strains
(018:11, 018:11 , 018:Krf and 06:15) grown to early stationary phase in nutrient broth and heat-
inactivated sheep serua respectively.
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Figure 63. Iaiunoblots of proteinase K whole ceil digests of S. coli strains separated by page (14%
w/v acrylaiide) followed by transfer to IIC paper and probed with two core-specific MAbs a) 27.150.3
and b) 43.27.11.2 Tracks 1-4 and 5-8 represent 4 E. coli strains (018:11, 018:11 , 018:Irf and 06:15)
grown to early stationary phase in nutrient broth and heat-inactivated sheep serua respectively.
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# E. coli 018 K1 in HSS
O E. coli 018 K1 in SS
A E. coli 018 K1 in HSS
A E. coli 018 K1 in SS
■ E. coli 018 K1 in NB
a E. coli 018 K1 in NB
Figure 64. Growth of S. coli strains 018:11 and 018:11 in nutrient broth (MB), heat-inactivated
sheep serui (HSS) and untreated sheep serui (SS) as deteriined by leasureient of absorbance of
bacterial suspension at 525 m.
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Figure_65. Silver stained LPS of proteinase I whole cell digests of a) S. coli 018:11 and b) S. coli
018:K1 separated by page (14* w/v acrylaaide). Tracks 1-6, 7-12 and 13-18 represent E. coli grown
in nutrient broth, heat-inactivated sheep serum and untreated sheep serum respectively. Samples were
removed at 1 h intervals from 2 h incubation to 6 h incubation, plus a sample from overnight
incubation for each growth condition.
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3.2 ELISA ON WHOLE BACTERIA GROWN IN VITRO
The binding activities of three anti-LPS MAbs to whole cells of four E.
coli strains, cultured under the different growth conditions were
investigated (Table 8). No significant differences in the binding of
the 018, 0-antigen specific MAb, 184.2.5.5 to 018:K1 and 018:Krf were
detected for the different growth conditions. The 018 non-capsulate
strain showed stronger affinity for both anti-core MAbs compared to its
capsulate parent, when both were cultured under each growth condition.
Growth of S-LPS E. coli strains in the nitrogen deficient/high carbon
medium resulted in lower binding of the two anti-core MAbs compared to
growth in nutrient broth. Significant increases in OD^ and Djq values
were demonstrated for S-LPS organisms grown in heat-inactivated sheep
serum and magnesium limitation (1%) and probed with anti-core MAbs
27.150.3 and 43.27.11.2. A similar, yet lower increase in binding of
anti-core MAbs occurred for growth under iron depletion compared to
nutrient broth.
The binding activities of two anti-core MAbs to E. coli 018:K1 grown in
_i 2+Malka minimal medium (17 mmol. L Mg ) and modifications of this medium
containing zero; IX (0.17 mmol. L 1 Mg^+); 5% (0.85 mmol. L 1 Mg^+) and 10%
-i 2+
(1.7 mmol. L Mg ) volume of the magnesium salt used for the standard
medium are shown in Figure 66. Increased binding of anti-core MAbs was
observed for growth in all media containing reduced magnesium ion
concentrations compared to the minimal medium. Maximal binding of MAbs
occurred for cells grown in media containing no added magnesium salt or
0.17 mmol. L"1 (1%).
3.3 FLOW CYTOMETRIC ANALYSIS OF WHOLE BACTERIA GROWN IN VITRO
The effect of growth conditions on the expression of LPS on whole
197
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Figure 66. ELISA activity of anti-core LPS Bibs 43.27.11.2 (a) and 43.3^4.8^1) against J. coli
018:11 grown to early stationary phase in fialka jtiniaal aediua (17 ual. l fig ), or aodificatiMs
of this aediua containing lot (1.70 mol. L Bg ); 5t (0.85 bio I. L fig ); It (0.17 aaol. L fig )
and zero voluae of the aagnesiua salt used for the Kalka ainiaal aediua. Each histograa bar
represents the aean optical density value of three separate expedients carried out in triplicate.
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bacteria was also investigated by flow cytometry. Flow cytometric
profiles, which relate to the intensity of fluorescence signal (ie
antibody binding to bacteria), were obtained consistently in three
separate experiments. Examples of representative profiles are
illustrated in Figures 67 and 68. The histograms produced by the
interaction of the 018, 0-antigen specific MAb, 184.2.5.5, and E. coli
018:K1 grown in nutrient broth and a magnesium depleted (1%) medium are
shown in Figure 67a. When compared with nutrient broth cells a 45%,
decrease in magnesium depleted bacteria exhibiting positive fluor¬
escence above background levels was observed. The biphasic fluor¬
escence pattern produced by magnesium depleted cells demonstrated the
presence of two distinct subpopulations of E. coli 018:K1 on the basis
of differential binding of 184.2.5.5. Probing the same cells with
core-specific MAb 43.27.11.2 resulted in a significant increase in
positive fluorescence compared to nutrient broth grown cells (Figure
67b). Significant increases in the binding levels of both anti-core
MAbs 43.27.11.2 and 27.150.3 were also observed when E. coli 018:K1 was
grown in heat-inactivated serum compared to nutrient broth (Figure 68).
Flow cytometry data, showing the effect of growing four E. coli strains
under the different growth conditions on MAb recognition of LPS
associated epitopes is presented in Tables 9 & 10. Although relative
differences between growth conditions remained constant, day to day
variations in percentage labelling within a given sample was evident.
Probing cells with 018, 0-antigen specific MAb 184.2.5.5, resulted in
similar binding levels for most conditions, whilst magnesium depleted
(150 cells, notably 018:K1 showed a significant decrease. Smooth cells
grown under heat-inactivated sheep serum and magnesium (1%) conditions
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Figure 67. Green fluorescence intensity histograas of two anti-LPS HAbs against whole cells of 018:11
grown to early stationary phase in nutrient broth and a aagnesiua depleted (ft) aediua. a) represents
the binding of an 018 0-antigen specific HAb, 184.2.5.5 and b) a core-specific HAb, 43.27.11.2






Figure_68. Green fluorescence intensity histograms of two anti-LPS HAbs against whole cells of
018:11 grown to early stationary phase in nutrient broth and heat-inactivated sheep seruii. (a A b)
represent the binding of two core specific HAbs 43.27.11.2 and 27.150.3 respectively. Percentage
values represent bacteria exhibiting positive fluorescence above background levels.
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Table 9. Flow cytometric analysis of anti-LPS MAb binding to whole
cells of 4 E. coli strains grown under different conditions.
Percentage values represent the mean positive fluorescence of bacteria
above background levels from three separate experiments. MAbs include
018, 0-antigen specific MAb 184.2.5.5, and core- specific MAb 27.150.3.
MAb Growth Medium
Percentage of cells showing
positive fluorescence*
E. coli
018:K1 018:K1" 018:Krf 06:K5
Nutrient Broth 70(19) 62(14) 2 (1) ND
Nitrogen Deficient/
High Carbon 73(10) 68 (7) 13 (6) ND
Iron Depleted 74 (6) 50 (3) 3 (1) ND
Magnesium Depleted (IX) 49 (9) 39 (9) 7 (0) ND
Serum 68(15) 67 (8) 8 (1) ND
Nutrient Broth 2 (1) 6 (1) 26(11) 3(2)
Nitrogen Deficient/
High Carbon 2 (0) 3 (1) 16 (6) 2(1)
27.150.3 Iron Depleted 3 (2) 8 (3) 20 (5) 14(9)
Magnesium Depleted (IX) 12 (4) 18 (2) 28 (7) 10(2)
Serum 16 (5) 34(11) 20(12) 32(8)
* = Mean (±SD)
ND = Not Done
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Table 10. Flow cytometric analysis of anti-LPS MAb binding to whole
cells of 4 E. coli strains grown under different conditions.
Percentage values represent the mean positive fluorescence of bacteria
above background levels from three separate experiments. MAbs include
core-specific MAbs 43.27.11.2 and 43.3.4.8.
Percentage of cells showing
positive fluorescence*
E. coli
MAb Growth Medium 018:K1 018:Kl" 018:Krf 06:K5
Nutrient Broth 3 (1) 3 (2) 68(11) 7 (1)
Nitrogen Deficient/
High Carbon 2 (0) 2 (1) 56(12) 1 (0)
43.27.11.2 Iron Depleted 10 (7) 7 (4) 66 (7) 7 (3)
Magnesium Depleted 21 (4) 24 (5) 75(13) 18 (8)
Serum 28(16) 61(11) 43(14) 26(12)
Nutrient Broth 32 (8) 38 (5) 81(14) 29 (4)
Nitrogen Deficient/
High Carbon 6 (1) 14 (8) 77(11) 8 (2)
43.3.4.8 Iron Depleted 38 (4) 51(11) 87 (8) 41 (7)
Magnesium Depleted (1%) 42 (9) 48 (6) 79 (9) 49 (9)
Serum 52 (6) 67(10) 84(12) 54 (5)
= Mean (±SD)
ND = Not Done
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Table 11. Flow cytometric analysis of anti-LPS MAb binding to whole
cells of E. coli strains 018:K1 and 018:K1 grown in absorbed and non-
absorbed heat-inactivated sheep serum. Percentage values represent the
mean positive fluorescence of bacteria above background levels from
triplicate readings. MAbs include core-specific MAb A3.27.11.2 and
018, 0-antigen specific MAb 18A.2.5.5.
Percentage of cells showing positive
fluorescence*
Mab A3.27.11.2 MAb 18A.2.5.5
E. coli E. coli
Absorbant 018:K1 018:K1 018:K1 018:K1
None 31 (6) 55 (8) 79 (8) 73 (9)
E. coli 018:K1 2A(12) 57(10) 83(12) 69 (7)
E. coli 06:K5 29 (8) A9 (5) 71 (5) 65(12)
Mean (±SD)
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E.coli 018:K1 labelled with O-antigen
specific MAb
/Sorted samples subcultured,^ksingle clones expandedovernight and reanalysed
b
Figure 69. Subpopulations of E. coli 018:11 identified and sorted by flow cytometry on the basis of
differential binding by 0-antigen specific Mb, 184,2.5.5. Green fluorescence intensity histograms
represent presorted (a) and postsorted (b) cell populations.
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Nitrogen deficient/high carbon cells showed an overall decrease in
percentage labelling when probed with anti-core MAbs, especially
43.3.4.8. Overall, greater binding of anti-core MAbs was demonstrated
against the rough mutant 018:Krf compared to smooth strains.
The binding activities of anti-LPS MAbs to E. coli 018:K1 and 018:Kl"
grown in absorbed and unabsorbed heat-inactivated sheep serum was
compared (Table 11). Absorption of serum was performed with organisms
possessing an identical or unrelated O-antigenic structure to that
under analysis. Growth of each organism in unabsorbed or absorbed
serum produced similar positive fluorescence values when probed with
either core or 0-antigen specific MAbs. The anti-core MAb again
demonstrated greater reactivity to the non-capsulate strain.
The feasibility of sorting viable bacteria on the basis of differential
fluorescence signals produced by surface-bound MAb was investigated.
An example of biphasic fluorescent labelling representing two distinct
subpopulations of cells was illustrated by the differential binding of
0-antigen reactive MAb 184.2.5.5 to E. coli 018:K1 grown in nutrient
broth. The two subpopulations were sorted into nutrient broth,
expanded and reanalysed by flow cytometry (Figure 69). Analysis of the
subcultured cells from both subpopulations following staining by MAb
184.2.5.5, revealed that they were unstable - each producing both
subpopu1ations.
3.4 IMMUNOGOLD ELECTRON MICROSCOPY OF BACTERIA GROWN IN VITRO
Immunogold electron microscopy was also used to assess the binding of
anti-LPS MAbs to E. coli cells grown under selected nutrient conditions
and processed for thin-sections. Figure 70a-c shows the binding of 0-
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Figure 70. Iuunogold electron iicrographs of thin sections fro« cells of E. coli 018:11 grown in
nutrient broth (a), nitrogen deficient/high carbon aediui (b) and heat-inactivated sheep serui (c).
Cells were prepared by probing with 0-antigen specific MAb 184.2.5.5 followed by anti-iouse IgS gold
conjugate. Bars, 1 fit.
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Figure 71. Inunogold electron licrographs of thin sections froi cells of E. coli 018:11 grown in
nutrient broth (a), nitrogen deficient/high carbon aediua (b) and heat-inactivated sheep serui (c).
Cells were prepared by probing with core specific MAb 27.150.3, followed by anti-iouse IgS gold
conjugate. Bars, 1 pa.
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antigen specific MAb 184.2.5.5 to representative E. coli 018:K1 cells
grown in nutrient broth, nitrogen deficient/high carbon medium and
heat-inactivated sheep serum. Immunolabelling of the sections resulted
in extensive gold labelling of the surface of the cells. Figure 71a-c
illustrates representative sections of cells grown under identical
conditions to those described above, and probed with a core-specific
MAb 27.150.3. Growth of E. coli 018:K1 in heat-inactivated sheep serum
showed the greatest MAb binding (c), whilst growth in nitrogen
deficient/high carbon medium showed the least (b).
3.5 LIPOPOLYSACCHARIDE ANALYSIS OF IN VIVO GROWN BACTERIA
The expression of LPS on in vivo grown bacteria was investigated using
two animal models: i) chambers implanted in the mouse peritoneal cavity
and ii) the mucin-haematin septicaemia model.
Chamber implants were removed after 2 days, at which stage the
8 9bacterial cultures had reached their maximal density of 10-10 cells
ml *. The silver stained LPS profiles of in vitro nutrient broth and in
vivo chamber implant grown E. coli 018:K1 are shown in Figure 72.
Compared with the in vitro cells, in vivo cells appeared to express
greater amounts of 0-antigen as well as an overall increase in 0-
polysaccharide chain length. In vivo LPS profiles also showed greater
expression of unsubstituted core material and other low molecular mass
bands.
Silver staining and immunoblot analysis were used to investigate the
LPS profiles of E. coli 018:K1 grown in vivo in chamber implants, and
recovered from the mouse peritoneal cavity 1-10 days after implantat¬
ion. Silver stained LPS showed no significant differences between
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Figure 72. Silver stained LPS profiles of proteinase I whole cell digests of E. coli 018:11 separated
by PA6E (141 w/v acrylaaide). Track 1, cells grown in vitro in nutrient broth, and Tracks 2-4, cells
grown in vivo in louse chaiber iaplants. Tracks 2-4 represent cell digests prepared froa chaabers
taken froa three separate aice 2 days after iaplantation.
211
incubation times (Figure 73). However, cells recovered between 2 and
10 days appear to express greater high molecular mass O-antigenic
material compared to cells recovered after 1 day (Track 1). Correspon¬
ding immunoblots probed with 018, 0-antigen specific MAb 184.2.5.5 and
core-specific MAb 43.27.11.2 are shown in Figure 74. Serotype
specificity of E. coli 018 :K1 was retained when the organisms were
grown in vivo. Reactivity of MAb 184.2.5.5 was greatest against the
LPS of cells recovered once 4 days implantation had elapsed. MAb
43.27.11.2 reacted weakly against samples recovered following an
incubation period of 1 day (Track 1) and 3 days (Track 3). The
strongest reactions were against samples recovered following an
incubation period of 4 days (Track 4) and 10 days (Track 6).
The mucin-haematin septicaemia model was used for the in vivo growth of
E. coli 018:K1 and 016:K1 in mice. Bacteria were recovered from whole
blood and subjected to silver staining analysis (Figure 75). The LPS
profiles of the two in vivo grown E. coli 018:K1 samples were shown to
contain longer O-polysaccharide chain lengths than in vitro grown
cells. The O-polysaccharide chain lengths of the two in vivo grown E.
coli 016:K1 samples were shown to be either the same (Track 2) or
longer (Track 3) than cells grown in vitro (Track 1).
Preliminary ELISA investigations compared the binding activities of
anti-LPS MAbs in vitro or in vivo grown whole bacterial cells coated
directly to the wells of microtitre plates. Results established high
background signals of wells coated with in vivo grown cells from
chamber implants or whole blood. Further studies compared the ability
of in vitro and in vivo whole bacterial cells to inhibit the ELISA
reactivity of anti-LPS MAbs against coated in vitro grown whole cells.
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Figure 73. Longitudinal study of silver stained LPS profiles of proteinase I whole cell digests of
in vivo grown f. coli 018:11 separated by PAGE (14* w/v acrylaiide). Chaiber implants were recovered
froi lice 1 day (Track 1); 2 days (Track 2); 3 days (Track 3); 4 days (Track 4); 7 days (Track 5) and
10 days (Track 6) after implantation.
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Figure 74. Itmunoblots of in vivo grown proteinase I whole cell digests of E. coli 018:11 separated
by PAGE (141 w/v aerylaaide) followed by transfer to SIC paper and probed with a) 018, O-antigen
specific HAb 184.2.5.5 and b) core-specific HAb 43.27.11.2. Chamber implants were recovered from mice
1 day (Track 1); 2 days (Track 2); 3 days (Track 3); 4 days (Track 4); 7 days (Track 5) and 10 days





Figure 75. Silver stained LPS profiles of proteinase I whole cell digests of 2 S. coli strains, S.
coli 018 (a) and S. coli 016 (h) separated by PAGE (14* w/v acrylaiide). For each strain, Track 1
represents cells grown in vitro in nutrient broth and Tracks 2 and 3, cells grown in vivo in a souse
septicaemia model. Tracks 2 and 3 represent cells recovered froa 2 separate aice.
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E. coli 018:K1 grown in either nutrient broth or chambers implanted in
the mouse peritoneal cavity were prepared in a ten-fold dilution series
from lxlO9 cells ml"1. All inhibitor dilutions were mixed with an equal
volume of MAb diluted in dilution buffer (184.2.5.5 1:40, 43.27.11.2
1:10), and preincubated at 37°C for 30 min before adding to ELISA.
Both in vitro and in vivo cell preparations demonstrated a similar
inhibitory activity of O-specific MAb 184.2.5.5 (Figure 76a). Binding
of the MAb was completely inhibited by both cell preparations at an
inhibitor concentration of lxio' cells ml . Overall, the inhibitory
activity of in vivo grown cells was slightly greater than in vitro
grown cells. The corresponding inhibition of anti-core MAb 43.27.11.2
is shown in Figure 76b. For each inhibitor dilution, in vivo cells
showed greater inhibition of ELISA activity compared to in vitro cells.
At an inhibitor concentration of lxlO9 cells ml 1 residual ELISA activity
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Figure 76. Inhibition of ELISA reactivity of O-specific IfAb 184.2.5.5 (1:40) (a) and core-specific
NAb 43.27.11.2 (1:10) (b) against in ritro nutrient broth grown E. coii 018:11 whole cells with in
vitro nutrient broth grow E. coli 018:11 whole cells and ^n vivo (lojise chaser isplantj) grown E.
co/r 018:11 whole cells. Inhibitors were diluted fros 1x10 cells ll to 1x10 cells si . Residual
ELISA reactivity in the presence of inhibitor is expressed as a percentage of reactivity with no




THE EFFECTS OF SUBINHIBITORY CONCENTRATIONS OF ANTIBIOTICS ON THE
BINDING OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES
TO ESCHERICHIA COLI
The binding capacity of anti-LPS MAbs to E. coli bacteria grown in both
the absence and presence of sub-MICs of various antibiotics was
studied. The effect of sub-MICs of antibiotics on the expression of
isolated LPS and outer membrane proteins was also investigated. Eight
E. coli strains (six clinical blood culture isolates and two isogenic
mutants of the 018:K1 parent: a non-capsulate mutant, 018:K1 , and a
rough mutant, 018:Krf) were grown in the absence and presence of the p-
lactam antibiotic ampicillin; chloramphenicol; the aminoglycoside
gentamicin and the fluoroquinolone ciprofloxacin. The MICs of each
antibiotic for the E. coli strains are shown in Table 12.
4.1 SILVER STAINING AND IMMUNOBLOT ANALYSIS OF LIPOPOLYSACCHARIDE FROM
ANTIBIOTIC TREATED AND UNTREATED CELLS
The silver stained LPS profiles of eight E. coli strains grown in the
absence and presence of sub-MICs of ampicillin, chloramphenicol and
gentamicin are shown in Figures 77 and 78. Major visible changes in
LPS expression were only observed for most of the strains cultured in
the presence of chloramphenicol. Changes included a decreased
expression of high molecular mass, O-antigen bearing LPS bands (for
example, Figure 77b & c, Tracks 5-7), and/or an increased expression of
low molecular mass substituted LPS bands (for example, Figure 78b,
Tracks 5-7). These changes were more prominent for the lowest sub-MIC
dilution (1:2). Immunoblotting LPS profiles of E. coli 018:K1 with
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Table 12. MICs of ampicillin, chloramphenicol, gentamicin and
ciprofloxacin for E. coli.
MIC (pg/ml)
Strain Ampicillin Chloramphenicol Gentamicin Ciprofloxacin
018:K5 (226) 4 16 0.5 0.032
018:K5 (281) 128 8 0.5 0.008
01 :K1 (316) 2 8 0.5 0.016
06 :K? (317) 256 16 0.5 0.032
0?:K5 (484) 2 16 0.5 0.016
018:K1 2 8 0.5 0.016
018:Kl" 2 8 0.5 0.016
(isogenic mutant
of above)
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Figure 77. Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains 018:15
(226) (a); 018:15 (281) (b); 01:11 (316) (c) and 06:1? (317) (d) separated by PA.6E (141 w/v
acrylaaide), For each strain, Track 1 represents cells grown in the absence of antibiotic and Tracks
2-4, 5-7 and 8-10 represent cells grown in the presence of 1:2, 1:4 and 1:8 SIC dilutions of
aapicillin, chloraaphenicol and gentaaicin respectively.
HA = no antibiotic, Amp - ampici11in, Chlor = chloramphenicol and Sent = gentamicin.
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Figure 78. Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains 0?:K5
(484) (a); 018:11 (b); 018:11 (c) and 018:Xrf (d) separated by PAGE (141 w/v acrylaiide). For eacb
strain, Track 1 represents cells grown in the absence of antibiotic and Tracks 2-4, 5-7 and 8-10
represent cells grown in the presence of 1:2, 1:4 and 1:8 MIC dilutions of anpici 11 in, chloraaphenicol
and gentaaicin respectively.
HA = no antibiotic, Amp = aapicillin, Chlor = chloraaphenicol and Sent = gentaaicin.
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018, 0-antigen specific MAb 184.2.5.5 and core-specific MAb 27.150.3
(Figure 79), demonstrates the increased expression of low molecular
mass LPS material from cells exposed to chloramphenicol (Tracks 5-7),
compared to untreated cells. Immunoblot analysis of antibiotic treated
and untreated cells of E. coli 018:K5 (226) against 27.150.3 (Figure
80), again highlights the greater reactivity against low molecular mass
LPS bands of chloramphenicol treated cells.
Figures 81 and 82 represent the silver stained LPS PAGE profiles and
their corresponding immunoblots (probed with MAb 27.150.3) of eight E.
coli strains grown in the absence and presence of sub-MICs of
ciprofloxacin. LPS of ciprofloxacin treated cells showed only minor
changes against untreated control cells, including a small increase in
the O-polysaccharide chain length for some strains (Figure 82, , Tracks
2-4). Probing LPS profiles of the four E. coli 018 smooth strains with
018-serotype specific MAb 184.2.5.5, again demonstrates an increased 0-
polysaccharide chain length for three of the four strains, notably at
a ciprofloxacin MIC dilution of 1:2 (Figure 83b-d).
4.2 BINDING OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES TO
ANTIBIOTIC TREATED BACTERIA IN ELISA
Viable bacteria, grown to early stationary phase in the absence and
presence of 1:2, 1:4 and 1:8 MIC dilutions of antibiotics were used to
coat microtitre plates. Coated whole cells were probed with four anti-
LPS MAbs: 018, 0-antigen specific MAb 184.2.5.5; outer-core-specific
MAb 43.3.4.8; Rc core-specific MAb 27.150.3 and Re core-specific MAb
43.27.11.2.
ELISA-titres were defined as the dilution of MAb that showed an OD of
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Figure 79. Iaaunoblots of proteinase X whole cell digests of S. coli 018:11 separated by PAGE (141
w/v aerylamide) followed by transfer to NIC paper and probed with O-antigen specific RAb 184.2.5.5
(a) and core-specific RAb 27.150.3 (b). Track 1 represents ceils grown in the absence of antibiotic
and Tracks 2-4, 5-7 and 8-10 represent cells grown in the presence of 1:2, 1:4 and 1:8 RIC dilutions
of aapicillin, chloraaphenicol and gentaaicin respectively.
HA = no antibiotic, Asp = aapicillin, Chior = chloraaphenicol and Gent = gentaaicin.
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Figure 80. Iuunoblot of proteinase I whole cell digests of J. coli 0?:I5 (484) separated by PAGE
(141 w/v acrylaiide) followed by transfer to MIC paper and probed witb core-specific HAb 27.150.3.
Track 1 represents cells grown in the absence of antibiotic and Tracks 2-4, 5-7 and 8-10 represent
cells grown in the presence of 1:2, 1:4 and 1:8 MIC dilutions of awpicillin, chloraiphenicol and
gentaiicin respectively.
HA = no antibiotic, Aip = awpicillin, Chlor = chloraiphenicol and Gent = gentawicin.
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Figure 81. A) Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
018:15 (226) (a): 018:15 (281) (b); 01:11 (316) (c); 06:1? (317) (d) and 0?;I5 (484) (e) separated
by PAGE (141 w/v acrylaiide). B) Iuunoblot of the equivalent proteinase I whole cell digests
separated hy PAGE (141 w/v acrylawide) followed by transfer to HIC paper and probed with core-specific
HAb 27.150.3. For each strain, Track 1 represents cells grown in the absence of antibiotic and Tracks
2-4 represent cells grown in the presence of 1:2, 1:4 and 1:8 HIC dilutions of ciprofloxacin.
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Figure 82. A) Silver stained LPS profiles of proteinase I whole cell digests of E. coli strains
018:11 (a), 018:11 (b) and 018:Irf (c) separated by PAGE (14* w/v acrylaiide). B) Imaunoblot of the
equivalent proteinase I whole cell digests separated by PAGE (14* w/v acrylaiide) followed by transfer
to MC paper and probed with core-specific BAb 27.150.3. For each strain, Track 1 represents cells
grown in the absence of antibiotic and Tracks 2-4 represent cells grown in the presence of 1:2, 1:4
and 1:8 BIC dilutions of ciprofloxacin.
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Figure 83. Iuunoblot of proteinase I whole ceil digests of E. coli 018:15 (226) (a); 018:15 (281)
(b); 018:11 (c) and 018:11 (d) separated by FUSE (14k w/v acrylaiide) followed by transfer to MIC
paper and probed with 0-antigen specific HAb 184.2.5.5. For each strain, Track 1 represents cells
grown in the absence of antibiotic and Tracks 2-4 represents cells grown in the presence of 1:2, 1:4
and 1:8 MIC dilutions of ciprofloxacin.
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0.2 at 590 nm. If an 0D of 0.2 was not reached, the reaction was
considered negative. Since differences in coating-efficiency may occur
between the different antigens, ELISA-titre ratios were compared
instead of the measured absolute titres (Overbeek et al, 1989). The
ratio was defined as the titre obtained with a certain MAb to a strain
grown in the presence of antibiotic, divided by the titre obtained with
the same MAb to this strain grown in the absence of antibiotic. A
ratio of more than one indicates an increase in binding of MAb to the
strain grown in the presence of antibiotic. However, growth of
bacteria in the presence of antibiotic may increase the coating
efficiency of antigens to plates, resulting in ratios of more than one,
not necessarily reflecting an increase in MAb binding. Therefore, in
terms of enhanced MAb binding, only ratios of more than two were
considered significant.
ELISA-titre ratios of anti-LPS MAb against eight E. coli strains grown
in the absence or presence of antibiotics are presented in Tables 13-
16. Overall, treatment of cells with various antibiotics did not alter
the binding of 0-antigen specific MAb 184.2.5.5. Any significant
differences that did occur were in cells treated with ciprofloxacin,
illustrated by E. coli 018:Kl", 1:2 MIC dilution (Table 16).
The three anti-core MAbs all showed increased reactivity against some
or all smooth E. coli grown in the presence of antibiotics compared to
untreated cells. Those antibiotics inducing the greatest increases
included ampicillin, chloramphenicol and ciprofloxacin. Gentamicin was
shown to exert the least effect on MAb binding, although significant
increases against some strains were observed. Exposure of E. coli
06:K? (317) and 018:K1 to antibiotics had the least effect on MAb
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Table 13. ELISA-titre ratios obtained with 4 anti-LPS MAbs to E. coli
018:K5 (226) and 018:K5 (281) grown in the presence or absence of sub-
MICs of antibiotics. MAbs include 018, 0-antigen specific MAb
184.2.5.5 and core-specific MAbs 27.150.3, 43.3.4.8 and 43.27.11.2.
Amp = Ampicillin; Chlor = Chloramphenicol; Gent = Gentamicin; Cipro =
Ciprofloxacin. Results were calculated from the means of triplicate
readings. ( ) - 0












1:2 1:4 1 :8
184.2.5.5 1 I 1 t 1 I 1 I 1 1 2 1
27.150.3 16 6 7 24 24 3 1 1 1 10 1 1
43.3.4.8 16 16 16 18 9 9 1 1 1 5 1 1
43.27.11.2 229 180 95 53 47 10 1 i I 69 43 10
E. coli 018:K5 (281)
Amp Chlor Gent Cipro
MAb 1:2 1:4 1:8 1:2 1:4 1:8 1:2 1:4 1:8 1:2 1:4 1 :8
184.2.5.5 1 1 1 i 1 1 1 \ I 1 1 1
27.150.3 14 14 10 20 20 16 10 6 J 12 9 9
43.3.4.8 2 2 1 6 3 3 4 6 ! 4 1 \
43.27.11.2 18 18 12 4 2 1 5 5 1 16 16 4
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Table 14. ELISA-titre ratios obtained with 4 anti-LPS MAbs to E. coli
01:K1 (316) and 06:K? (317) grown in the presence and absence of sub-
MICs of antibiotics. MAbs include 018, 0-antigen specific MAb
184.2.5.5 and core-specific MAbs 27.150.3, 43.3.4.8 and 43.27.11.2. NC
= Not calculated (0D<0.2); Amp = Ampicillin; Chlor = Chloramphenicol;
Gent = Gentamicin; Cipro = Ciprofloxacin. Results were calculated from
the means of triplicate readings. 0 =
Antibiotic and MIC dilution
E. coli 01:K1 (316)
Amp Chlor Gent Cipro
MAb 1:2 1:4 1:8 1:2 1:4 1:8 1:2 1:4 1:8 1:2 1:4 00
184.2.5.5 NC NC NC NC NC NC NC NC NC NC NC NC
27.150.3 1 4 1 86 93 8 6 1 1 20 16 17
43.3.4.8 16 16 4 35 30 29 5 4 4 16 16 14













184.2.5.5 NC NC NC NC NC NC NC NC NC NC NC NC
27.150.3 31 1 1 6 1 1 1 1 1 1 1 1
43.3.4.8 15 18 12 4 4 3 1 1 1 4 1 1
43.27.11.2 5 5 5 1 2 1 1 1 I 3 3 1
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Table 15. ELISA-titre ratios obtained with A anti-LPS MAbs to E. coli
0?:K5 (A8A) and 018:K1 grown in the presence or absence of sub-MICs and
antibiotics. MAbs include 018, 0-antigen specific MAb 18A.2.5.5 and
core-specific MAbs 27.150.3, A3.3.A.8 and A3.27.11.2. NC = Not
calculated (0D<0.2); Amp = Ampicillin; Chlor = Chloramphenicol; Gent =
Gentamicin; Cipro = Ciprofloxacin. Results were calculated from the
means of triplicate readings, (l ~ ^l)
Antibiotic and MIC dilution
E. coli 0?:K5 (A8A)
Amp Chlor Gent Cipro
MAb 1:2 1: A 1:8 1:2 1: A 1:8 1:2 1:A 1:8 1:2 1:A 1:8
18A.2.5.5 NC NC NC NC NC NC NC NC NC NC NC NC
27.150.3 16 6A 16 1 1 1 62 62 55 1A 10 10
A3.3.A.8 NC NC NC NC NC NC NC NC NC NC NC NC










1:2 1 :A 1:8
18A.2.5.5 1 1 1 ) I I 1 1 1 1 1 t
27.150.3 16 16 A 8 8 8 1 1 1 13 8 10
A3.3.A.8 A 1 1 1 1 1 A 1 1 3 3 i
A3.27.11.2 3 2 2 6 8 A 3 I 1 6 7 6
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Table 16. ELISA-titre ratios obtained with 4 anti-LPS MAbs to E. coli
018:K1 and 018:Krf grown in the presence or absence of sub-MICs of
antibiotics. MAbs include 018, 0-antigen specific MAb 184.2.5.5 and
core-specific MAbs 27.150.3, 43.3.4.8 and 43.27.11.2. Amp =
Ampicillin; Chlor = Chloramphenicol; Gent = Gentamicin; Cipro =
Ciprofloxacin. Results were calculated from the means of triplicate
readings. (J =
Antibiotic and MIC dilution
E. coli 018:K1
Amp Chlor Gent Cipro
MAb 1:2 1:4 1:8 1:2 1:4 1 :8 1:2 1:4 1:8 1:2 1:4 1:8
184.2.5.5 1 1 1 i 1 ( I I 1 3 1 1
27.150.3 16 16 4 6 6 2 i I 1 7 8 5
43.3.4.8 1 1 1 f I 1 1 ! 1 1 I 1
43.27.11.2 4 3 3 13 16 16 i ! I 4 4 1
E. coli 018:Krf
Amp Chlor Gent Cipro
MAb 1:2 1:4 1:8 1:2 1:4 1 :8 1:2 1:4 1:8 1:2 1:4 1:8
184.2.5.5 1 1 1 1 1 ! I 1 1 2 1 1
27.150.3 4 1 1 1 1 1 * 1 1 i 1 t
43.3.4.8 1 1 1 i I \ 1 I 1 1 1 1
43.27.11.2 1 1 1 1 I I \ 1 » 1 I 1
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binding compared to other untreated smooth strains. Growth of the
rough mutant, E. coli 018:Krf in the presence of antibiotics showed
only occasional increases in MAb reactivity.
A.3 FLOW CYTOMETRIC ANALYSIS OF THE BINDING OF ANTI-LIPOPOLYSACCHARIDE
MONOCLONAL ANTIBODIES TO ANTIBIOTIC TREATED BACTERIA
To investigate changes in binding activities of anti-LPS MAbs to whole
cells exposed to sub-MICs of antibiotics further, flow cytometric
analysis was performed. Figures 84-86 show the flow cytometric
profiles of MAbs to selected whole cells grown in the absence or
presence of one half of the MIC of various antibiotics.
The fluorescence patterns produced by 018, 0-antigen specific MAb
184.2.5.5 against treated and untreated cells varied considerably for
each E. coli strain. Exposure of E. coli 018:K5 (281) to the anti¬
biotics gentamicin and ciprofloxacin in particular resulted in cells
exhibiting greater fluorescence intensity (Figure 84a). However, both
antibiotic treated and untreated samples showed similar percentage
cells exhibiting positive fluorescence. Significant changes in
positive fluorescence levels for E. coli 018:K1 probed with 184.2.5.5
were observed for cells exposed to chloramphenicol (45%) and
ciprofloxacin (87%) compared to untreated cells (70%). The presence of
small amounts of 0-antigen on the rough mutant (018:Krf) reflects low
binding levels of 184.2.5.5 (Figure 86a). Those cells exposed to
ampicillin and chloramphenicol demonstrated highest positive fluor¬
escence values.
The core-specific MAbs 27.150.3 and 43.3.4.8 exhibited similar levels
of binding to cells of the rough mutant, E. coli 018:Krf, grown in the
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presence or absence of antibiotics (Figure 86b & c). Mab 27.150.3
showed weak binding levels (< 5%) to smooth E. coli 018:K1 (Figure 85b)
and 018:K5 (281) (Figure 84b) not exposed to antibiotics. However,
growth of these strains in the presence of sub-MIC levels of
ampicillin, chloramphenicol and ciprofloxacin all resulted in signifi¬
cant increases in positive fluorescence levels when probed with
27.150.3. Those samples exhibiting an increased percentage of cells
with positive fluorescence also demonstrated greater fluorescence
intensity levels as shown by differences in the flow cytometric
profiles of antibiotic treated and untreated cells. Small increases in
positive fluorescence values were observed for most smooth E. coli,
exposed to the different antibiotics and probed with MAb 43.3.4.8. The
greatest increase was shown for E. coli 018:K5 (281), grown in the
presence of chloramphenicol (42%) against cells grown in the absence of
antibiotics (25%) (Figure 84c). Gentamicin induced only minor
increases in binding of MAbs 27.150.3 and 43.3.4.8 to smooth strains,
against untreated control cells.
A number of antibiotic treated samples also produced biphasic fluor¬
escence patterns as shown in Figures 84-86 indicating the presence of
subpopulations of cells.
4.4 OUTER MEMBRANE PROTEIN ANALYSIS OF ANTIBIOTIC TREATED E. COLI
SDS-PAGE was used to analyse the effects of one half of the MIC of
various antibiotics on the expression of outer membrane proteins of six
E. coli strains (Figures 87 and 88). The outer membrane proteins of
cells grown in the absence or presence of subinhibitory concentrations
of the antibiotics ampicillin, chloramphenicol and gentamicin are shown
in Figure 87. The most prominent changes in proteins involved the
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Figure 87. SDS-PAGE of Sarkosyl outer teabrane proteins of E. coli strains 018:11 (a); 018:11 (b);
018:Irf (c); 018:15 (281) (d); 06:1? (317) (e) and 0?:I5 (484) (f) separated on acryiaaide 10* slab
geis stained with Cooraassie blue. Track 1 represents cells grown in the absence of antibiotic and
Tacks 2-4, cells grown in the presence of one half of the MIC of ampicillin, chloramphenicol and
gentaaicin respectively. The arrowhead indicates the absence of a protein band from E. coli 018:15
exposed to gentaiicin.
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Figure 88. SDS-PAGE of SarkosyI outer aeabrane proteins of six E. coli strains separated on
acrylaaide 10* slab gels stained with Cooaassie blue. Cells were grown in the absence of antibiotic
or presence of one half of the HIC of ciprofloxacin. Tracks 1 and 2 represent 018:11; Tracks 3 and
4 018:I1~; Tracks 5 and 6 018:Irf; Tracks 7 and 8 018:15 (281); Tracks 9 and 10 06:1? (317) and Tracks
11 and 12 0?:I5 (484). The first track of each strain represents cells grown in the absence of
antibiotic.
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appearance of several minor high molecular mass proteins (> 45 kDa) in
most E. coli strains exposed to gentamicin (Track 4), which were absent
from untreated, control cells. The ampicillin resistant strain of E.
coli 018:K5 (281) expressed a protein of approximately 40 kDa for all
samples except those cells grown in the presence of gentamicin (absent
protein band indicated by arrowhead) (Figure 87d).
The outer membrane proteins of E. coli strains grown in the absence and
presence of ciprofloxacin are shown in Figure 88. E. coli 018:K1
(Track 4), 018:Krf (Track 6) and 018:K5 (281) (Track 8) expressed
several additional minor high molecular mass proteins (> 45 kDa) when
exposed to ciprofloxacin, which were absent from untreated cells. No
changes involving the major outer membrane proteins were evident.
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CHAPTER 5
ANALYSIS OF THE WHOLE CELL ELISA TECHNIQUE
The whole cell ELISA technique, using bacteria attached to the solid-
phase matrix of microtitre plates was used to monitor the binding of
anti-LPS MAbs in studies previously described. Failure of some of the
anti-core LPS MAbs to react against whole cells in flow cytometry,
suggested possible differences in antigenic presentation of these
suspended cells, compared to those used in the whole cell ELISA
technique. The aim of this work, was to establish if binding manipula¬
tions of the assay altered the accessibility of LPS epitopes on
nutrient broth grown coated whole cells, compared to their native whole
cells.
5.1 BINDING ACTIVITIES OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL
ANTIBODIES TO WHOLE CELLS, HEAT-KILLED CELLS AND SONICATED CELLS IN
ELISA
Initial investigations were designed to establish if different cell
preparations affected the accessibility of LPS epitopes. ELISA
activities of two anti-LPS MAbs against whole cells, heat-killed cells
(15 min at 100°C) and sonicated cells (six, 1 min bursts with 30 s
intervals) of E. coli 018:K1 and 018:Krf were studied. Cell samples
were prepared from the same original cell suspension, diluted to a
7 -1
density of 2x10 cells ml The greatest reactivity of 0-antigen
specific MAb 184.2.5.5 was against sonicated cells, followed by heat-
killed cells of each E. coli strain (Figure 89). The lowest reactivity
was against live whole cells. Core-specific MAb 43.27.11.2 also








Figure 89. ELISA activity of 018, 0-antigen specific HAb, 184.2.5.5 against whole cells, heat-killed










Figure 90. ELISA activity of core-specific HAb, 43.27.11.2 against whole cells, heat-killed cells
and sonicated cells of E. coli 018:11 (a) and E. coli 018:Irf (b). Results represent the means of
triplicate readings.
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E. coli 018:K1 and 018:Krf, whilst the lowest reactivity was against
their respective whole cell preparations (Figure 90).
5.2 ELISA INHIBITION STUDIES
The ability of whole cells in suspension to inhibit the ELISA activity
of anti-LPS MAbs against homologous whole cells coated to microtitre
7 -1
plates at a concentration of 2x10 cells ml was also investigated.
Four-fold dilutions of MAbs (184.2.5.5 and 43.27.11.2) were pre-
G -1
incubated with 1x10 cells ml at 37°C for 30 min before adding to
ELISA. Inhibition of each MAb was compared to uninhibited MAb
reactivity. The binding activity of 0-antigen specific MAb 184.2.5.5
was completely inhibited by E. coli 018:K1 at each MAb dilution (Figure
91a). The same MAb retained some, although reduced activity, after
inhibition by the rough mutant 018:Krf at the higher MAb concentrations
(Figure 91c). E. coli 018:K1 demonstrated limited inhibitory activity
against core-specific MAb 43.27.11.2 (Figure 91b), whilst E. coli
018:Krf showed significant inhibitory activity against the same MAb
(Figure 91d).
Inhibition of ELISA was also performed using a fixed dilution of MAb
against ten-fold dilutions of whole cell inhibitor from 1x10^ cells ml
All inhibitor dilutions were mixed with an equal volume of MAb diluted
in dilution buffer (184.2.5.5 1:40, 43.27.11.2 1:10), and preincubated
at 37°C for 30 min before adding to ELISA. The inhibitory effect of E.
coli 018:K1 on the binding of 0-antigen specific MAb 184.2.5.5 was
shown to increase progressively with an increasing inhibitor concentra¬
tion (Figure 92a). Residual ELISA activity was completely inhibited at
0 .1
a concentration of 1x10 cells ml . The rough mutant E. coli 018:Krf
also showed an inhibitory effect against MAb 184.2.5.5, although a
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% 0 Inhibitor present
o—o Control, no inhibitor
Figure 91. Inhibition of KLISA reactivity of four-fold dilutions of 018, 0-antigen specific HAb
184.2.5.5 (a 4 c) and core-specific HAb 43.27.11.2 (b 4 d), against the whole ^ells of ^ coli 018:11
(a 4 b) and its rough autant 018:Irf (c 4 d) with homologous whole cells (1x10 cells al ). Controls
represent the binding activity of HAbs with no inhibitor present.
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Figure 92. Inhibition of ELISA reactivity of Q-specific BAb 184.2.5.5 (1:40) (a) and core-specific
BAb 43.27.11.2 (1:10) (b) against whole cells of E. coli 018:11 and its roughjiutajit 018:Ir^ with
homologous whole ceils. Inhibitors were diluted in a ten-fold series from 1x10 ml to 1x10 cells
al . Residual ELISA reactivity in the presence of inhibitor is expressed as a percentage of
reactivity with no inhibitor (the 1001 value, represented by the dotted line). Results represent the
means of triplicate readings.
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residual ELISA activity of 32% was retained at 1x10' cells ml ^ inhibitor
concentration. The corresponding inhibition of core-specific MAb
A3.27.11.2 is shown in Figure 92b). Both E. coli 018:K1 and 018:Krf
were shown to inhibit MAb binding, although residual ELISA activities
of 50% and 12% respectively, were retained at inhibitor concentrations
of 1x10^ cell ml '.
5.3 SUSPENSION ELISA
To examine the possible effects of coating cells onto microtitre plates
further, the ELISA reactivity of anti-LPS MAbs against whole cells in
suspension was compared to coated whole cells. The binding activities
of 0-antigen specific MAb 184.2.5.5 and core specific MAb 43.27.11.2,
against coated or suspended whole cells of E. coli 018:K1 and its rough
mutant 018:Krf are shown in Figure 93. MAb 184.2.5.5 showed similar
reactivity against coated or suspended whole cells of both 018:K1 and
018:Krf (Figure 93a & c). Significant reductions in the binding
activity of MAb 43.27.11.2 were shown against suspended whole cells of
018:K1 compared to those cells coated onto microplates (Figure 93b).
Suspended cells of 018:Krf showed only minor reductions in binding





#—• Cells coated onto
microtitre plates
O-O Cells in suspension
Figure 93. ELISA activity of 018, 0-antigen specific HAb 184.2.5.5 (a & c) and core-specific KAb
43.27.11.2 (b 4 d) against whole cells of E. coJi 018:11 (a 4 b) and its rough mtant 018:Irf (c 4
d). The ELISA assays were performed against cells coated onto microtitre plate3 and cells in




CHARACTERIZATION OF ANTI-LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODIES
Monoclonal antibodies recognizing the lipid A, core oligosaccharide and
O-polysaccharide components of the LPS molecule were selected from an
existing panel exceeding 200, produced from more than 30 fusions as
part of a collaborative multicentre study with the ultimate aim of
identifying an anti-LPS cross-reactive antibody for immunotherapy of
Gram-negative septicaemia and septic shock. Although several show
promise as possible immunotherapeutic agents, others have proved
invaluable as probes for studying the expression of LPS and its
detection.
Several MAbs (27.150.3, 27.193.3, 30.A.2.8, A3.11.5.1 and A3.27.11.2)
demonstrated some degree of cross-reactivity in ELISA against heat-
killed cell preparations of selected Gram-negative species, represent¬
ing a number of different LPS-core structures. This cross-reactivity
supports the idea that shared antigenic determinants are present in the
LPS of different species. The inner core region of LPS is believed to
exhibit a high degree of structural conservation among all Entero-
bacteriacae (Eskenazy et al, 1977; Jansson et al, 1981; Perez-Perez et
alt 1986). Serial absorption studies were used to identify the region
in the LPS core to which the antibodies were directed. Those MAbs
showing some cross-reactivity were indeed directed against the
conserved inner or intermediate core region of LPS: 27.193.3 lipid A;
A3.27.11.2 Re ('anti-lipid A-KDO'); A3.11.5.1 and 27.150.3 Rc ('anti-
heptose'). MAbs 27.193.3 and A3.27.11.2 reacted with the full panel of
Gram-negative heat-killed cell preparations in ELISA, suggesting the
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site it recognizes is present in all these species. However, preferen¬
tial binding of MAbs 27.193.3 and A3.27.11.2 to the E. coli core R3 and
R1 respectively, may indicate that their epitopes are relatively
exposed in some core types and not in others, perhaps as a function of
differences in core structure. In contrast, the Rc reactive MAbs
27.150.3 and A3.11.5.1 appeared to recognize epitopes present only on
E. coli and Salmonella, two genera with similar core structure.
MAb 30.A.2.8, although demonstrating cross-reactivity against most
heat-killed cell preparations, preferentially reacted against the
smooth serotype of E. coli 018. Immunoblotting established an affinity
for the O-polysaccharide of the 018 serotype (Figure 18b). Since the
MAb was cloned from a fusion prepared after a vaccination procedure
which included the immunogen lipid A, but no 018, 0-antigen, it was
considered unusual for the MAb to show serotype reactivity. A mix-up
in cell lines with those of other fusions is a possibility which cannot
be discounted. However, it is possible that the MAb is multispecific,
binding to epitopes present on both lipid A and 0-antigen LPS compon¬
ents. Indeed, chemical analysis of the 018, O-polysaccharide (Gupta et
al, 198A; Jann & Jann, 1987) revealed the presence of glucosamine, a
sugar also present in lipid A. Serial absorption (Figure 25) and
inhibition studies (data not shown) demonstrated that 30.A.2.8 does
have some affinity for lipid A, although incomplete absorption of MAb
reactivity by S. typhimurium lipid A indicates that this affinity is
rather weak.
The core-glycolipid reactive MAbs of A3.3.A.8, A3.5.1.A, A3.35.1.A and
AO.18.7.1 were restrictive in their specificities, preferentially
binding to selected E. coli core types. Results indicated that these
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MAbs recognize epitopes in the outer core hexose region, structurally
representing the most variable part of the core (Llideritz et al, 1982;
Westphal et al, 1983; Perez-Perez et al, 1986). The induction of
specific core or R antibodies is not uncommon, since the terminal sugar
of rough mutant bacteria represent the immunodominant sugar (Brade et
al, 1988). It is postulated that the host will be exposed to Gram-
negative bacteria containing complete (Ra) core, LPS with S-LPS,
stimulating the production of core "type' specific antibody responses
of limited cross-reactivity (Scott et al, 1990). Such antibodies may
not be depressed during endotoxaemia while antibodies to the LPS inner
core are depressed (Barclay et al, 1989). Failure to observe any
reduction in ELISA activity for E. coli R1 reactive MAbs 43.3.4.8,
43.5.1.4 and 43.35.1.4 after serial absorption with lipid A and R
chemotypes of S. typhimurium reflected differences in the outer core
structure of S. typhimurium and E. coli R1. The corresponding
absorption for MAb 40.18.7.1, reactive primarily against E. coli R2 and
Salmonella strains, indicated specificity for the Rc chemotype. In
contrast to other E. coli core types, R2 possesses an almost identical
core structure to Salmonella, only differing in the nature of one
hexose residue (Figure 5). Similarity in these core structures
reflects this selective specificity of 40.18.7.1 for the intermediate
/outer core region of both E. coli R2 and Salmonella.
The discrete core type specificity of many of these core-reactive MAbs
represents an extremely valuable set of tools for studing the serology
of the endotoxin core. Indeed, colleagues within the laboratory have
used similar anti-LPS MAbs of limited cross-reactivity to assign core
types to 80 E. coli clinical blood culture isolates, A.P. Gibb, G.R.
Barclay, I.R. Poxton and F. Di Padova; unpublished data.
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Immunoblot analysis of core-glycolipid reactive MAbs established that
the majority reacted against unsubstituted core oligosaccharide. The
epitopes recognized by these MAbs may represent the immunodominant
terminal sugars of rough mutant bacteria which become unavailable when
O-polysaccharide is linked. Alternatively, the presence of O-poly-
saccharide may induce a conformational change in the core structure,
restricting epitope accessibility. Cross-reactive MAb 27.150.3 (Figure
17b) represented the only antibody investigated in this study which is
reactive against the ladder pattern of unsubstituted core and core
substituted with 0-antigen.
The overall binding specificities of particular core-glycolipid
reactive MAbs appeared similar in different assays. Yet, significant
differences were noted in the recognition of certain antigens by
particular MAbs. Examples included the reactivity of 43.27.11.2 and
27.193.3. Both MAbs showed broad cross-reactivity against heat-killed
cells in ELISA, yet restricted specificity against E. coli expressing
the R1 and R3 cores respectively in immunoblotting and flow cytometry.
A comprehensive study by Aydintug et al (1989) established that in
addition to epitope specificity, cross-reactivity of MAbs is a function
of the method of preparation of bacterial antigens and the assay
itself. The differing results between ELISA and immunoblotting
implies: immunoblotting is less sensitive than ELISA, or differences in
the physical presentation of LPSs between the assays results in
antigenic alteration or differences in antigen accessibility. Aydintug
et al (1989) attempted to increase the sensitivity on immunoblots using
avidin-biotin reagents. As a result, the intensity of positive results
increased, but the negative results were unchanged. The latter
hypothesis is a more likely explanation for differences in results.
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The amphipathic nature of the LPS molecule confers susceptibility to a
variety of noncovalent interactions with, and conformational influences
imparted by, its physical environment (Galanos & Liideritz, 1984).
Altered conformation of the molecule may stereochemically hide cross-
reactive epitopes. Detergent used for electrophoresis would solubilize
LPS to a monomeric form, possibly influencing antigenic activity.
The development of a proteinase K extracted LPS ELISA allowed the
direct comparison of MAb specificity against similarly prepared
antigens in ELISA and immunoblotting. The cross-reactivity of MAbs
appeared greater in ELISA employing proteinase K extracted LPS than in
immunoblotting. Indeed, binding specificities of MAbs in the protein¬
ase K ELISA were generally similar to the heat-killed cell ELISA.
Whilst ELISA is perhaps a more sensitive assay than conventional
immunoblotting, LPS is probably displayed differently in the two
assays, accounting for distinctive patterns of recognition by certain
MAbs. Assay dependent differences in antibody specificity suggest the
need for more than one assay when defining MAb specificity. This
requirement is important for core- and lipid A-reactive antibodies
because of the unique physicochemical and immunological properties of
LPS (Pollack et al, 1989).
The extraction of LPS by the proteinase K digestion of cells for
coating to ELISA plates established itself as a simple method, having
the additional advantage of requiring only small culture volumes. The
main concern of the extraction procedure was the nature of the digested
product. Despite establishing optimal conditions for the efficient
digestion of cells, microscopy confirmed the presence of cell fragments
which were removed by centrifugation. Silver stain analysis demon-
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strated that LPS was the only major macromolecular component of
digested samples. Initial studies established the poor reproducibility
of coating extracted R-LPS in particular, directly onto ELISA plates.
Complexing LPS with polymyxin B gave stable binding of proteinase K
extracted LPS to microplates. Polymyxin B is a small cyclic cationic
polypeptide with a fatty acid side chain which probably binds predomi¬
nantly to the inner core region of LPS through both hydrophobic and
cationic interactions, to form a relatively stable complex (Morrison &
Jacobs, 1976; Schindler & Osborn, 1979). The reproducibility of the
LPS-polymyxin assay was better than LPS alone when results of initial
and two repeat experiments were compared (Figure 29). Similar results
were presented by Scott & Barclay (1987) who developed a method of
complexing purified LPS to polymyxin B for the detection of anti-core-
glycolipid IgG antibodies in blood donor sera. This procedure enhanced
the antigenicity of the LPS, enabling detection of antibodies to R-LPS
which were not detected in ELISA where purified R-LPS alone was used.
Scott & Barclay (1987) proposed that polymyxin may stabilise the LPS
structure, allowing the LPS to mimic its natural conformation where it
is complexed to protein in the bacterial outer membrane (Costerton et
al, 1974; Vaara & Hiroshi, 1984) or complexed to various host plasma
constituents or cells (Ulevitch et al, 1981; Munford & Dietschy, 1985).
Inhibition of ELISA reactivity with different LPS antigen preparations,
was performed to determine the antigenic configuration of proteinase K
extracted LPS (complexed or uncomplexed) relative to other LPS
preparations. The most efficient inhibitor of MAb ELISA activity was
purified LPS complexed with polymyxin. The inhibitory effect of
proteinase K extracted LPS (either complexed or uncomplexed) was
similar, although generally lower than that of purified LPS-polymyxin
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complexes, indicating good antigenic presentation. Failure of
polymyxin to improve antigenicity significantly, when complexed with
proteinase K extracted LPS, suggests natural accessibility of the
uncomplexed form to antibodies. The optimal coating concentration of
the complex was 1:10 dilution in coating buffer. Greater concentra¬
tions may present an excess of complex to binding sites on the solid
phase, giving rise to unstable coating and loss of complex from the
solid phase during assay.
Flow cytometry on whole intact bacteria indicated that the 0-antigen of
LPS restricted access of antibody to epitopes in the inner core region
of the molecule in particular. The absence of 0-antigen on rough
mutants appeared to increase the availability of core LPS epitopes to
antibodies, resulting in better binding than to smooth strains. The
overall effect was striking MAb exclusivity, with the majority of core-
specific MAbs showing either low or no reactivity against smooth
bacteria. The core-reactive MAbs exhibiting the highest binding levels
were specific for the more accessible outer core region. Thus,
although there are shared antigenic determinants in the core-glycolipid
region of LPS, they are not necessarily available for binding by
antibody (Elkins & Metcalf, 1985; Gigliotti & Shenep, 1985). However,
heat treating smooth bacteria prior to flow cytometric analysis
significantly increased anti-core MAb binding. Conserved antigenic
determinants that may be cryptic on intact bacteria may be unmasked
only after heat treatment. Tsuchido et al (1985) proposed that heating
may disrupt the integrity of the outer membrane and thereby increase
permeability. Studies demonstrating extensive MAb cross-reactivity
against heterologous intact bacteria (Nelles & Niswander, 1984; Miner
et al, 1986; Baumgartner et al, 1987) may have been exaggerated on the
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basis of using binding experiments employing boiled cells.
Flow cytometry has been used extensively to analyse eukaryotic cell
populations (Muirhead et al, 1985), although its application to
bacteria has remained limited. Several investigations have employed
the technique to measure changes in bacterial protein or DNA content
during cell growth (Steen & Boye, 1980; Boye et al 1983), and also to
detect or identify bacteria in body fluids and environmental water
supplies with varying success (Mansour et al, 1985; Tyndall et al,
1985; Robertson & Button, 1989). A recent study by Lutton et al (1991)
also used flow cytometry to obtain a qualitative indication of epitope
expression on different populations of Bacteroides fragilis. Flow
cytometric analysis of the binding of anti-LPS MAbs to bacteria
presented in this thesis was a successful application of this technol¬
ogy to bacteria. It offers a means of investigating surface properties
of individual cells in large numbers with great speed and efficiency,
whilst also analysing cells in their natural form, devoid of some of
the potential distorting influences present in other methods. Despite
the undoubted potential of flow cytometric analysis of bacteria and
perhaps other prokaryotes, it remains largely unexplored and still in
its infancy. Indeed, the only other known study applying the technique
to analyse LPS-reactive MAbs to bacteria includes that of Evans et al
(1990). Their work established only limited ability of all core- and
lipid A-reactive antibodies to recognize corresponding epitopes on
wild-type smooth bacteria.
Phillips et al (1987) centrifuged fluorescent labelled reaction
mixtures through a sucrose solution as a means of removing unreacted
antibody, thus reducing the antibody component of the fluorescent
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signal without encouraging aggregation of bacteria. It was stressed
that the potential of flow cytometry for studying antigen distribution
in bacteria will only be fulfilled by accurately measuring single
bacteria in a population, without confusion from aggregates. Clumps of
cells were removed by the use of gates on the log forward angle light
scatter signal for work presented in this thesis, whilst Lutton et al
(1991) used mild sonication to break bacterial aggregates. In addition
to encouraging aggregate formation, centrifugation washing during the
preparation of bacterial samples for flow cytometric analysis has the
added disadvantage of possible loss of bound antibody during the
resuspension process. Consequently, a reduction in the intensity of
fluorescent signal and perhaps the actual proportion of positive
fluorescent cells in a population may result.
Concern regarding the possible effects of binding whole bacterial cells
to a solid-phase matrix was highlighted in the analysis of the whole
cell ELISA technique. A comparison of the binding characteristics of
LPS reactive MAbs in ELISA, against coated untreated whole cells, and
cells disrupted to different extents by heating and sonication,
indicated that whole cells, whose core LPS epitopes were the least
accessible, represented the most intact preparation. Studies using
suspended whole cells revealed that although the outermost O-antigenic
side chains were very inhibitory against homologous MAb binding
(184.2.5.5), a very weak inhibitory effect was shown against inner
core-reactive MAb 43.27.11.2. These results suggested possible
differences in the presentation and accessibility of suspended and
coated whole cells. An attempt to compare directly the binding of
core-reactive MAbs to suspended and coated cells in ELISA, again
indicated greater availability of epitopes for cells attached to the
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solid-phase, due probably to their alteration during binding
manipulations. In contrast, flow cytometric analysis under near
physiological conditions, circumvents the problems of solid-phase
induced antigen alteration. However, ELISA offers the advantages of
speed, flexibility, quantitative accuracy and perhaps greater
sensitivity.
Failure to demonstrate cross-reactivity of selected MAbs specific for
the conserved regions of the LPS molecule in certain assays, highlights
the ongoing controversy regarding the existence of broad cross-reactive
core-glycolipid antibodies capable of binding to a variety of smooth
strains. The use of different procedures for the characterization of
MAbs by several investigators, has led to inadequate proof of MAb
cross-reactivity, and emphasized the need for a reliable and reproduc¬
ible in vitro technique for measuring reactivity of MAbs to
heterologous Gram-negative bacteria and LPS. Heumann et al (1991)
developed an ELISA employing LPS complexed with HDLP, a natural carrier
of LPS in vivo (Ulevitch et al, 1981). Similar to LPS-polymyxin
complexes, the LPS-HDLP complex is thought to result in a more
physiologic presentation of the antigen, and to possess the additional
advantage of reducing non-specific binding to LPS. Warren et al (1991)
developed a fluid-phase radioimmunoassay, performed in the presence of
normal serum to facilitate the detection of IgG in antisera that binds
to heterologous S-LPS. The assay avoided binding of antigen to a
solid-phase and was considered appropriate for the accurate analysis of
anti-LPS MAbs.
It was apparent from a variety of selected MAbs with specificities for
different epitopes in the core-glycolipid region of LPS that most of
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these MAbs were more restrictive in their specificity than cross-
reactive. Results emphasize the immunochemical complexity of the core-
lipid A region of enterobacterial LPS. Despite acknowledged structural
conservation among core-glycolipids from different Gram-negative
bacteria, substantial microheterogeneity is likely to occur which will
affect the degree of MAb cross-reactivity (Pollack et al, 1989). The
fine-binding specificity of MAbs may not allow for the desired broad-
spectrum protection against infections with Gram-negative bacteria.
Indeed, limited binding specificities of anti-LPS MAbs has implications
which question whether a therapeutic product should be a single




ENVIRONMENTAL MODULATION OF ESCHERICHIA COLI LIPOPOLYSACCHARIDE
EXPRESSION
2.1 EFFECTS OF NUTRIENT GROWTH CONDITIONS
The environmental modulation of cell surface components of both Gram-
positive and Gram-negative bacteria has been intensively investigated
(Brown & Williams, 1985). Among the environmental factors that
commonly influence the properties of microbial cells, the availability
of essential nutrients assumes particular importance (Harder &
Dijkhuizen, 1983). Numerous studies have determined the binding of
anti-LPS MAbs to purified LPS or intact bacteria grown under laboratory
conditions not associated with the in vivo environment. This study
examined the effects of a number of nutrient growth conditions relating
to those in vivo on the accessibility and expression of LPS antigens on
bacteria using MAbs.
The expression of E. coli core LPS was increased when grown in
2imodifications of Malka minimal medium, containing depleted Mg
concentrations (between no added magnesium salt and 1.7 mmol L cf.
0.65-1.0 mmol L^ in serum). This was reflected in greater binding of
anti-core MAbs using the techniques of immunoblotting, whole cell ELISA
and flow cytometry. Magnesium is important in maintaining the
stability of the structural arrangement of larger molecules such as LPS
within the outer membrane of Gram-negative bacteria (Costerton et al,
1974). Cell walls of magnesium-limited cells of Bacillus subtilis
showed an increased Mg binding affinity over magnesium-sufficient
cells (Meers & Tempest, 1968). Thus certain organisms may respond to
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magnesium limitation by improving their ability to bind the ions by
increasing negatively charged cell surface components such as LPS,
therefore maintaining the structural integrity of the bacteria and its
functional ability to grow. Using both batch and continuous culture,
Day & Marceau-Day (1982) reported gross changes in both the amount of
LPS produced per cell and the composition of the LPS in response to
changes in Mg^+ concentration. Compositional changes in the molecule
were also reflected as functional alteration in the LPS. Data
indicated a change in core size of LPS relative to the O-antigen,
suggesting the possibility of magnesium having a regulatory role on one
or more of the LPS biosynthetic enzymes. Similarly, an increased
production of low molecular mass LPS was shown for E. coli grown at
intermediate growth rates under magnesium limitation (Dodds et al,
1987), whilst magnesium depleted cells of P. aeruginosa produced more
LPS as quantified by changes in KDO content than glucose depleted cells
(Gilbert & Brown, 1978).
Flow cytometric analysis identified bacterial subpopulations exhibiting
distinct patterns of MAb reactivity. E. coli 018:K1 possessed two
subpopulations of cells when grown under magnesium depleted conditions
and probed with an O-antigen specific MAb (Figure 67a). Reasons for
this variability of MAb binding within a population of cells include:
differences in the accessibility and composition of LPS; capsule
expression (shown to be inhibited under these conditions by Taylor et
al, 1981b); or morphological heterogeneity of bacteria grown under
magnesium depletion. The ability of flow cytometry to analyse
individual cells also lent itself to sorting bacteria on the basis of
differential MAb binding due to variations in antigenic surface
structure. The instability of sorted phenotypic variants (Figure 69)
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suggests that the basis of any difference between subpopulations is not
due to a stable genetic alteration. The phenomenon of antigenic phase
variation was demonstrated for strains of H. influenzae, capable of
expressing antigenic changes in LPS by spontaneous loss or acquisition
of O-antigen specific MAb reactivity (Kimura & Hansen, 1986). Genetic
variation at a chromosome locus responsible for the expression of LPS-
associated epitopes was in part responsible for the observed variation
in H. influenzae LPS. Flow cytometric analysis also identified two
distinct phenotypic variants showing differences in reactivity with a
core-specific MAb (Evans et al, 1990). Increased identification of
antigenic variation among assumedly homogeneous bacterial populations
has important implications regarding the potential for bacteria to
evade LPS-specific host defence mechanisms.
The changes in LPS composition in response to magnesium depletion could
also be expected to influence the functioning of the cell envelope.
Magnesium concentration affected the capacity of the LPS molecule to
bind charged molecules such as lysozyme and gentamicin (Day & Marceau-
Day, 1982) which in turn may be reflected in other such physiological
changes as antibiotic resistance. In terms of the cell however,
increased LPS production appears to offset the decreased binding of
these molecules. Changes in the envelope structure and cation content
of magnesium depleted cells have been associated with increased
resistance to polymyxin and EDTA (Finch & Brown, 1975; Kenward et al,
1979). Polymyxin is bactericidal through its interaction with the
outer membrane, which results in disruption of that membrane with a
loss in permeability function (Teuber, 1974). Since polymyxin appears
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to compete with Mg and Ca for binding sites within the outer
membrane, changes in the LPS and phospholipid composition of the outer
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membrane reduce the number of binding sites and render the membrane
less permeable to polymyxin (Gilleland, 1988).
Detailed chemical analysis of LPS samples involving nuclear magnetic
resonance studies was restricted to LPS isolated from nutrient broth
and magnesium depleted conditions (data not presented). The structure
of the 018 0-antigen for both capsulate and non-capsulate strains
resembled that of other published data (Gupta et al, 1984; Jann & Jann,
1987). Magnesium depleted E. coli 018 LPS samples contained reduced 0-
antigen, whilst other complex data indicated that rhamnose, a constitu¬
ent of 018 0-antigen was replaced by an as yet unidentified sugar.
More detailed studies concerning the phenotypic heterogeneity of the
chemical composition of LPS structures is clearly needed, complementing
analysis of LPS expression as presented in this thesis.
The low availability of iron is acknowledged as a key determinant of
virulence (Griffiths, 1987). Initial investigations showed little
effect of iron depletion on LPS expression as determined by silver
staining and immunoblotting. However, increasing the degree of iron
deprivation using the iron chelator 2,2* dipyridyl, led to a greater
expression of rough core at the expense of high molecular mass 0-
polysaccharide LPS, possibly reflecting a regulatory effect of iron on
LPS biosynthetic enzymes. Alternatively, reduced growth rates under
these conditions may also have produced this effect. Growth rate per¬
se can have significant effects on the composition of the cell envelope
and LPS (Gilbert & Brown, 1978; Kenward & Brown, 1978). In a chemostat
culture at high dilution rate, E. coli 015:H7 cells produced more low
molecular mass LPS than high molecular mass LPS, compared to slow
growing or batch cultured cells (Dodds et al, 1987). Since variables
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other than nutrient limitation influence the expression of LPS, it is
acknowledged that in using the batch culture model, the significance of
altering one variable cannot be divorced with certainty from the
influence of others. Only chemostat continuous culture offers the
facility to examine the effects of a single environmental variable with
all other factors remaining constant.
Although changes in the expression of LPS have been illustrated, growth
under stress conditions such as iron and magnesium depletion are likely
to alter the structure and composition of other components of the outer
membrane. Thus, LPS core determinants normally showing limited
accessibility may become better exposed on the cell surface. Whilst
this study attempted to assess the binding of anti-LPS MAbs to whole
cells, release of membrane fragments from cells must also be cons¬
idered. Indeed, variations in growth conditions could alter the extent
and nature of the excretion of such fragments (Hoekstra et al, 1976).
Growth conditions showing changes in binding of anti-LPS MAbs to
assumedly whole cells in ELISA and flow cytometry were however
reproduced in immunogold electron microscopy studies, which demon¬
strated binding to whole bacterial thin sections.
An increased expression and accessibility of core LPS was shown for
smooth E. coli grown in heat-inactivated sheep serum. Immunoblotting,
ELISA and flow cytometry all showed significant increases in binding of
anti-core MAbs despite an apparent increased production of O-antigen as
revealed by silver staining. Growth under nutrient limiting conditions
of serum, including iron and magnesium depletion may have been
responsible for changes in the expression of LPS components and
exposing previously inaccessible epitopes. The presence of any natural
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anti-LPS antibodies within the serum may have also caused a false
impression of MAb binding. However, since MAbs were raised in a
different species to the serum used, antibody conjugate should
recognize only mouse MAbs, and removing any anti-LPS antibodies from
the serum by absorption had no effect on results. Frank et al (1987)
postulated that natural antibodies against O-antigen permitted access
of core-glycolipid antibodies. Absorption of serum antibodies with
either E. coli 018 or unrelated E. coli 06:K5 showed no difference in
anti-core MAb binding. Other investigators have proposed that
'enzymatic factors' present in serum are able to unmask the conserved
rough antigenic structures of smooth Gram-negative bacteria, making
these sites available for antibody binding (Chedid et al, 1968). It is
possible that core-reactive antibodies could bind bacteria after
partial disruption of the cells by other host defence mechanisms. For
example, the iron-binding proteins of lactoferrin and transferrin may
have additional antimicrobial effects. Recent work suggested that
these proteins can directly damage the outer membrane of Gram-negative
bacteria in a manner similar to the synthetic chelator EDTA (Ellison et
al, 1988; 1990). Furthermore, it is known that the physiochemical
configuration of LPS is considerably altered in the presence of serum
or plasma (Warren et al, 1991), perhaps promoting enhanced anti-core
MAb binding.
Greater expression of O-antigen from cells grown with serum at each
stage of the growth cycle compared to nutrient broth conditions (Figure
65), may reflect the selection of factors which increase resistance to
the bactericidal activity of serum (Taylor & Robinson, 1980; Goldman et
al, 1984; Porat et al, 1987). The bactericidal activity of complement
was highlighted when comparing the growth kinetics of E. coli 018:K1
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and its non-capsulate isogenic mutant 018:K1 in heat-inactivated sheep
serum and normal sheep serum. Both growth rate and final cell numbers
were reduced when E. coli 018:K1 in particular were grown in untreated
serum.
The progressively increased substitution of core LPS by 0-antigen
throughout the growth curve, underlined the importance of growth phase
on LPS expression in addition to other factors, including nutrient
growth conditions. These results were related to the finding that
whole cell binding of core-reactive antibodies were maximal during the
early log phase of bacterial growth, diminishing markedly thereafter
(McCallus & Norcross, 1987; Pollack et al, 1987). Thus, intermediate
or incomplete forms of the LPS molecule with relatively exposed core
determinants may be produced early in the normal bacterial growth
curve. McCallus & Norcross (1987) described how this phenomenon may be
used as a basis for speculation that active immunization, whereby the
antibody is present before the invading bacteria, may be more effective
than passive administration of specific antibodies at a time when the
bacteria are more mature. Growth of bacteria to the early stationary
phase under all nutrient conditions was an attempt to eliminate the
effects of isolating organisms from different growth phases on LPS
composition.
Although capsule plays an important role in the serum resistance of
many bacteria (Leying et al, 1990), it has been reported not to provide
a barrier function for binding of anti-0 antibodies to Klebsiella
species (Williams et al, 1988) and some E. coli including 0-serotype
018 (Cross et al, 1986). Indeed, binding of the anti-018 MAb to K1
capsulate and non-capsulate strains of E. coli 018 showed no effect due
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to the presence of capsule. However, greater binding of anti-core MAbs
to the non-capsulate strain indicates capsules may function as a
barrier for the penetration of anti-core LPS antibodies. The ability
of both O-antigen and core-reactive MAbs to bind capsulate and non-
capsulate strains of E. coli 018:K1 and 018:K5 were compared (data not
presented). Both K1 and K5 capsules again showed no barrier function
against O-antigen specific MAbs, whilst capsule presence appeared to
impede anti-core MAb binding. However, E. coli 018:K5 and its non-
capsulate isogenic mutant showed lower binding levels of both anti-core
and O-antigenic MAbs against equivalent capsulate and non-capsulate
strains of 018:K1. When LPS size distribution were assessed using
PAGE, capsulate and non-capsulate mutants of both 018:K1 and 018:K5
were identical. These findings suggest the behaviour of the same 0-
phenotype may alter depending upon its associated K types. Kim et al
(1986) demonstrated differences between the ability of K1 and K5
capsules in preventing anti-LPS antibody from mediating the killing of
E. coli bacteria. A neonatal rat model of infection showed that the
018:K5 capsule conferred resistance against an anti-LPS MAb by
preventing interaction with its target. In contrast, this same MAb
protected these animals from lethal infection with an E. coli 018:K1.
This data highlighted differences between the two capsules in their
ability to prevent anti-LPS antibodies from mediating the destruction
of the bacterium, possibly due to differences in their permeability to
opsonins or their distribution on the bacterial cell wall (Cross,
1990). Further work is required to determine the effect of growth
conditions on capsule expression, their influence on penetration of
antibodies to cell surface components, and subsequent opsonisation and
phagocytosis of capsulate bacteria.
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Growth under nitrogen deficient/high carbon conditions has previously
shown to promote capsule formation (Sutherland & Wilkinson, 1965).
Reduced binding of anti-core MAbs to both capsulate and non-capsulate
bacteria grown under these conditions suggested another factor, other
than capsule exerting an influence. Silver staining and immunoblotting
revealed an increase in the fraction of LPS species containing Ch¬
ant igen, and an increase in the length of the attached O-antigen
polymers. This suggested that the polymerization of O-antigen and its
transfer to core-glycolipid may increase relative to synthesis of core-
glycolipid in this nutritionally rich, high carbon medium. Since 0-
antigen is known to reduce accessibility of antibody to core LPS
(Welles & Niswander, 1984; Gigliotti & Shenep, 1985), a change in both
its production and possible arrangement may have strengthened this
effect.
The influence of growth in vivo on LPS composition and binding of LPS
reactive MAbs to whole cells was attempted in this study. Great
emphasis has been placed on the importance of studying the in vivo
characteristics of bacterial envelopes which will differ markedly in
physiology, biochemistry and immunogenicity from standard in vitro
conditions (Williams, 1988; Smith, 1990). Indeed, putative determi¬
nants of pathogenicity indicated by in vitro studies may not be
produced in vivo, whilst virulence determinants found in vivo may be
missed under certain in vitro conditions (Smith, 1990). Animal models
employing chamber implant devices have been used to mimic the in vivo
environment and permit the recovery of sufficient quantities of
bacteria for analysis. Permeable to humoral factors and antibiotics,
and having the advantage of localising the infection, they do however
prevent the access of host cellular defences (Williams, 1988).
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Although not precisely mimicking infection, the model can be used to
demonstrate bacterial cell properties while cells are growing on
available nutrients in vivo. The recent development of a novel
titanium chamber implant enjoys the advantages of a sampling portal
located subcutaneously; is reusable; easily constructed and avoids
inherent leakage problems of the traditional self-constructed plastic
chambers used in this thesis (Pike et al, 1991). The mucin-haematin
mouse septicaemia model was used to mimic a true infection, starting
with inocula in the range of those found in human septicaemia, and
characterized by in vivo multiplication of the bacteria.
The major difference noted for smooth E. coli strains grown in vivo
when compared with its in vitro grown counterpart related to the
increased length of the LPS O-antigen chain (Figures 72 and 75). The
heterogeneity of LPS chain length implies that the polysaccharide chain
formation is not tightly controlled, and thus readily modulated by
changes in the growth environment. Several possible environmental
effects on O-antigen chain formation by wild-type strains have been
identified, including carbon supply, growth rate and temperature
(McConnell & Wright, 1979; Taylor et al, 1981b). The susceptibility of
Gram-negative bacteria to phagocytosis and to the bactericidal action
of complement is thought, at least in part, to be determined by the
properties of the LPS-polysaccharide chain (Goldman & Leive, 1980;
Taylor, 1983). Therefore, the increase in chain length for in vivo
grown E. coli may enhance its ability to resist multiple host defence
systems. In vitro studies by Weiss et al (1986) demonstrated a close
correlation between changes in the LPS chain length induced under
different growth conditions and sensitivity to bactericidal/permea¬
bility-increasing protein. Changes in the LPS composition of N.
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gonorrhoeae and P. aeruginosa cells grown in vivo in chamber implants
have also been reported (Demarco de Hormaeche et al, 1988; Kelly et al,
1989). The latter study showed that compared with growth in vitro, in
vivo grown P. aeruginosa cells lacked a series of high molecular mass
O-antigen bands and gained a new series of lower molecular mass bands.
This phenotypic alteration in LPS composition had no effect on
bacterial serum resistance.
Analysis of the binding of LPS reactive MAbs to in vivo grown whole
cells was limited by high background signals, probably caused by
natural antibodies against cell surface components and binding of host
proteins to bacteria. However, ELISA inhibition studies indicated that
core epitopes, relatively inaccessible on in vitro nutrient broth grown
bacteria were more exposed on in vivo grown bacteria, despite a longer
polysaccharide chain length. These results lend support to the theory
that anti-core-glycolipid antibodies bind to intact organisms under
certain conditions. Further studies on the bacterial growth character¬
istics and phenotypic expression of LPS on bacteria grown in vivo are
however still required, to establish clearly the binding capacity of
core-glycolipid MAbs on intact bacteria.
The techniques of immunoblotting and silver staining were invaluable
for analysing the LPS composition of cells grown under different
nutrient conditions. However, concern exists regarding the accuracy of
using optical density of washed bacteria to quantify the amount of
loaded LPS. Absorbances (A^j) of between 0.5 and 0.6 have been shown
to produce no significant differences in staining intensity, suggesting
changes that do occur, result largely from alteration in LPS expression
(Dr D. Smith, pers. comm.). Inherent variability in the staining
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intensity of different silver stained gels, highlighted the need to
restrict comparison of LPS profiles to the same gel. The greater
resolution provided by gradient gels indicated what was previously
thought to represent a single unsubstituted LPS band may actually
represent several distinct bands (Figure 56). Alternatively these may
represent aggregates of LPS molecules.
The presence of small amounts of S-LPS on the E. coli rough mutant
018:Krf was revealed by immunoblotting with 018, 0-antigen specific MAb
184.2.5.5. This may be a result of partial reversion to the parent
strain or the presence of small amounts of S-LPS in native 018:Krf cell
walls. Failure of silver staining to detect this 'leakage* may reflect
the relative insensitivity of the technique in detecting small amounts
of 0-antigen LPS. Fomsgaard et al (1990) however, established that LPS
fractions containing a low number of fatty acids are washed out of the
gel during the initial fixation stage. Omitting this step and
increasing LPS oxidation time restored the ability to detect previously
unstained LPS fractions.
This study has underlined that changes in the growth environment can
lead to variation in LPS expression. Presumably the amount of LPS is
a dynamic variable controlled by the bacterium to maintain fixed
parameters such as surface charge. These and other outer membrane
alterations allow the cell to adjust to changes in its surroundings,
enhancing its survival in that particular environment. The diversity
of phenotypic responses to environmental conditions by individual
bacteria, suggests selective expression of a microbe's genome.
Implicit in this is the role of DNA supercoiling and its involvement in
the environmental regulation of gene expression, reviewed by Dorman
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(1991).
Variation in the expression of LPS and other outer membrane components
in response to altered growth conditions, has both important implica¬
tions and applications. In vitro and in vivo studies demonstrating
greater exposure and expression of specific LPS epitopes on the
bacterial cell surface may increase the potential of immunotherapeutic
MAbs targeted towards conserved regions of the LPS molecule. The
possibility of similar changes in LPS expression taking place during
cases of septicaemia must be viewed with caution but cannot be
excluded. LPS in vivo may exist, bound to the bacterium or host
components such as HDLP and endothelial surfaces, or be 'free' in
micelles, all of which can also reasonably affect the availability of
core structure to antibody. Efforts to stimulate the production of
MAbs or high titre antisera against conserved LPS epitopes, should also
consider the possibility of increasing antigenicity by controlling the
environment.
2.2 EFFECTS OF SUBINHIBITORY CONCENTRATIONS OF ANTIBIOTICS
In contrast to the considerable accumulation of information on the
effects of antibiotics on primary targets such as peptidoglycan,
protein synthesis or DNA supercoiling, it is only relatively recently
that attention has focused on the multiple secondary effects of
antibiotics on the cell, especially on its envelope. Such secondary
effects are of interest, particularly when sub-MICs of antibiotics,
which can appear in body fluids and tissues during the course of
chemotherapy, are involved. Growth in the presence of sub-MICs of
antibiotics has been shown to affect the synthesis of a variety of
virulence factors, many of which may help the host to eradicate
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bacteria (Shibl, 1983; Gemmell, 1987).
Several reports have shown that inhibition of peptidoglycan can
influence LPS synthesis. Taylor et al (1982) described a reduction in
the length of the O-antigen side chain of E. coli following growth in
the presence of sub-MICs of mecillinam and a concomitant increase in
sensitivity to serum complement. A similar loss of O-antigen was
reported by Overbeek et al (1987) when E. coli 0111 was grown in the
presence of sub-MICs of carumonam, exposing core-glycolipid. In
contrast, a stimulation of LPS incorporation into the outer membrane
has been demonstrated for certain p-lactam antibiotics (Essig et al,
1982). The major change in LPS expression shown in this thesis after
growth in sub-MICs of antibiotics was caused by chloramphenicol. A
relatively small reduction in the length of O-antigen side chain and/or
greater expression of lower molecular mass LPS bands was observed.
This effect appeared to be dependent on both the E. coli strain and
concentration of antibiotic. Sub-MICs of chloramphenicol may affect
the production of enzymes involved in the polymerization of the 0-side
chains. An increase in the length of the 0-side chains after treatment
with 1:2 sub-MIC of ciprofloxacin may reflect the antibiotic's mode of
action. Interference with the enzymatic activity of the DNA-gyrase may
affect the expression of pathogenic determinants, including LPS.
Alternatively, other factors including a reduction in growth rate in
the presence of ciprofloxacin may have also increased the chain length.
This study demonstrated that sub-MICs of various antibiotics signifi¬
cantly enhanced the binding of core-reactive murine MAbs to a number of
smooth E. coli strains. Failure to demonstrate any significant
differences in LPS or protein composition of the bacterial cell wall by
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PAGE for most antibiotics, indicates that major qualitative differences
in cell wall composition are not responsible for the increased anti-
core LPS MAb binding. However, alteration in LPS composition for some
chloramphenicol treated E. coli strains may have contributed towards
the increased exposure of core epitopes.
Certain antibiotics, present at subinhibitory levels, are known to
render capsulate strains of Gram-negative bacteria more susceptible to
opsonophagocytosis and to the bactericidal activity of human serum
(Taylor et al, 1982; Williams, 1987; Veringa et al, 1988; Raponi et al,
1990). The direct influence of antibiotics on the production of
capsules appears to be responsible for this effect, although at present
there appears to be no known common mechanism to explain the influence
of antibiotics on capsule formation. However, the synthesis of
peptidoglycan, LPS and exopolysaccharide is coordinately regulated with
cell growth and division, and certain sugar nucleotide precursors are
common to each pathway. The translocation of precursors through the
cytoplasmic membrane is also mediated via a common carrier, the
undecaprenyl phosphate lipid intermediate (Troy et al, 1971). Thus,
interference with peptidoglycan by certain antibiotics may indirectly
affect exopolysaccharide production by a feedback mechanism on the
lipid intermediate or by the accumulation of sugar nucleotides
(Kadurugamuwa et al, 1985a). Whitfield et al (1984) also demonstrated
that the initiation of K1 capsule appearance was dependent on protein
synthesis, and the addition of chloramphenicol before temperature
upshift prevented any expression of the K1 antigen. Chloramphenicol
appears to affect a protein in the translocation of the polysaccharide
across the cytoplasmic membrane (Kroncke et al, 1990b). Ciprofloxacin
has also been shown to inhibit K1 production in a dose-dependent
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manner, although the link between the antibody's primary mechanism of
action and secondary effects is unknown (Suerbaum et al, 1987).
Growth of a capsulated strain of K. pneumoniae in sub-MIC of anti¬
biotics reduced expression of capsule whilst increasing the exposure of
several outer membrane proteins (Kadurugamuwa 1985a & b). Considering
earlier studies demonstrating the role of capsule in masking inner
core-glycolipid epitopes of E. coli strains, it is feasible that a
similar loss of capsule after sub-MIC treatment may equally enhance
binding of core-reactive MAbs. Similar increases in binding of core-
reactive MAbs to antibiotic treated cells of capsulate E. coli 018:K1
and its non-capsulate isogenic mutant, indicate that any reduction in
capsule expression played only a minor role in increasing the exposure
of core epitopes. In contrast, observations by Overbeek et al (1989)
suggested that the retention of some capsule actually limited the
increased accessibility of deeper situated antigenic epitopes compared
to non-capsulate strains. This effect was dependent on the relative
thickness of the capsule. Variability among different E. coli strains
of the effect of antibiotics on the binding of anti-LPS MAbs observed
in this thesis, is perhaps a combination of factors, including type and
thickness of capsule, 0-serotype, and the ability of the antibiotic to
permeate the outer membrane. Similarly, the relative increase in MAb
binding between those directed towards either inner or outer core LPS
epitopes also varied amongst E. coli strains, again perhaps reflecting
differences in the ability of strains to mask specific epitopes after
antibiotic treatment. The importance of bacterial strain was also
highlighted by Taylor et al (1981a) who demonstrated variation in serum
susceptibility of E. coli treated with mecillinam.
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The ability of sub-MICs of various, unrelated antibiotics to increase
the exposure of relatively inaccessible epitopes is perhaps mainly
attributable to their modes of action. (3-lactam antibiotics such as
ampicillin directly affect the synthesis of the bacterial cell wall by
interfering with the cross-linking of the peptidoglycan backbone
(Atkinson & Amaral, 1982). Ciprofloxacin affects the DNA synthesis of
bacteria (Wolfson & Hooper, 1985) which may cause several different
metabolic and structural disorders. An enhanced binding of core-
reactive MAbs to bacteria, grown in the presence of either antibiotic,
could therefore be explained by a disturbed cell wall composition which
unmasks relatively inaccessible R-LPS determinants. Cell elongation
induced by both ampicillin and ciprofloxacin may also impair the
integrity of the cell wall, permitting greater accessibility of
antibody to cell surface antigens such as LPS. Sub-MICs of protein
synthesis inhibitors, including chloramphenicol and gentamicin could
feasibly impair synthesis of enzymes that are involved in cell wall
synthesis, exposing inner core structures and subsequent enhanced
binding of MAbs. Although traditionally gentamicin has been considered
an inhibitor of protein synthesis, Martin & Beveridge (1986) also
demonstrated an outer membrane destabilizing mechanism for gentamicin
to increase penetration of the antibiotic. Peterson et al (1985)
proposed that polycationic antibiotics such as gentamicin disrupt the
LPS-Mg cross bridges, rearranges its packaging, resulting in the
formation of 'cracks' in the membrane structure. However, observations
made in this study indicate that of those antibiotics used, gentamicin
had the least effect on anti-LPS MAb binding. Despite this, Artenstein
& Cross (1989) recently reported a direct endotoxin-neutralizing effect
of aminoglycosides. Considering that many of the sequelae of sepsis
may be related to endotoxin release after bacterial lysis, an agent
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that directly inhibits LPS may be a vital component of an antimicrobial
regimen.
Further evidence of greater accessibility of LPS epitopes following
antibiotic treatment was highlighted in an investigation using HA-1A,
a human IgM MAb recently licenced for therapeutic use against septic
shock (Bogard & Siegel, 1991). These authors demonstrated a dramatic
increase in the expression of its epitope on the lipid A domain of
endotoxin, after treatment of bacteria with cell wall active antib¬
iotics. In addition, the immunization of mice with ciprofloxacin-
treated bacteria has been shown to enhance protection against a
challenge with homologous and heterologous untreated bacteria, thought
to relate to a significant increase in anti-LPS antibody titres (Raponi
et al, 1991). These results indicated that host defences against Gram-
negative bacteria may be influenced not only by a direct effect of
antibiotics on the bacteria, but also an indirect effect of antibiotics
on host defences by enhancing production of antibodies against
untreated bacteria.
Data presented in this study lends additional support to the growing
body of evidence suggesting possible clinical applications of sub-MICs
of antibiotics. Possible synergism between antibodies and antibiotics
presents intriguing possibilities surrounding both the prevention and
treatment of septicaemia and septic shock in immunocompetent as well as
immunocompromised hosts, recently reviewed by Overbeek & Veringa
(1991). The potential of antibiotics to improve the exposure of
conserved LPS epitopes targeted by immunotherapeutic MAbs, by overcom¬
ing the masking effect of overlying O-antigen in particular is likely
to improve the clinical efficacy of such MAbs. The exposure of deeper
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antigenic determinants by sub-MICs of certain antibiotics has the
additional advantage of influencing host defences as previously
described, including the promotion of opsonization by serum complement
or antibodies, thus enhancing phagocytosis.
The in vivo relevance of this, and other studies concerning the effect
of sub-MICs of antibiotics needs to be clearly established. Most
investigations have been staged in vitro, quite different from the in
vivo environment where nutrient limitation and presentation of the LPS
molecule will also profoundly influence its susceptibility to both host
defences and therapeutic agents (see section 2.1). The in vitro
situation also allows growth of bacteria in a given concentration of
antibiotic, whilst the in vivo concentration will be determined by body
sites and a human's capacity to metabolize drugs. Limited in vivo
studies however, indicate a possible decrease in mortality from Gram-
negative septicaemia using combination therapy. Young et al (1989)
studying mice challenged with P. aeruginosa demonstrated protection
only when anti-lipid A MAbs were given in combination with certain
antibiotics. Similarly, protection of leukopenic rats from lethal
infection with P. aeruginosa was thought to be related to the synergis¬
tic action of suboptimal doses of ciprofloxacin and an anti-LPS MAb
(Collins et al, 1989). However, only through additional studies will
more insight be gained into the in vivo relevance of in vitro studies.
In conclusion, whilst much interest is focused on developing cross-
reactive LPS MAbs for treating and preventing Gram-negative septicaemia
and endotoxaemia, appreciation of the potential of additional therapy
with appropriate antimicrobials and dosages is clearly indicated.
Consideration must also be given to the standardization of
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antimicrobial treatment when testing the efficacy of immunotherapeutic
MAbs in clinical trials.
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CHAPTER 3
DEVELOPMENT OF A MONOCLONAL ANTIBODY IMMUNOASSAY
FOR THE DETECTION OF ESCHERICHIA COLI LIPOPOLYSACCHARIDE
The LAL assay is the classic method for detection of endotoxin in
biological fluids. Despite high sensitivity, the usefulness of the
Limulus method is, however, somewhat limited by non-specific activators
and inhibitors of LAL (Cohen & McConnell, 1984; Obayashi et al, 1986).
In addition, the LAL assay does not allow discrimination of different
types of endotoxin, making the assay vulnerable to trace amounts of
contamination involving endotoxins from other bacteria. Furthermore,
endotoxins from different bacterial species exhibit significant
differences in their relative abilities to activate LAL (Friberger et
al, 1987).
The purpose of this study was to develop and evaluate a MAb based
enzyme immunoassay for the detection of specific E. coli LPS core- and
O-types in the serum of septic patients. The ability to detect
specific endotoxins in body fluids would have numerous applications for
patients with endotoxaemia. Classically, LPS is responsible for shock
accompanying Gram-negative bacterial sepsis, although much debate
exists concerning the role of endotoxins originating from the gut in
addition to LPS from original infective organisms. The ability to
monitor septic patients for specific endotoxins would help establish
any relationship between detectable LPS and bacteraemic culture
isolate. Results would have obvious implications for the potential of
immunotherapeutic MAbs. The efficacy of MAbs targeted against the LPS
of commonly isolated bacteria such as E. coli, would be severely
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limited where LPS originates primarily from the gut. The specific
detection of endotoxin in patients may also facilitate the selection of
suitable therapeutic anti-LPS MAbs, possibly including cocktails of
antibodies with specificity for accessible core- and O-antigenic
epitopes.
There has been increasing interest in the development of assays capable
of detecting specific LPSs. LPS is specific, highly immunogenic and
easily released into the surrounding medium (Cadieux et al, 1983;
Kusama, 1983) and therefore considered an appropriate antigen for the
detection of certain Gram-negative bacteria. Enzyme immunoassays have
been developed for the detection of LPS or related LOS from a variety
of microorganisms including: P. aeruginosa for the early identification
of respiratory colonization by the organism (Nelson, 1990); H.
influenzae for the diagnosis of meningitis caused by this organism
(Mertsola et al, 1989; 1990); Brucella abortus for the diagnosis of
brucellosis (Perera et al, 1983; Limet et al, 1988) and Salmonella
species for the diagnosis of Salmonella infection (Araj & Das Chugh,
1987; Lim, 1990 & Luk & Lindberg, 1991).
The use of MAbs in ELISA overcomes the problems encountered by using a
polyclonal antibody. MAbs can be supplied in almost unlimited amounts
once the hybridoma cell line is established; problems arising from
batch variations are avoided when MAbs are used; MAbs generally show
higher specificity since each molecule of antibody is directed at the
antigen in question, and high concentrations of specific antibody can
be obtained (Yolken, 1982; Harlow & Lane, 1988).
There are a number of ways in which enzyme immunoassay systems can be
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formulated to measure infectious agents directly in body fluids
(Yolken, 1982). In this particular study MAb based double antibody
sandwich ELISA systems were developed for the detection of E. coli LPS
core types R1-R4, specific E. coli LPS core types of either R1 or R3
and the E. coli 018 0-antigen in dilution buffer and in spiked serum.
Bio-MAbs were used in the assays developed. Biotin labelling of
antibodies is a simple mild reaction, allowing antibodies to retain
full biological activity and giving high labelling efficiency. The
stable monomeric conjugates also enjoy a number of advantages for use
in enzyme immunoassays. A very high affinity between biotin and avidin
provides stable complexes and has the potential for amplification at
the level of co-factor enzyme interaction (Guesdon et al, 1979).
Biotin/MAb ratios of 1:1, 2:1 and 4:1 all yielded usable reagents and
corresponds to other reports (Kendall et al, 1983; Yolken et al, 1983).
Since one molecule of streptavidin can efficiently bind four molecules
of biotin, multiple avidin-biotin interactions can be achieved,
offering the possibility of increased sensitivity (Yolken, 1982). In
this study the most efficient immunoassay system was one employing
streptavidin labelled alkaline phosphatase to bind to the bio-MAbs.
The use of streptavidin-biotin-alkaline phosphatase complexes is
theoretically more sensitive, since it employs a second amplification
step where each 'bridging* streptavidin molecule can bind three
biotinylated alkaline phosphatase molecules. However, in this study,
whilst showing slightly higher sensitivity, background signals were
unacceptably high. Although biotin-streptavidin reagents are non-
sticky in nature (Kendall et al, 1983) it is possible that bad
backgrounds may reflect the sticky nature of certain MAbs or the
presence of any free biotin.
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The competition assays revealed complex, yet useful information
concerning the relative binding sites of MAbs considered for detection
studies. Although no two antibodies appeared to recognize the same or
overlapping epitopes, results gave an indication of the proximity of
MAb binding sites. Those MAbs showing the closest binding sites
included antibodies 27.150.3, A3.11.5.1 and AO.18.7.1, all previously
shown to be Rc reactive. The double MAb sandwich ELISAs developed,
employed the most suitable MAb combinations for the detection of
specific endotoxins.
The 0-antigen polysaccharide chains, formed by the polymerization of
repeating units, will perhaps represent the most suitable LPS component
detectable in such an assay because of the availability and accessibil¬
ity of multiple epitopes. Indeed, this was reflected in both the good
sensitivity (0.01 ng m 1 purified E. coli 018 LPS) and ability to use
the same MAb (30.A.2.8) as both the primary capture antibody and the
secondary detector probe. The ability of MAb 30.A.2.8 to detect other
non-018 LPSs at high concentrations only, reflects the antibody's low
affinity for other LPS components as described earlier. Those assays
developed for the detection of E. coli core LPS proved more sensitive
for purified R-LPS than equivalent S-LPS. These results perhaps
reflect both the accessibility of relevant epitopes and the binding of
most MAbs to unsubstituted R-LPS only. The two most cross-reactive
MAbs, 27.150.3 and A3.11.5.1 were capable of detecting E. coli core
types Rl-RA at between 0.1 and 10 ng ml 1 purified LPS. Poor sensitiv¬
ity for R3 appears to relate to the weak affinity of MAb A3.11.5.1 for
this core type. The detection of individual E. coli core types was
afforded by MAbs reacting almost exclusively (A3.3.A.8) or preferen¬
tially (27.193.3) against R1 and R3 core types respectively.
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In addition to developing double MAb sandwich ELISAs, those based on
the use of polymyxin B-MAb combinations were also attempted. Micro-
titre plates were coated with polymyxin B, a polypeptide antibiotic
with strong affinity for lipid A (Morrison & Jacobs, 1976). E. coli
LPS bound to polymyxin was detected by single labelled MAbs. Although
the sensitivity was generally comparable to most sandwich ELISAs,
preliminary results gave poor reproducibility and high backgrounds,
thought to reflect non-specific binding of MAbs to the polymyxin.
Offering the advantages of theoretically capturing all LPS molecules
retaining the lipid A domain, and requiring only a single labelled
antibody for the detection of specific LPS, the technique may warrant
future consideration. Indeed, it has been applied successfully for the
detection of H. influenzae LOS (Mertsola et al, 1989; 1990). The
development of alternative immunoassay may also be of benefit. Limet
et al (1988) reported an assay based on latex agglutination for the
detection of B. abortus LPS; Luk & Lindberg (1991) employed an
immunomagnetic technique to detect specific Salmonella 0-antigen LPSs,
and Gagliardi et al (1986) developed a biotin-avidin amplified
inhibition assay for the detection of lipid A.
The double MAb sandwich ELISAs developed in this study detected a
minimum concentration of 0.01 ng ml * purified LPS in solution, although
were less sensitive against certain purified LPS samples. The clinical
usefulness of endotoxin assays such as these will depend on their
ability to detect the relatively low concentrations of endotoxin in
blood of between 0.005 and 0.1 ng ml *, indicative of endotoxaemia
(Fomsgaard, 1990; Bottoms et al, 1991). However, there are many
problems associated with the quantification of LPS in blood because
endotoxin or lipid A binds to several substances present in plasma or
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serum: natural antibodies (Gagliardi et al, 1986), high and low density
lipoproteins, complement, serum albumin and acute phase and some other
proteins (Ulevitch & Tobias, 1988). Preliminary experiments involving
measurement of serum spiked with purified LPS showed that serum
definitely has a significant effect on the ability of the assay to
detect E. coli LPS. Similar findings have been reported by Gagliardi
et al (1986) and Mertsola et al (1989).
The detection of LPS in blood serum has been demonstrated following
various methods of deproteinization which, in this study, were largely
unsuccessful in producing the required sensitivity. The isolation of
LPS from serum using a phenol extraction method appeared to offer
greater promise than other methods attempted. Preliminary results
however, were not reproducible and methods other than overnight
dialysis to remove phenol, such as desalting columns, need to be
considered for future studies. Further investigations will also need
to assess the ability of assay systems employing antibodies to detect
LPS in vivo. Sensitivity will again be influenced by the physio-
chemical presentation of LPS, which will affect both availability and
accessibility of specific epitopes. Bacterial death and subsequent
cell lysis may result in liberation of outer membrane fragments of
different sizes, as well as free LPS molecules or their aggregates
(Munford et al, 1984). The presentation of host LPS as monovalent
fragments for example, would render a double sandwich MAb assay
useless. Speculation also exists about the most suitable test material
for the detection of LPS in blood. LPS adheres to cellular as well as
humoral components in blood, therefore cell-bound endotoxin will be
missed when serum or plasma is chosen as a sample (Tamura et al, 1991).
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The clinical utility of the immunoassays described herein is clearly
dependent on further studies which improve assay sensitivity in whole
blood or serum/plasma. However, these detection systems are poten¬
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A comparison of immunoblotting, flow cytometry and ELISA
to monitor the binding of anti-lipopolysaccharide
monoclonal antibodies
D. Nelson, W. Neill and I.R. Poxton
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This study was designed to assess the use of flow cytometry to observe the binding, under physiological
conditions, of anti-lipopolysaccharide (LPS) monoclonal antibodies (mAbs) to whole bacteria, and to
compare this with the more conventional whole cell ELISA and immunoblotting techniques. The bacteria
consisted of two clinical isolates of E. coli 018:K1 and 06:K5 and two isogenic mutants of the 018 parent:
a non-capsulate (018:K~) and a rough mutant (018rf). Two cross-reactive anti-core mAbs and one 018
0-antigen-specific mAb were used. ELISA and flow cytometry showed that capsule and O-polysaccharide
influenced the binding of mAbs to the bacteria, whilst the latter technique demonstrated that sub-popula¬
tions existed. Immunoblotting showed the two anti-core mAbs to be different, one bound only to core
which was not substituted with O-antigen, whilst the other bound both to substituted and unsubstituted
core. This comparison for monitoring the binding of anti-LPS mAbs demonstrates the potential use of
flow cytometry in bacterial cell surface research, and complements results obtained by ELISA and
immunoblotting.
Key words: Flow cytometry; ELISA; Immunoblotting; Lipopolysaccharide; E. coli; Monoclonal antibody
Introduction
Lipolysaccharide (LPS) or endotoxin is a major
constituent of the outer membrane of all Gram-
negative bacteria and is known to be responsible
for the range of pathophysiological features of
endotoxic shock. In general, LPS consists of three
regions: the outer O-polysaccharide - the com¬
position of which varies with the serotype of the
organism, the core oligosaccharide - which is less
variable, especially in the inner part, and the inner
Correspondence to: I.R. Poxton, Bacteriology Department,
University of Edinburgh Medical School, Teviot Place, Edin¬
burgh EH8 9AG, U.K.
lipid A - a highly conserved structure, responsible
for the toxicity and many of the biological activi¬
ties of LPS (Rietschel et al., 1984).
Limitations of existing therapeutic agents for
endotoxic shock have led to active investigation of
protective antibodies. It is thought that antibodies
directed against the conserved elements of the
core oligosaccharide and lipid A region of LPS
may be cross-reactive and possess anti-endotoxic
properties (Chedid et al., 1968). An area of great
debate is whether antibodies can bind to these
inner regions of LPS in its natural states either on
the bacterial cell surface or bound to serum com¬
ponents in the circulation (Pollack et al., 1989).
Flow cytometry has been used extensively to
analyse eukaryotic cell populations (Melamed et
0022-1759/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)
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al., 1979; Muirhead et al., 1985), although its
application to bacteria has remained limited. This
study was undertaken to assess the use of flow
cytometry for monitoring the binding of different
anti-LPS monoclonal antibodies (mAbs) to whole
bacteria, and to compare this with the more con¬
ventional techniques of enzyme-linked immuno¬
sorbent assay (ELISA) and immunoblotting.
Materials and methods
Bacteria and culture conditions
Four strains of Escherichia coli were kindly
supplied by Dr. A.S. Cross, Walter Reed Institute
for Army Research, Washington, DC, U.S.A. They
consisted of two clinical isolates (018:K1 and
06:K5 serotypes) together with two isogenic
mutants from the 018 parents: a non-capsulate
mutant (018:K~) and a rough mutant (018rf).
Cultures were grown in 100 ml filter-sterilised
nutrient broth (Gibco) in 250 ml conical flasks at
37 °C for 16 h in an orbital incubator. Cells were
harvested and washed twice in phosphate-buffered
saline, pH 7.4 (PBS). Total counts were made in a
haemocytometer (Thoma ruling).
Monoclonal antibodies
Monoclonal antibodies (mAbs) were prepared
by fusing spleen cells from immune BALB/c mice
with NSO myeloma cells by standard techniques
(Kipps and Hertzenberg, 1986). The reactivity of
the mAbs was determined by an LPS-polymyxin
ELISA method as described by Scott and Barclay
(1987). The 018-specific mAb was screened by its
binding to 018 LPS, while a cocktail of four rough
LPS was used as a primary screen for the anti-core
mAbs, followed by a broad secondary screen of
both rough and smooth LPS. Full details of the
immunisation of mice, selection of hybridomas
and characterisation of the mAbs are to be pub¬
lished elsewhere. Three mAbs with known
specificities in LPS-polymyxin ELISA were
selected for this study: mAb 0-1 (specific for 018
O-antigen), and mAbs C-l and C-2 (both cross-
reactive with core epitopes). Supernatant fluids of
hybridoma cell cultures grown in RPMI 1640 sup¬
plemented with 5% foetal calf serum in 150 cm2
flasks were used throughout. Cell cultures were
grown to maximum cell density and harvested at
50% cell viability. These three hybridomas gave
yields of approximately 50 jag/ml.
Preparation of LPS
LPS was prepared from whole washed bacteria
by the Proteinase K method of Hitchcock and
Brown (1983). The method is described in detail
by Hancock and Poxton (1988). Briefly, bacteria
grown overnight were washed twice in PBS and
adjusted to an A525 between 0.5 and 0.6. After
centrifugation, the pellet from 1.5 ml of the
bacterial suspension was suspended in 50 ^tl of
sample buffer (2% SDS, 4% 2-mercaptoethanol,
10% glycerol, 0.002% bromophenol blue in 1 M
Tris-HCl pH 6.8) and heated for 10 min at 100 °C.
Proteinase K (25 jag in 10 jal sample buffer: pro¬
tease Type XI, Sigma) was added, and the mixture
incubated at 60 °C for 60 min.
SDS-PAGE
SDS-PAGE was performed on 14% acrylamide
slab gels with the Laemmli buffer system (Laem-
mli, 1970). Samples (10 jal for silver stain, or 20 p\
for immunoblotting) of the proteinase K LPS ex¬
tracts were loaded on to the gels. The LPS separat¬
ing gels were stained with silver by a method
developed by Tsai and Frasch (1982), modified by
Hancock and Poxton (1988). Briefly, gels were
fixed overnight in 200 ml of 25% propan-2-ol, 7%
acetic acid followed by oxidation in freshly pre¬
pared periodic acid. After frequent washing over 4
h in distilled water, fresh ammoniacal silver nitrate
solution (1.4 ml of ammonia solution, 21 ml of
0.36% NaOH, 4 ml of 19.4% AgNO, and distilled
water to 100 ml) was added for 15 min. Following
at least four washes in distilled water over 40 min,
gels were transferred to fresh 0.005% citric acid in
200 ml of 0.019% formaldehyde at 25 °C. On
development gels were washed repeatedly in dis¬
tilled water.
Immunoblot analysis
This was based on the method of Towbin et al.
(1979) as described by Hancock and Poxton (1988)
with Bio-Rad buffers and substrate. Electro-
phoretic transfer of LPS to nitrocellulose sheets of
a 0.2 jam pore size (Schleicher and Schuell) was
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performed at 12 V in electroblotting apparatus for
16 h at 4°C. After transfer, the nitrocellulose
membrane was washed in Tris-buffered saline
(TBS) for 10 min and blocked with 3% gelatin to
prevent non-specific binding of antibodies. A 1 in
10 dilution of culture supernatant fluids (shown
previously to give optimum staining) was added
for 3 h, followed by two 10 min washes in Tween
Tris-buffered saline (TTBS). After a 60 min treat¬
ment with an anti-mouse IgG/M/A -horseradish
peroxidase conjugate (Zymed), diluted 1 in 500,
membranes were washed in TTBS as before.
Freshly prepared HRP colour development re¬
agent was added and left for 30 min before wash¬
ing in distilled water.
Flow cytometry
Washed, overnight cultures of E. coli were re-
suspended to an A525 of between 0.5 and 0.6,
equivalent to approximately 1 X 108 cfu/ml. Sus¬
pensions (1 ml) were centrifuged at 10,000 X g in
a Microfuge (Beckman) for 2 min and the pellets
resuspended in 1 ml of mAb culture supernate,
diluted 1 in 10 in dilution buffer (see ELISA
methodology), and incubated for 60 min at 37 ° C.
Samples were washed twice in PBS followed by
addition of 0.5 ml, sheep FITC-conjugated anti-
mouse IgG (ICN) diluted 1 in 100 in dilution
buffer. After a further incubation of 60 min at
37 °C, samples were washed twice in PBS and
resuspended in 1 ml PBS containing 0.5% for¬
maldehyde. Prepared samples, diluted 1 in 50 in
PBS, were analysed in an EPICS 'C' (Coulter
Electronics) flow cytometer equipped with a 5 W
argon ion laser operating at 500 MW output and
exciting at 488 nm. Cells were passed through the
beam at approximately 500/s from a standard 76
jam flow cell tip. With the use of gates on the log
forward angle light scatter (LFLS) signal, both
background noise and clumps of cells were ex¬
cluded from the analysis. Cells stained with FITC
conjugate but no primary antibody provided a
background staining level which was set at 1% +
0.5% by adjusting the voltage applied to the green
fluorescence log (GFL) photomultiplier tube. A
total of 50,000 cells were analysed from each
sample and the percentage of cells exhibiting
positive staining on GFL was calculated by the
EPICS 'Stat Pack' programme.
ELISA
Whole cell ELISA was based on the method of
Scott (1988). ELISA strips (Immuno module Poly-
sorp F8, Nunc) were coated with washed bacteria
(100 /xl/well) from a 16 h culture diluted with
coating buffer (0.05 M carbonate/bicarbonate pH
9.6 containing 0.02% sodium azide) to a con¬
centration of 2 X 107 cells/ml. Coating was pro¬
moted by centrifugation at 630 X g for 4 min and
leaving overnight at room temperature. Plates were
washed four times with PBS pH 7.2, containing
Tween 20 (0.05% v/v) and sodium azide (0.02%
w/v) and were then post-coated with bovine serum
albumin (5% w/v BSA) and sodium azide (0.02%
w/v) in PBS at 100 fi1/well followed by overnight
incubation at room temperature. After washing
12 3 4
Fig. 1. Silver-stained PAGE of proteinase K digests of E. coli
grown in filter-sterilised nutrient broth at 37 °C for 16 h in an
orbital incubator. Track 1, 018:K1; 2, 018:K~; 3, 018rf; and
4, 06:K5.
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four times, plates were rinsed in distilled water
and stored at — 20 ° C until used.
Dilutions of mAb supernatant fluids and con¬
jugate were made in dilution buffer consisting of
PBS, with Tween 20 (0.05% v/v), BSA (0.5% w/v),
polyethylene-glycol 6000 (4% w/v) and sodium
azide (0.02%). Antibody dilutions were added to
coated plates at 100 jal/well in triplicate and
plates incubated at 37 ° C for 90 min before wash¬
ing four times. Urease-conjugated sheep anti-
mouse Ig (Seralab) was diluted 1 in 500, added at
100 /xl/well and plates incubated for a further 90
min at 37 °C. Plates were washed four times and
rinsed with distilled water before addition of
urease substrate (Seralab) at 100 /xl/well. Plates
were incubated at room temperature and reactions
stopped by addition of thimerosal (1%) in distilled
water (20 /il/well). Absorbances (A) were read at
590 nm in a Titertek Multiscan.
Results
Silver stain
The silver-stained SDS-PAGE profiles of LPS
from the four E. coli strains are shown in Fig. 1.
The LPS from the three smooth strains showed
the characteristic ladder pattern, with each band
differing in Mr by one repeating unit of O-anti-
gen. The rough LPS lacked any of the high molec¬
ular mass bands which corresponded to LPS sub¬
stituted with O-polysaccharide chains.
Immunoblots on LPS
Fig. 2. shows the reaction of the anti-LPS anti¬
bodies with the four LPS preparations in im¬
munoblots. The 018, O-antigen-specific antibody
(mAb 0-1), bound strongly to the high Mr bands
of both the smooth 018 strains but not to the 06
LPS (Fig. 2a). It also revealed a small amount of
high molecular mass O-antigen leaking from the
rough mutant of 018. Of the two anti-core mAbs,
mAb C-l bound only to the fast migrating species
that corresponded to the core glycolipid demon¬
strated on silver-stained gels (Fig. 2b). Staining
was strongest for the rough E. coli LPS and
weakest for the E. coli 06. The reactivity of mAb
C-2 again was to the fast migrating core region,
but there was also binding to the high Mr, O-anti-
gen bearing molecular species of the smooth strains
(Fig. 2c).
Fig. 2. Immunoblots of proteinase K extracts of E. coli strains arranged as in Fig. 1, probed with an anti-018-specific mAb, 0-1 (a),
and two cross-reactive, core-specific mAbs, C-l (6) and C-2 (c).
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Flow cytometry on whole bacteria
Fig. 3. shows the binding of anti-LPS mAbs to
whole cells by flow cytometry. The reactivity of
the 018-specific mAb, mAb 0-1 is shown in Fig.
3a. The percentage of bacteria exhibiting positive
fluorescence above background levels was in ex¬
cess of 70% for the two smooth 018 strains, whilst
the E. coli 06 cells showed negligible binding. The
non-capsulate 018 strain showed two distinct
populations of cells, indicative of differences in
amount of antibody bound. The presence of small
amounts of O-antigen on the rough mutant is
again evident. The three smooth strains bound
anti-core mAb C-l and mAb C-2 antibodies at
less than 10% above background levels (Figs. 3b
and 3c). However, binding of mAb C-l to 018:K~
was almost double that of 018:K1. Percentage
binding to the rough mutant by mAb C-l was 84%
compared to a much lower figure of 14% for mAb
C-2.
ELISA on whole bacteria
The binding activities of the three mAbs to
whole cells in a urease ELISA system are shown in
Fig. 4. Reactivity of the 018-specific mAb 0-1
mirrored results of immunoblotting and flow cy-
Fluorescence intensity channel number X 10
Fig. 3. Flow cytometry. Green fluorescence intensity histograms of culture supernates of three mAbs against whole cells of four E.
coli strains, (018:K1; 018:K~; 018rf and 06:K5). a, b and c represent binding of the anti-018-specific mAb 0-1, and two
cross-reactive, core-specific mAbs, C-l and C-2 respectively. Percentage values represent bacteria exhibiting positive fluorescence
above background levels (indicated by vertical dotted line).
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Fig. 4. Binding activities of culture supernates of three mAbs
against whole cells of four E. coli strains in EL1SA: 018:K1;
018: K~; 018rf and 06:K5. a, b and c represent binding of the
anti-018-specific 0-1, and two cross-reactive, core-specific mAbs
C-1 and C-2, respectively.
tometry. Smooth 018 strains had the highest A590
readings, whilst binding to the rough mutant re¬
flected the presence of some leaking O-antigen.
The binding of the mAb at high concentrations
was much stronger to the non-capsulate strain
than to the capsulate parent. The three smooth E.
coli strains all showed lower A 590 values compared
to the rough E. coli when probed with dilutions of
the two anti-core mAbs, C-1 and C-2. Again, the
018 non-capsulate strain showed stronger affinity
for the anti-core mAbs compared to its capsulate
parent.
Discussion
The individual techniques used in this study
provide a means of assessing the binding specific¬
ity of anti-LPS mAbs. In combination, a much
more comprehensive picture can be built up of the
accessibility of endotoxin sites to antibody. Im-
munoblot patterns of proteinase K LPS extracts
against mAbs provide general information regard¬
ing their specificity. Indeed, the different reactiv¬
ity patterns of the two anti-core antibodies was
only apparent by immunoblotting. The ladder pat¬
tern or single core band effect reflected the bind¬
ing of C-2 to substituted and unsubstituted core,
and C-1 to unsubstituted core material only. It
should be noted that the binding of mAbs to
blotted LPS does not suffer from the loss or
denaturation of epitopes in the same way as pro¬
teins.
Results obtained by flow cytometry and ELISA
on whole bacteria showed that the absence of
O-polysaccharide side chains on the rough mutant
appeared to increase the accessibility of core LPS
to antibodies, resulting in better binding than to
smooth strains. This shielding effect by O-anti-
genic chains of LPS was also demonstrated by
Gigliotti and Shenep (1985). A comparison of the
ability of 018:K1 and 018:KA to bind antibody
suggests that capsule may have a role in masking
LPS binding sites. Flow cytometry, however, also
reveals further information about antibody bind¬
ing to LPS not detected in ELISA. Within a
population of cells showing positive fluorescence
an indication of the affinity of an antibody for its
antigen can be obtained. The presence of two
distinct populations of E. coli 018:K" cells when
probed with 0-1 indicates possible differences in
structure or amount of LPS.
Flow cytometry offers a means of investigating
surface properties of individual cells in large num¬
bers with great speed and efficiency. The tech¬
nique also has the added advantage of analysing
cells in their natural form, devoid of potential
distorting influences present in other methods.
However, despite the unequivocal potential of flow
cytometric analysis of bacteria, it remains an un¬
der-used tool, still in its infancy. Phillips and
Martin (1988) used flow cytometry for the specific
detection of bacteria in aqueous samples. Their
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work established problems with background noise
as a result of stray light scatter in the optical
system, or possibly signals from sub-micron par¬
ticles in sheath fluids and PBS which had not been
removed by filtration. Selective gating near the
origin of the cytogram was not feasible in Philips
and Martin's study, although it was used in our
study to eliminate background noise.
ELISA is an established method for the detec¬
tion of antibodies to bacteria, offering advantages
of speed, flexibility and quantitative accuracy. The
apparent higher binding of anti-LPS mAbs to
smooth cells in ELISA than to flow cytometry
may reflect the better sensitivity of the whole cell
ELISA. However, in contrast to flow cytometry,
recent data (not shown) suggested that in some
instances the expression of coated whole cells on
ELISA plates differs from whole cells in suspen¬
sion, probably due to their alteration during bind¬
ing manipulations. Our results suggest that ELISA
has tended to over-emphasise the binding of anti-
core mAbs to whole cells. Indeed, Aydintug et al.
(1989) established that both the physical state of
bacteria and type of assay used affect the cross-re-
activity of an antibody.
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Monoclonal antibodies as probes for detecting lipopolysaccharide
expression on Escherichia coli from different growth conditions
David Nelson, Andrew J. Bathgate and Ian R. Poxton*
Department of Medical Microbiology, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 9AG, UK
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Monoclonal antibody (mAb) probes were used to investigate the expression of lipopolysaccharide (LPS) on four
Escherichia coli strains, grown under a variety of conditions in batch culture which mimicked some of the in vivo
environmental conditions of an infected host. Techniques of silver staining, immunoblotting, whole cell ELISA and
flow cytometry were all used to monitor the expression of LPS on the bacteria and the binding of the anti-LPS
mAbs. Growth in heat-inactivated sheep serum and magnesium-depleted conditions demonstrated increased
expression of LPS core and subsequent increased binding of anti-core mAbs. Magnesium-depleted conditions also
resulted in decreased production ofO-polysaccharide material. Iron-depleted bacteria showed only minor changes
in LPS expression, although increased binding of anti-core mAbs was observed. Nitrogen-deficient/high-carbon
conditions, chosen to promote capsule production, resulted in increased expression of O-polysaccharide and
decreased binding of anti-core mAbs.
Introduction
The potential of antibody therapy for the prevention and
treatment of Gram-negative sepsis and endotoxaemia
with anti-lipopolysaccharide (LPS) antibodies has been
intensively investigated recently (Dunn et al., 1986)."?
Much attention has been focussed on the production and
characterization of monoclonal antibodies (mAbs) to
common epitopes of endotoxin in the LPS core. There
are many reports in the literature of the development of
such mAbs (Ziegler et al., 1991; de Jongh-Leuvenink,
1990; Mayoral & Dunn, 1990; Pollack et al., 1989). The
therapeutic potential of anti-LPS mAbs is, however,
open to much debate (Heumann et al., 1991; Aydintug et
al., 1989; Chia et al., 1989). Concern exists as to whether
it is possible for these antibodies to bind to sites deep
within the LPS molecule, either when the LPS is bound
to the bacterium or to host components such as high
density lipoprotein and endothelial surfaces, or 'free' in
micelles. A further complication exists by which the
heterogeneity of O-polysaccharide chain length and
degree of substitution of the LPS core may affect
antibody accessibility (Gigliotti & Shenep, 1985).
We have shown recently that it is possible, with a
combination of ELISA and flow cytometry, to use
is) monoelon-a-I-aftt-ibod+e^ to detect LPS expression on
whole bacteria (Nelson et al., 1990). Results showed,
however, that although anti-O-polysaccharide mAbs
could readily be observed binding to bacteria by both
techniques, anti-core mAbs could be shown to bind
significantly only by the sensitive ELISA and not by flow
cytometry.
It is now well recognized that the growth environment
of bacteria greatly influences the phenotypic expression
of surface characters (Smith et al., 1991; McGroarty &
Rivera, 1990; Kelly et al., 1989; Morse et al., 1983). This
study attempts to investigate with mAb probes the
expression of LPS on bacteria cultured in conditions
which mimic those in vivo.
Methods
Bacteria. Four strains of Escherichia coli were kindly supplied by Dr
A. S. Cross, Walter Reed Institute for Army Research, Washington,
DC, USA. They consisted of two clinical isolates (018: K 1 and 06 :K5
serotypes) together with two isogenic mutants from the OlS parent: a
non-capsulate mutant (018:K~) and a rough mutant (Olj^rf).
Culture conditions. The following growth media were' used, (a)
Nutrient broth (Gibco), filter-sterilized. (b) Magnesium-depleted
medium. This was prepared as a modification of the Malka minimal
medium of Robert-Gero et al. (1970) as follows: solution A, Na,HP04
(73-4 mg ml-'), KH;P04 (32-4 mg ml"1); solution B, MgS04.7H,0
(20-5 mg ml-1); solution C, 20% (w/v) glucose; solution D, Fe-
S04. 7H.0 (1-83 mg ml-1) in sterile distilled water to which one drop of
concentrated hydrochloric acid was added; solution E (NH4),S04
(50 0 mg ml"'). All chemicals were from BDH. Solutions were
prepared with sterile distilled water and were filter sterilized. All
0001-6972 © 1991 SGM
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solutions except C were stored over chloroform. To prepare 1 litre of
Malka. 20 ml A, 20 ml B. 20 ml C, 1 ml D and 20 ml E were added to
919 ml of sterile distilled water. Magnesium-depleted medium contain¬
ing 0-17 mmol 1"' was prepared by the addition of only a 1% vol.
(0-2 ml) of solution B as used for the standard minimal medium. (c)
Nitrogen-deficient,high-carbon medium. This was prepared following
the method of Sutherland & Wilkinson (1965) and contained: 1 gyeast
extract (Oxoid); 1 g Casamino acids (Difco technical grade); 10 g
Na-HPCU; 3 g KH;P04; 0-2 g MgSOj.7H.O; 11 g K,SOj; 1 g NaCl;
\^0-01 g CaCl-CH-Tp; and 0 01 g FeSO_f/7H TY The volume was made
up to 1000 ml with sterile distilled waterYtrthSutoclaved. To this, 20%
(w/v) filter-sterilized glucose was added to give a final concentration of
2% (w/v) glucose, (d) Iron-depleted medium. This was prepared by the
addition of 150pmol 2,2'-dipyrtdyl 1"' to Gibco nutrient broth, (e)
Heat-inactivated sheep serum (obtained from the Moredun Research
Institute. Edinburgh. UK): the serum was filter-sterilized (0-45 pm
pore size) and heat-inactivated at 56 °C for 60 min and stored at
-20 'C.
Exponential phase starter cultures were prepared by growth in
nutrient broth at 37 'C for 4 h before harvesting and washing twice in
phosphate-buffered saline (PBS: 015 M-NaCl, 50 rnM-potassium phos¬
phate buffer), pH 7-4. A 1 % inoculum was added to each growth
medium. Cultures were grown at 37 °C in 100 ml of each medium to
early stationary phase in an orbital incubator prior to harvesting and
washing as above.
Monoclonal antibodies. mAbs were prepared by fusing spleen cells
from immune BALB/c mice with NS-O myeloma cells by standard
techniques (Kipps & Hertzenberg, 1986). The reactivity of the mAbs
was determined by the LPS-polymyxin ELISA method of Scott &
Barclay (1987) as described by Nelson el at. (1990). Full details of the
immunization ofmice, selection of hybridomas and characterization of
mAbs are to be published elsewhere. Three mAbs with known
specificities in LPS-polymyxin ELISA were selected for this study:
mAb O-1, specific for 018 O-antigen, and two cross-reactive anti-core
mAbs (C-I and C-2), reactive to either core not substituted with O-
antigen (C-1) or to both substituted and unsubstituted core material (C-
2) (for more details see Nelson el ai, 1990). Supernatant fluids of
hybridoma cell cultures grown in RPMI 1640 supplemented with 5%
(v/v) foetal calf serum in 150 cm-1 flasks were used throughout. Cell
cultures were grown to maximum cell density and harvested at 50% cell
viability. These three hybridomas gave yields of approximately 50 pg
ml"1.
Preparation of LPS. LPS was prepared from whole washed bacteria
by the proteinase K method of Hitchcock & Brown (1983) as described
by Hancock & Poxton (1988). For each growth condition the density of
washed bacteria was adjusted to an OD5:5 of 0-5 prior to proteinase K
treatment. This allowed direct comparison of cells from each growth
medium.
PAGE. PAGE was performed on 14% (w/v) acrylamide slab gels
with the Laemmli buffer system (Laemmli, 1970), except SDS was
omitted from the stacking and separating buffers. Samples (10 pi for
silver stain, or 20 pi for immunoblotting) of the proteinase K LPS
extracts were loaded onto the gels. The LPS separating gels were
stained with silver by a method developed by Tsai & Frasch (1982), as
modified by Hancock & Poxton (1988).
Immunobhl transfer. LPS separated by PAGE was electroblotted to
nitrocellulose by the method of Towbin et al. (1979) as described by
Hancock & Poxton (1988) with Bio-Rad buffers and substrate.
Nitrocellulose membrane of 0-2 pm pore size was obtained from
Schleicher and Sehuell and an anti-mouse IgG-horseradish-peroxidase
conjugate used (ICN). Antibody culture supernates were diluted 1 in
10.
Diluents and buffers used in ELISA. (1) Coating buffer consisted of
0-05 M-carbonate/bicarbonate, pH 9-6. (2) Post-coat buffer consisted of
PBS (pH 7-2) containing 2% (w/v) bovine serum albumin (BSA) (ICN).
(3) Wash buffer consisted of PBS containing 0-05% (v/v) Tween 20. (4)
Dilution buffer consisted of PBS containing 0 05% (v/v) Tween 20,
0-5% BSA and 4% (w/v) polyethylene glycol 6000 (Sigma).
All solutions contained 0-02% sodium azide.
ELISA procedure. ELISA strips (Immuno module Polysorp F8,
Nunc) were coated with washed bacteria (100 pi per well) after
measuring the OD540 and diluting with coating buffer to a concentra¬
tion of 2 x 107 cells ml"1. Coating was promoted by centnfugation at
630 g for 4 min and leaving overnight at room temperature. Plates were
washed four times in wash buffer, before post-coating with post-coat
buffer at 100 pi per well overnight at room temperature. After further
washing, plates were rinsed in distilled water and stored at — 20 °C
until used. mAb supernatant fluids were diluted 1 in 10, 40, 160 and 640
in dilution buffer and added to coated microplates at 100 pi per well in
triplicate. Plates were incubated at 37 °C for 90 min before washing
four times with wash buffer. Urease-conjugated sheep anti-mouse Ig
(SeraLab) was diluted 1 in 500, added at 100 pi per well and plates were
incubated for a further 90 min at 37 °C. Plates were washed four times
and rinsed in distilled water before urea3substrate (SeraLab) at 100 pi
per well was added. Plates were incubated for 60 min at room
temperature and reactions stopped by adding 1 % (w/v) thimerosal
(Sigma) in distilled water (20 pi per well). The A of wells was read on an
automated microplate reader Titertek Multiscan (MC, Flow Laborato¬
ries). Final results were expressed after subtraction of the absorbance
readings of negative control wells (coated with BSA post-coat only) for
each mAb.
Flow cytometry. Flow cytometry was based on the method described
by Nelson et at. (1990). Briefly, washed cultures of bacteria were
resuspended to a concentration of about 1 x 10s cellsml"1. Pellets from
I ml were resuspended in 1 ml ofmAb culture supernate, diluted 1 in 10
in dilution buffer (see ELISA methodology), and incubated for 60 min
at 37 °C. After washing twice in PBS, 0-5 ml sheep FITC-conjugated
anti-mouse IgG (ICN), diluted 1 in 100 in dilution buffer, was added
and incubated for 60 min at 37 °C. After further washing in PBS, the
pellet was resuspended in PBS containing 0-5% formaldehyde. Samples
were diluted 1 in 50 in PBS and analysed in an EPIC 'C' (Coulter
Electronics) flow cytometer with a 5 W argon ion laser operating at
500 mW and exciting at 488 nm. A total of 50000 cells at 500 cells s"1
were passed through the beam from a 76 pm tip. Background noise and
clumps of cells were excluded by a gate on the log forward angle light
scatter. The percentage of cells exhibiting positive staining was
calculated with the EPICS 'Stat Pack' program(f\^_
Results
Silver-staining and immunoblot analysis of LPS
Figs 1-3 represent silver-stained PAGE profiles of LPS
and their corresponding immunoblots from four E. coli
strains grown under different batch culture growth
conditions. The three smooth strains showed the charac¬
teristic ladder pattern, each step up representing LPS
substituted with a progressively increasing number of O-
polysaccharide repeating oligosaccharide units. These
were missing from the rough mutant. The effect of each
growth condition oil Jhe expression of LPS was com-
paredTocnutrient brotfiASilver-stained profiles of LPS of
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Table 1. ELISA results of the three anti-LPS mAbs titrated against whole cells oj E.
coli OI8. K1 and OI8. K' grown in five different media
mAb
Growth




. 018: K1 018:K- 018 :K1 018:K"
O-l Nutrient broth 1-26 1-34 120 260
Nitrogen-deficient/ 1-31 1-33 145 280
high-carbon
Iron-depleted 119 1-24 105 110
Serum 1-31 1 -41 150 210
Magnesium-depleted 1-39 1-19 120 75
C-l Nutrient broth 0-32 0-55 37 36
Nitrogen-deficient/ 017 0-20 23 40
high-carbon
Iron-depleted 0-65 0-82 32 90
Serum 0-97 1-15 140 180
Magnesium-depleted 0-88 1-18 66 120
C-2 Nutrient broth 0-45 0-51 40 40
Nitrogen-deficient/ 0-08 0-23 50 60
high-carbon
Iron-depleted 0-62 0-98 56 36
Serum 0-73 1-24 270 370
Magnesium-depleted 0-87 1-01 34 200
* Maximum /1590 for the 1 in 10 dilution (first dilution) of antibody,
t The dilution factor when the absorbance is 50% of the maximum.
proteinase-K-digested whole cells grown in nutrient
broth, iron-depleted and nitrogen-deficient/glucose-en¬
riched media are shown in Fig. 1 (a). LPS from iron-
depleted cells showed only minor changes compared to
the LPS from cells grown in nutrient broth, whilst cells
grown in a nitrogen-deficient/glucose-enriched medium
showed an increased expression of both mid-range and
high molecular mass bands. Immunoblotting of trans-
blotted gels against mAb O-l (Fig. 1 b), demonstrates the
specificity for the O-antigen of E. coli 018 and small
amounts of high molecular mass O-antigen leaking from
the rough mutant of 018. The immunoblot again
illustrates greater expression of O-antigen as well as an
overall increase in O-polysaccharide chain length for
cells grown under nitrogen deficiency. Probing with C-2,
an anti-core mAb reactive against both substituted and
unsubstituted core material showed no significant
differences between growth conditions (Fig. lc). PAGE
of LPS from the four E. coli strains grown in magnesium-
depleted medium showed a significant increase in the
expression of unsubstituted core-glycolipid material and
other low molecular mass bands (Fig. 2a). Immunoblot¬
ting with mAb O-l showed similar expression of O-
antigen for both nutrient broth and magnesium-depleted
conditions (Fig. 2b), whilst probing with mAb C-2
further highlighted a pronounced increase in core LPS
(Fig. 2c). Growth in sheep serum resulted in greater
expression of both the fast migrating core region, as well
as high molecular mass O-antigen-bearing molecular
species of the smooth strains compared to growth in
nutrient broth (Fig. 3a). Immunoblot analysis with mAb
C-l, reactive only with unsubstituted core material, and
C-2, demonstrated better expression of predominantly
rough form LPS when grown in serum (Fig. 3b, c).
ELISA on whole bacteria
The binding activities of the three mAbs to whole cells of
E. coli strains 018:K1 and 018:K-, cultured under
various growth conditions are summarized in Table 1. To
give an indication of the amount of antibody bound by
bacteria from each growth condition, the Amax (maxi¬
mum AS90 reading obtained for the first dilution of the
mAb) should be compared. The affinity which each
antibody has for the bacteria from the various growth
conditions is compared by calculating the Dso for each
dilution curve, that is the dilution factor required to give
the 50% value of the maximum absorbance reading. No
significant differences in binding of the anti-0 mAb to
E. coli 018:K1 were detected for the different growth
conditions. However, at high antibody dilutions (> 1 in
160) the non-capsulate mutant E. coli 018 :K~ showed a
significant decrease in binding of mAb O-l to cells
grown under both iron and magnesium limitation (data
not shown). On comparing the £>50 values, the 018 non-
capsulate strain showed stronger affinity for both anti-
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core and the anti-O mAbs compared to its capsulate
parent when grown under most growth conditions, the
exceptions being the magnesium-depleted medium for
the anti-0 mAb and the iron-depleted medium for mAb
C-2. Growth of both E. coli strains in the nitrogen-
deficient/glucose-enriched medium resulted in much
lower binding of the two anti-core mAbs compared to
growth in nutrient broth. However, significant increases
in Asgo were observed when both strains were grown in
serum and magnesium limitation and probed with mAbs
Detection of E. coli LPS by monoclonal antibodies 0005
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Fig. 1 (a) Silver-stained LPS profiles of proteinase K whole cell digests of four E. coli strains (018:Kl,018:K~,018:K.rf and 06 : K.5)
separated by PAGE (14%, w/v, acrylamide). (b.c) Immunoblots of the four E. coli strains transferred to nitrocellulose paper and probed
with (b) an anti-018 specific mAb, O-l, and (c) a core-specific mAb, C-2. Tracks 1-4, 5-8 and 9-12 represent the four E coli strains
grown to early stationary phase in nutrient broth, an iron-depleted medium and a nitrogen-deficient medium respectively.
Table 2. Flow cytometric analysis ofanti-LPS mAb binding to whole cells offour E. coli
strains grown under different conditions.
Percentage values represent the mean positive fluorescence of bacteria above background
levels from three separate experiments. nd, Not done.




medium E. coli. . . 018 :K1 018.K- 018: Krf 06:K5
O-l Nutrient broth 70(± 19) 62(+ 14) 2(± 1) ND
N itrogen-deficient/ 73(± 10) 68(±7) 13( ± 6) ND
high-carbon
Iron-depleted 74( + 6) 50(±3) 3(± 1) ND
Serum 68(+ 15) 67( + 8) 8(±1) ND
Magnesium-depleted 49( ± 9) 39(±9) 7(±0) ND
C-l Nutrient broth 3(± 1) 3(±2) 68(4-11) 7(± 1)
Nitrogen-deficient/ 2(±0) 2(± 1) 56(± 12) 1 (± 0)
high-carbon
Iron-depleted 10( ± 7) 7(±4) 66(4-7) 7(±3)
Serum 28( + 16) 61(+11) 43(4-14) 26(4-12)
Magnesium-depleted 21 (± 4) 24( ± 5) 75(± 13) 18(±8)
C-2 Nutrient broth 2(± 1) 6(±1) 26(4-11) 3(± 2)
Nitrogen-deficient/ 2(±0) 3(± 1) 16( ± 6) 2(± 1)
high-carbon
Iron-depleted 3(±2) 8(±3) 20( ± 5) 14(4-9)
Serum 16(±5) 34(4-11) 20(4-12) 32(4-8)
Magnesium-depleted 12(±4) 18(±2) 28( + 7) 10(±2)
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Fig. 2. (a) Silver-stained LPS profiles of proteinase K.
whole cell digests of four E. coti strains (018 :K1,
018:K",018:Krf aiid 06 :K5) separated by PAGE
(14%, w/v, acrylamide). (b, c) Immunoblots of the
four E. coti strains transferred to nitrocellulose paper
and probed with (b) an 0-18 specific mAb, O-t, and
(c) a core-specific mAb, C-2. Tracks 1-4 and 5-8
represent the four E. coli strains grown to early
stationary phase in nutrient broth and a magnesium-
depleted medium respectively.
(c)
1 2 3 4 5 6 1 8
C-l and C-2. A similar, yet slightly lower increase in
binding of anti-core mAbs was seen for growth under
iron-limitation compared to nutrient broth.
Flow cytometric analysis
The effect of growth conditions on the expression of LPS
on whole bacteria was also investigated by flow
cytometry. Flow cytometric profiles, which relate to the
intensity of fluorescence signal (i.e. antibody binding to
bacteria), were obtained consistently in three separate
experiments. Examples of representative profiles are
illustrated in Fig. 4(a, b). Histograms representing
interaction of the 018-specific mAb, C-l and cells grown
in nutrient broth and magnesium-depleted medium are
shown in Fig. 4(a). A 41% decrease in magnesium-
depleted bacteria exhibiting positive fluoresence above
background levels compared to nutrient broth cells was
Detection of E. coli LPS by monoclonal antibodies 0007
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Fig. 3. (a) Silver-stained LPS p'ofiles of proteinase K
whole cell digests of four £. coli strains (018:K1,
018 :K018 :Krf and 06: K5), separated by PAGE
(14%, w/v, acrylamide). (6, c) Immunoblots of the
four E. coli strains transferred to nitrocellulose paper
and probed with two core-specific mAbs, C-l (b) and
C-2 (c). Tracks 1 -4 and 5-8 represent the four E. coli
strains grown to early stationary phase in nutrient
broth and heat-inactivated sheep serum respectively.
(c)
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Fig. 4. Green fluorescence intensity histograms of (a) the anti-018 mAb (O-l) against whole cells of E. coli 018:K.l grown to early
stationary phase in nutrient broth and in a magnesium-depleted medium and (b) an anti-core mAb (C-l) against E. coli 018 : K~ grown
in nutrient broth and in a heat-inactivated sheep serum medium. Percentage values represent bacteria exhibiting positive fluorescence
above background levels.
observed. The biphasic fluoresence pattern produced by
magnesium-depleted cells demonstrated the presence of
two distinct subpopulations of E. coli 018:K1 on the
basis of differential binding by mAb O-l. Prebiftg-the.
same .cells,with..C-l, a mAbxeactive-^gamsronsubstrtut-
ecLcore LPS, resulted in positive fluorescence levels of
for-RutftenVbf^h-a«4i9^^5i-TrTag7Tesmm-deplet4on.
Significant increases in the binding levels of the two anti-
core mAbs C-l and C-2 (a mAb reactive against both
substituted and unsubstituted core LPS) were
observed when E. coli 018 : K~ cells were grown in serum
compared to nutrient broth. The results obtained with
C-l are shown in Fig. 4(£), where serum-grown bacteria
showed a positive fluorescence level 66% higher than
nutrient-broth-grown bacteria.
Flow cytometry data, showing the effect of growing all
four E. coli strains under the different growth conditions
on mAb recognition of LPS-associated epitopes is
presented in Table 2. Although relative differences
between growth conditions remained constant, day-to-
/ day variation in percentage labelling^within a given
sample was evident. Smooth cells grown with serum and
under magnesium-depleted conditions again showed the
largest increases in binding of anti-core mAbs. Iron-
depleted and nitrogen deficient cells showed only minor
differences compared to nutrient-broth-grown cells.
Probing cells with the O-antigen-specific mAb resulted
in similar binding levels for most conditions, whilst
magnesium-depleted cells, notably 018 :K~ showed a
significant decrease. Enhanced binding of the two anti-
core mAbs, especially C-l, was observed against the
rough mutant 018 : Krf, compared to the smooth strains.
Minor variations between growth conditions of 018 : Krf
cells reacted with anti-core mAbs, favoured higher
percentage labelling for bacteria grown in magnesium-
depleted conditions.
Discussion
The environmental modulation of cell surface compon¬
ents of both Gram-positive and Gram-negative bacteria
has been intensively investigated (Brown & Williams,
1985). Among the environmental factors that commonly
influence the properties of microbial cells, the availabil¬
ity of essential nutrients assumes particular importance
(Harder & Dijkhuizen, 1983). LPS is a major cell surface
component of all Gram-negative bacteria, and is
implicated as a cause of endotoxic shock (Ryan, 1985).
This study has examined using mAbs, the effects of a
number of nutrient growth conditions, relating to those in
vivo, on the accessibility and expression of LPS antigens.
In an earlier study (Nelson et al., 1990) we showed that
immunoblotting, ELISA and flow cytometry could be
used in combination to give both qualitative and
quantitative data on how mAbs bind to LPS. Immuno¬
blotting gives information as to the location of the
epitope within the LPS molecule: viz. O-antigen, or
substituted or unsubstituted core. ELISA with whole
cells gives an extremely sensitive and quantitative
indication of the binding of mAbs to whole cells, but
suffers from the disadvantage that the procedure for
immobilizing the bacteria to plastic may have distorting
influences on the cells which may change binding
characteristics. Flow cytometry lacks the sensitivity and
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automation of ELISA but is quantitative and the binding
occurs in physiological conditions.
The results presented in the current study indicate that
the expression of E. coli core LPS increases when grown
in magnesium-depleted conditions (0T7 mmol l-1, cf.
O-65-l-Ommol 1"' in serum). This was reflected in
greater binding of anti-core mAbs in whole cell ELISA
and flow cytometry, and this was supported by PAGE
and immunoblotting. Magnesium is important in main¬
taining the stability of the structural arrangement of
larger molecules such as LPS within the outer membrane
of Gram-negative bacteria (Costerton et al., 1974). Cell
walls of magnesium-limited cells of Bacillus subtilis show
an increased Mg:+-binding affinity over magnesium-
sufficient cells (Meers & Tempest, 1968). Thus, certain
organisms may respond to magnesium limitation by
improving their ability to bind the ions by increasing
negatively charged cell surface components such as LPS.
Using both batch and continuous culture Day &
Marceau-Day (1982), also reported compositional
changes in Pseudomonas aeruginosa LPS in response to
Mg2+ concentration, reflecting functional alterations in
the LPS. Data indicated a change in core size of LPS
relative to the O-antigen component, suggesting the
possibility of magnesium having a regulatory role on one
or more of the LPS biosynthetic enzymes. An increased
production of low molecular mass LPS was seen for E.
coli grown at intermediate growth rates under magne¬
sium limitation (Dodds et al., 1987). The amino-sugar, 2-
aminohexose was also found to be absent from the O-
polysaccharide. Flow cytometric analysis of E. coli
018:K1 grown under magnesium-depleted conditions
and probed with an O-antigen specific mAb revealed two
populations of bacteria. Possible reasons for this include:
differences in the structure or amount of LPS; the
amount of capsule [shown to be inhibited under these
conditions by Taylor et al. (1981)]; or morphological
heterogeneity of bacteria grown under magnesium-
depletion. The composition of LPS from E. coli 018 :K~
LPS was shown to differ from nutrient-broth-grown LPS
using nuclear magnetic resonance spectrometry (unpub¬
lished data). As well as a decrease in the amount of O-
polysaccharide, rhamnose, a constituent of the 018 O-
antigen, was found to be replaced by an as yet
unidentified sugar.
The low availability of iron is acknowledged as a key
determinant of virulence (Griffiths, 1987). Alterations in
the outer membrane of many bacterial species under
conditions of iron-deprivation include the production of
high molecular mass, iron-regulated outer-membrane
proteins (Neilands, 1982). Little effect of iron depletion
on LPS production was observed by silver-staining and
immunoblotting. However, increasing the degree of iron
deprivation led to a greater expression of rough core at
the expense of high molecular mass O-polysaccharide
LPS (data not shown). Indeed, binding of anti-core
mAbs to whole cells was shown to improve by whole cell
ELISA (Table I), although not significantly using flow
cytometry (Table 2). This may be partly explained by
differences in the two techniques for, as discussed above,
ELISA is prone to distortions not present in flow
cytometry, possibly leading to improved accessibility of
antibodies to LPS epitopes. Although changes in the
expression of LPS per se have been illustrated, growth
under streps conditions such as iron or magnesium
deficiencylikely to alter the structure and composition of
other components of the outer membrane. Therefore,
LPS core determinants normally showing limited acces¬
sibility may become better exposed on the cell surface.
Although this study attempted to assess the binding of
anti-LPS mAbs to whole cells, release of membrane
fragments from cells must also be considered. Indeed,
variations in growth conditions could alter the extent and
nature of the excretion of such fragments (Koekstra et
al., 1976).
The present findings also show a significant increase
in binding of anti-core mAbs when smooth E. coli,
especially the non-capsulate 018 :K~, were grown in
heat-inactivated sheep serum. Immunoblotting, ELISA
and flow cytometry all showed marked increases in
binding of mAbs to the core region, despite an apparent
increase in the expression of O-antigen as revealed by
silver staining. The possible presence of endogenous
anti-LPS antibodies within the serum may have caused a
false impression of mAb binding. However, since mAbs
were raised in a species different from that in which the
serum was obtained, antibody conjugates might be
expected to recognize only mouse mAbs. Also, removal
of any anti-LPS antibodies from the serum by absorption
with bacteria had no effect on the results (data not
shown). Thus heat-inactivated sheep serum appears to
alter the antigenic expression of LPS to permit binding of
mAbs to the core region. Chedid etal. (1968) proposed an
enzymic process within serum capable of attacking cell
wall components, thereby unmasking the conserved
rough antigenic structures.
Although capsule plays an important role in the serum
resistance of many bacteria (Leying et al., 1990), it has
been reported not to provide a barrier function for
binding of anti-0 antibodies to Klebsiella (Williams et
al., 1988) and some E. coli strains including 018 (Cross et
al., 1986). Indeed, binding of the anti-018 mAb to
capsulate and non-capsulate strains of E. coli 018
showed no effect due to the presence of capsule.
However, greater binding of anti-core mAbs to the non-
capsulate strain indicates capsules may have a function
as a barrier for the penetration of anti-core LPS
antibodies. Growth under nitrogen-deficient/high-car-
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bon conditions has been shown previously to promote
capsule formation (Sutherland & Wilkinson, 1965).
Reduced binding of anti-core mAbs to both capsulate
and non-capsulate bacteria grown under these conditions
suggested another factor, other than capsule exerting an
influence. Indeed, an observed increase in chain length
and production of O-polysaccharide was revealed by
silver staining and immunoblotting (Fig. 1). Since O-
polysaccharide is known to reduce accessibility to core
LPS (Gigliotti & Shenep, 1985), a change in both its
production and possible arrangement may have strength¬
ened this effect. A variety of growth conditions have
been shown to alter the expression of O-antigenic LPS
molecules. McGroarty & Rivera (1990) demonstrated a
very marked decrease in the length of the O-specifk LPS
of cells grown under a number of stress conditions, whilst
growth phase (Day & Marceau-Day, 1982) and growth
rate (Dodds et al., 1987) also influence its expression.
Such variability in the expression of LPS polysaccharide
formation may contribute towards the ability of bacteria
to adapt to changes in the environment. Since variables
other than nutrient limitation influence the expression of
LPS, it is acknowledged that in using the batch culture
model, the significance of altering one variable cannot be
divorced with certainty from the influence of others.
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